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Abstract 
 
 Tuberculosis is a major cause of mortality worldwide.  Elucidation of the host resistance 
against Mycobacterium tuberculosis infection and the pathogenesis of tuberculosis is a priority.  
The host response to M. tuberculosis in the lungs includes the formation of granulomas, focal 
accumulations of mononuclear cells coming together to fight infection.  The signals required for 
the migration of cells into the lungs and those required for the formation of granulomas have not 
been well defined.  In this thesis, we will describe the advances we have made in understanding 
chemokine expression and cell migration to the lungs in response to M. tuberculosis.  We have 
determined that Tumor Necrosis Factor (TNF) partially controls cell migration by modulating 
chemokine expression by macrophages in vitro and CD11b+ cells in vivo.  In addition, we have 
taken the subset of chemokines that are affected by TNF and addressed their functions in vivo 
through knockout and neutralization models.  Specifically, we have used an aerosol model of 
tuberculosis in the mouse to address the roles of CXCL9 (MIG), CXCL10 (IP-10), chemokine 
receptor–5 (CCR5) and chemokine receptor–2  (CCR2).  In our studies, there was no apparent, 
strong phenotype in mice without functional CXCL9 or CXCL10.  CCR5-/- mice had altered 
pathology and increased inflammation in response to M. tuberculosis infection, but they were 
able to control the infection.  The CCR5 -/- mice may be hyper-responsive due to higher antigen 
load in the lymph nodes in conjunction with increased dendritic cell migration and more primed 
lymphocytes.  CCR2-/- mice had a clear defect in macrophage migration and a delay in T cell 
 iv
migration, and the course of the disease was governed by the initial dose.  Specifically, when a 
low dose aerosol infection route was used, CCR2-/- mice were able to control infection with the 
reduced number of cells migrating into the lungs; however with a higher dose, the mice 
succumbed to infection.  Our findings are relevant to understanding the immune response and 
granuloma formation during aerosol M. tuberculosis infection, and will contribute to an 
appreciation of the potential effects of anti-inflammatory or anti-chemokine therapies on 
infections.   
 
 v
 Acknowledgements 
The work you will read about in this thesis could not have been carried out without the hard 
work and support of many important people.  My mentor, JoAnne Flynn, has been a great 
scientific advisor.  JoAnne has acted as a mentor with just the right balance of patience, 
knowledge, persistence and support.  I am grateful to Amy Myers for excellent technical 
assistance.  Amy puts in many hours to help all of us get our work done more efficiently.  I thank 
all the members of the Flynn lab for they have become some of my best friends.   
 
I am grateful to all of my committee members, Dr. Basse, Dr. Hendricks, Dr. Kinchington, and 
Dr. Reinhart.  I appreciate all the time and effort they have put into my education.  Their 
guidance has been a strong asset to this research.  
 
I would also like to thank the Chan (Albert Einstein College of Medicine) and Nau laboratories 
for helpful discussions and I am extremely grateful for the Reinhart lab’s technical assistance on 
the ISH protocol, particularly the guidance of Craig Fuller.  The graduate program and the 
department’s administrative staff are the best, trying to keep our lives less stressful.  In addition, 
I could not imagine having a more supportive dean than Dean Stephen Phillips.  Thank you! 
 
The love and support my family and friends have shown me over the past 5 years has been 
tremendous.  Mom and Dad always cared enough to try to understand the research and its 
implications.  They have taught me the value of balance, education and hard work.  I thank my 
siblings for their love.  My brother’s jokes always keep me smiling.  I thank my sister and 
brother in law for bringing me 3 wonderful nieces into this world that I might get a good laugh 
and a reality check every once and awhile.  I will be eternally grateful to my husband, David, for 
his love and support.  David has always supported my goals and been unbelievably patient with 
me when I have been at my wits end.  David motivates me to do my best and because of him I 
believe that I can balance my life (achieving while still appreciating every beautiful moment God 
has given us). 
 
This work was supported by National Institutes of Health HL71241 (J.C., J.L.F), American Lung 
Association CI-016-N, Western Pennsylvania Lung Association Dissertation Grant (H.M.S.) and 
T32 Molecular Microbial Persistence and Pathogenesis AI49820 (H.M.S).   
 
 
 
 vi
 
 
 
 
TABLE OF CONTENTS 
 
 
Abstract .......................................................................................................................................... iv 
Acknowledgements........................................................................................................................ vi 
1.0 Introduction............................................................................................................................... 1 
1.1 Global Impact of Tuberculosis.............................................................................................. 1 
1.2 Potential Outcomes to infection............................................................................................ 3 
1.3 Influence of external factors ................................................................................................. 5 
2.0 Animal Models of Tuberculosis................................................................................................ 7 
2.1 Monkey ................................................................................................................................. 7 
2.2 Rabbit.................................................................................................................................... 8 
2.3 Guinea Pig............................................................................................................................. 8 
2.4 Mouse.................................................................................................................................... 9 
3.0 Initiation of Infection .............................................................................................................. 12 
4.0 Acquired Immune Response ................................................................................................... 15 
4.1 Granuloma Formation......................................................................................................... 16 
4.2 Cellular Interactions during the protective immune response ............................................ 19 
4.21 Dendritic Cells .............................................................................................................. 19 
4.22 Macrophages................................................................................................................. 21 
4.23 CD4+ T lymphocytes .................................................................................................... 22 
4.24 CD8+ T lymphocytes .................................................................................................... 23 
4.25 B lymphocytes ............................................................................................................... 24 
4.3 Cytokine mediated actions.................................................................................................. 25 
4.4 Cytokines and cells involved in granuloma formation ....................................................... 28 
5.0 Chemokines............................................................................................................................. 30 
5.1 Chemokines and M. tuberculosis ........................................................................................ 33 
5.2 Induction of chemokine expression by M. tuberculosis ..................................................... 34 
5.3 Difficulties in studying chemokines and infectious disease ............................................... 37 
6.0 Statement of the problem........................................................................................................ 39 
7.0 Chapter 1  TNF-alpha influences chemokine expression of macrophages in vitro and CD11b+ 
cells in vivo during M. tuberculosis infection, affecting cell migration and granuloma formation
....................................................................................................................................................... 40 
7.1  Introduction........................................................................................................................ 40 
7.2  Materials and Methods....................................................................................................... 41 
7.3  Results................................................................................................................................ 49 
7.4  Discussion .......................................................................................................................... 77 
8.0 Chapter 2  CXCL9 and CXCL10 are not required for granuloma formation and control of M. 
tuberculosis infection.................................................................................................................... 84 
8.1 Introduction......................................................................................................................... 84 
8.2 Materials and Methods........................................................................................................ 86 
8.3 Results................................................................................................................................. 90 
 vii
8.4 Discussion ........................................................................................................................... 98 
9.0 Chapter 3 Enhanced dendritic cell migration and T cell priming in lymph nodes result in 
increased pulmonary lymphocytic infiltration in chemokine receptor 5 (CCR5)-deficient mice 
following Mycobacterium tuberculosis infection. ...................................................................... 101 
9.1 Introduction....................................................................................................................... 101 
9.2 Materials and Methods...................................................................................................... 102 
9.3 Results............................................................................................................................... 109 
9.4 Discussion. ........................................................................................................................ 124 
10.0 Chapter 4 Mycobacterium tuberculosis in chemokine receptor 2 (CCR2) deficient mice: the 
influence of dose on disease progression.................................................................................... 128 
10.1 Introduction..................................................................................................................... 128 
10.2 Methods and Materials.................................................................................................... 130 
10.3 Results............................................................................................................................. 133 
10.4 Discussion ....................................................................................................................... 144 
11.0 Summary ............................................................................................................................. 150 
APPENDIX A............................................................................................................................. 157 
A.0 IL-10 expression during aerosol M. tuberculosis infection is a result of increased bacterial 
burden and does not lead to immunosuppression ....................................................................... 157 
A.1 Introduction...................................................................................................................... 157 
A.2 Materials and Methods..................................................................................................... 158 
A.3 Results.............................................................................................................................. 161 
A.4 Discussion ........................................................................................................................ 165 
APPENDIX B ............................................................................................................................. 167 
B.0 Anti-TNF treatment in the presence of antibiotics............................................................... 167 
APPENDIX C ............................................................................................................................. 173 
C.0 mRNA expression of extracellular matrix proteins and adhesion molecules during M. 
tuberculosis infection.................................................................................................................. 173 
C.1  Introduction. .................................................................................................................... 173 
C.2  Materials and Methods. ................................................................................................... 174 
C.3  Results and Discussion.................................................................................................... 176 
BIBLIOGRAPHY....................................................................................................................... 180 
 
 
 viii
 
LIST OF TABLES 
 
Table 1.  Susceptibility chart on transgenic knockout mice infected with M. tuberculosis. ........ 16 
Table 2.  Chemokine Nomenclature. ............................................................................................ 34 
Table 3.  Primers and Probes used in the Taqman Real time RT-PCR assay............................... 46 
Table 4.  Gene Expression by Laser Capture Microscopy  (LCM) in granulomas isolated through 
Laser Capture Microscopy.................................................................................................... 67 
Table 5.  MACs column isolation of CD11b+ cells. .................................................................... 68 
Table 6.  Algorithm used for ISH analysis. .................................................................................. 73 
Table 7.  Summary of the effects of anti-TNF Ab on the expression chemokines in M. 
tuberculosis infected  macrophages. ..................................................................................... 81 
Table 8.  Cell migration in chronic infection in CCR5-/- and wild type mice (6 months post-
infection). ............................................................................................................................ 112 
Table 9.  Numbers of immune cells within the lungs 3 weeks post infection. ........................... 138 
Table 10. Cell migration to the lung following challenge of memory mice with aerosol M. 
tuberculosis. ........................................................................................................................ 144 
Table 11.  Cellular infiltrate differences in chemokine or chemokine receptor deficient mice.. 152 
Table 12.   IL-10 gene expression in the lungs of M. tuberculosis infected mice. ..................... 162 
 
 
 ix
 
LIST OF FIGURES 
 
Figure 1.  Potential Outcomes of exposure to the M. tuberculosis bacillus.................................... 4 
Figure 2.  Bacterial burden in the lungs of wild type C57Bl/6 mice. ........................................... 10 
Figure 3.  Granuloma formation in the lungs of M. tuberculosis infected mice........................... 17 
Figure 4.  Cell mediated immune response to M. tuberculosis..................................................... 25 
Figure 5.  Deficiencies in TNF signaling led to rapid disease progression. ................................. 50 
Figure 6.  Lung pathology in M. tuberculosis infected TNFRp55-/- mice and wild type mice. .. 52
Figure 7.  Immune cells migrate into the lungs in TNFRp55-/- mice........................................... 53 
Figure 8.  As bacterial burdens increased in MP6XT-22 treated mice, the numbers of cells 
migrating into the lung increased significantly..................................................................... 54 
Figure 9.  Neutralization of TNF in chronically infected mice leads to severe lung pathology. .. 55
Figure 10.  Macrophage expression of chemokines is partially dependent on TNF..................... 58 
Figure 11.  Control macrophage experiment. ............................................................................... 59 
Figure 12.  Macrophage expression of chemokines is partially dependent on TNF..................... 60 
Figure 13.  Chemokine protein expression in M. tuberculosis infected macrophages was affected 
by anti-TNF Ab treatment..................................................................................................... 62 
Figure 14.  Chemokine RNA expression in the whole lung of TNFRp55-/- mice and wild type 
mice after M. tuberculosis infection. .................................................................................... 64 
Figure 15.  Chemokine expression in the lungs of chronically infected mice.............................. 66 
Figure 16.  Chemokine expression in CD11b+ cells isolated from low dose infection of TNFR 
and WT mice......................................................................................................................... 69 
Figure 17.  RNA expression of CCR5 ligands and CXCR3 ligands is transiently reduced in 
CD11b+ cells of TNFRp55-/- mice infected with a high dose of M. tuberculosis............... 70 
Figure 18.  In chronically infected, MP6XT22 treated mice, chemokine RNA expression was 
transiently reduced in CD11b+ cells isolated ex vivo from the lungs. ................................. 71 
Figure 19.  Sense and anti-sense in situ hybridizations to detect CXCL9, CXCL10 and CCL5 in 
lung tissue infected with M. tuberculosis. ............................................................................ 72 
Figure 20.  The number of cellular infiltrates, whether classified as category 2 or 3, was not 
different between anti-TNF Ab treated and IgG treated mice. ............................................. 74 
Figure 21.  Expression of CXCL9 and CXCL10 are reduced in MP6XT-22 treated mice during 
acute aerosol.......................................................................................................................... 76 
Figure 22.  Mice control M. tuberculosis infection in the absence of functional CXCL9 and 
CXCL10................................................................................................................................ 92 
Figure 23.  T lymphocytes migrate to the lungs of CXCL10-/- and anti-CXCL9/anti-CXCL10 
treated mice........................................................................................................................... 93 
Figure 24.  T lymphocytes in the lung are activated in CXCL10-/- and anti-CXCL9/anti-
CXCL10 treated mice. .......................................................................................................... 94 
Figure 25.   Cell migration to the lymph nodes was delayed in anti-CXCL9/anti-CXCL10 treated 
mice....................................................................................................................................... 95 
Figure 26.  IFNγ production in the absence of functional CXCL9 and CXCL10. ....................... 96 
Figure 27.  Cytotoxic activity and proliferative ability of T lymphocytes from CXCL10-/- mice.
............................................................................................................................................... 97
Figure 28. Expression of CCR5 ligands increased in M. tuberculosis-infected bone marrow 
derived macrophages and in the lungs of aerosol M. tuberculosis-infected mice. ............. 110 
 x
Figure 29.  CCR5-/- mice control aerosol and intravenous M. tuberculosis infection. .............. 111 
Figure 30.  Infection of CCR5-/- mice led to greater numbers of lymphocytes in the lungs 
compared to wild type mice................................................................................................ 113 
Figure 31.  CCR5-/- mice formed granulomas with greater lymphocytic infiltrate. .................. 115 
Figure 32.  CCR1 mRNA expression in the lungs of M. tuberculosis infected, wild type and 
CCR5-/- mice. ..................................................................................................................... 116 
Figure 33.   CCR5-/- mice had altered chemokine expression late in infection. ........................ 117 
Figure 34.  T helper 1 inflammatory cytokines increased to significantly higher levels in CCR5-/- 
mice compared to C57Bl/6 mice......................................................................................... 119 
Figure 35.  CCR5-/- mice did not have a decrease in apoptosis. ................................................ 120 
Figure 36.  CCR5-/- mice do not have fewer CD4+CD45RBloCD25+ cells than wild type mice, 
but rather have significantly more cells of this phenotype. ................................................ 121 
Figure 37.  CCR5-/- mice had more dendritic cells and more primed lymphocytes within the lung 
draining lymph nodes.......................................................................................................... 123 
Figure 38.  Expression of CCR2 ligands, CCL2, CCL7 and CCL12 increases following M. 
tuberculosis infection.......................................................................................................... 134 
Figure 39.  CCR2 deficient mice control low dose infection with M. tuberculosis. .................. 136 
Figure 40.  Macrophages are present in fewer numbers throughout M. tuberculosis infection in 
the CCR2 deficient mice..................................................................................................... 139 
Figure 41.  Migration of T lymphocytes to the lung is delayed following low dose aerosol M. 
tuberculosis infection.......................................................................................................... 140 
Figure 42.  Granulomas form in the lungs with delayed kinetics in CCR2 deficient mice. ....... 142 
Figure 43.  Expression of IFN-γ and inducible nitric oxide synthase (NOS2) is delayed in the 
lungs of CCR2-/- mice infected with a low dose of M. tuberculosis H37Rv via aerosols. 143 
Figure 44.  Chemokine expression and cell migration in the absence of TNF........................... 156 
Figure 45.  Colony forming units in the lungs of M. tuberculosis infected mice. ...................... 163 
Figure 46.  TNF neutralization leads to increased disorganized pulmonary infiltrate in IL-10-/- 
and wild type mice. ............................................................................................................. 164 
Figure 47.  Colony Forming Units in the Lung following antibiotic treatment and antibody 
treatment in chronically infected mice................................................................................ 168 
Figure 48.  Histological Images of chronically infected mice treated with antibiotics and anti-
TNF Ab. .............................................................................................................................. 170 
Figure 49.  Cellular infiltrate in the lungs of chronically infected mice treated with antibiotics.
............................................................................................................................................. 171
Figure 50.  Cell Adhesion Molecules (Ig Superfamily, Cadherins and Catenins, Selectins). .... 176 
Figure 51.   Cell adhesion Molecules (Integrins)........................................................................ 177 
Figure 52.  Matrix Metalloproteinases........................................................................................ 178 
 
 
 
 xi
 1.0 Introduction 
Mycobacterium tuberculosis, an intracellular bacterium, is the causative agent of 
tuberculosis, an ancient disease that remains a major burden in some societies.  Amazingly, the 
diagnostic methods and treatments have remained largely unchanged in the last few decades, and 
the current vaccine is relatively ineffective [1].  From a public health prospective, progress 
toward controlling tuberculosis has advanced with the implementation of directly observed 
treatment, short course therapy (DOTS).  In addition, recent scientific advances over the last 
decade have raised hopes that new therapies and strategies for immunization will emerge.  A 
wealth of knowledge has been gained towards understanding the immune response to M. 
tuberculosis.   This thesis describes the advances we have made in understanding immune cell 
migration into the lung during M. tuberculosis infection in a murine model.  These studies have 
focused on the influence of tumor necrosis factor on cell migration and chemokine expression.  
In addition, we addressed the roles of chemokine receptors CCR2 and CCR5 and chemokines 
CXCL9 and CXCL10.   
1.1 Global Impact of Tuberculosis 
 3.8 million new cases of active tuberculosis were reported in 2001 with a corresponding 
global incidence rate of tuberculosis growth of 0.4%.  In some countries such as Russia (6%/ 
year) and eastern and southern African countries (5%/ year), the incidence has been rising since 
1997, but in other countries the incidence has been slowly falling [2].  The number of cases 
reported to the World Health Organization is only 45% of the estimated new tuberculosis cases 
in 2001, leaving the disease underreported and probably under diagnosed.  There were 1.84 
million deaths from TB in 2000, with about 12% of those deaths attributable to co-infection with 
HIV [3].   
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 In the United States, there has been a decline in tuberculosis cases every year since the 
resurgence of tuberculosis cases in 1992.  The CDC has described a plan to eliminate 
tuberculosis in the United States (defined as <1 case per 1,000,000) by the year 2010.  In 2002, 
there were approximately 15,000 new cases reported to the CDC, representing a 5.7% decline 
from 2001.  Despite the decline in the percentage of cases, the rate of tuberculosis incidence 
remains higher than the country’s target goal in its plan towards tuberculosis elimination.  On a 
positive note, there was also a decrease in the proportion of multidrug-resistant (MDR) 
tuberculosis (from 2.7 to 1.3% in 10 years) [4]. 
Tuberculosis is in principle, a curable and preventable disease.  Its continuing global 
impact highlights the disparity between the developing world and the industrialized nations.  In 
the early 20th century, industrialized nations made improvements on their populations’ nutrition, 
sanitation, and economy, leading to declines in the incidences of many infectious diseases, but 
today some developing countries are still struggling in these areas.  In the 1940s, treatment for 
tuberculosis improved with the advent of anti-mycobacterial drugs such as isoniazid, 
streptomycin and para-amino salicylic acid (PAS).  Since that time, more anti-mycobacterial 
drugs have been developed including pyrazinamide, ethambutol and rifampicin, but no new 
specific antimycobacterial drugs have been approved over the last 40 years.  The current vaccine 
for tuberculosis (BCG) is in use in most of the world has shown its effectiveness primarily in 
preventing disseminated forms of tuberculosis in young children, but has shown little protection 
against pulmonary tuberculosis in adults [reviewed in [1]].   
With the initiation the DOTS strategy in 1995, many more countries have started to 
address this global health problem.  Under the DOTS program, each country adopts the 
program’s 5 Pillars:  government commitment, diagnosis by smear microscopy, multi-drug 
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 chemotherapy treatment for at least 2 months, reliable supply of anti-TB drugs, and outcome 
evaluation and records of every patient.  The number of countries implementing DOTS has 
increased each year since 1995, with 7 countries newly implemented DOTS in 2001 [2], 
increasing the number of countries currently implementing DOTS to 155.  The percentage of the 
world’s population that is consequently covered under DOTS is 61%, and the overall treatment 
success rate in DOTS areas is 82%. 
1.2 Potential Outcomes to infection 
 Transmission of M. tuberculosis is principally human-to-human through contaminated 
aerosol droplets that enter the alveolar spaces.  Therefore, the most common site of infection is 
the lung.  Although the infection is initiated in the lung, infection can spread throughout the 
body, including lymph nodes, central nervous system, pericardium, skin, bone, kidneys, and 
larynx.  Exposure to M. tuberculosis can lead to three potential outcomes (Figure 1).  In ~ 90% 
of exposed individuals, a strong cell mediated immune response is mounted by 4-5 weeks after 
exposure and results in a subclinical form of the infection, defined as latent tuberculosis.  Latent 
tuberculosis refers to M. tuberculosis infection without clinical signs of disease [5]; a person can 
remain infected for life without developing active tuberculosis, and not be infectious.  The 
second potential outcome is active clinical tuberculosis. About 5% of exposed persons will 
develop active tuberculosis within 2 years of exposure.  A final possibility, although it is not 
clear how often this occurs, is exposure without successful infection also referred to as clearance 
[reviewed in [6]].    
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 Exposure to Aerosoled Droplets
Clearance
(?)
Control
(>90%)
Latency
(1/3 World’s Population)
Active Disease
(5%- 8 million/year)
Reactivation
(5-10%)
Death
(2million/year)
Treatment
 
Figure 1.  Potential Outcomes of exposure to the M. tuberculosis bacillus.   
Following exposure to M. tuberculosis bacillus there are three potential outcomes.  In some cases the bacillus may 
be cleared without detection by the immune system.  In a majority of cases the infection is controlled through the 
cell mediated immune response and leads to clinical latency.  About 5% of individuals exposed to M. tuberculosis 
will develop active disease in the first 1-2 years after exposure.  In addition, it is possible for latent disease to 
become active.  Reactivation of disease can result from immunosuppression.   
 
 
Typical diagnosis of M. tuberculosis infection in the United States can be achieved 
through a delayed type hypersensitivity skin test to purified protein derivatives (PPD) of 
mycobacteria.  A positive PPD test does not indicate a person has active infection, but rather that 
he was exposed and initiated an immune response to M. tuberculosis.  Consequently, in the 
United States, a PPD positive individual without disease is often treated with isoniazid for 6 
months, to reduce the risk of reactivation. In countries where BCG vaccination against 
tuberculosis is practiced, transmission of M. tuberculosis is not easy to assess, since BCG results 
in PPD positivity for a number of years.  Persons with active tuberculosis are treated with multi-
drug therapy  (4 different antibiotics for 2 months and an additional 4-10 months of 2 antibiotics) 
to prevent drug resistant strains from emerging.  Active tuberculosis can be accompanied by 
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 night sweats and intermittent fever, weight loss and anorexia, fatigue, and coughing. Active 
infection is confirmed through a positive smear test, where the sputum is stained for acid-fast 
bacilli, and by culture of the sputum sample.   Due to the presence of inflammatory lesions, 
granulomata, a chest radiograph can also be a diagnostic tool during or after the infection. 
1.3 Influence of external factors 
Many factors influence the success rate of tuberculosis control.  In Russia, the increased 
rates of tuberculosis are related to the destruction of the health care infrastructure, the emergence 
of MDR strains, and the lack of monies to treat tuberculosis cases. In the United States, 
tuberculosis is most common among immunocompromised individuals, such as the elderly or 
HIV+ persons.  HIV infection leads to a decline in the numbers of CD4+ lymphocytes, leaving 
HIV+ individuals severely immunocompromised.  In the absence of CD4+ lymphocytes, M. 
tuberculosis cannot be controlled [7-10].  Immunocompromise induced by steroids, anti-
inflammatory therapies, alcohol, or malnourishment causes increased risk of tuberculosis. 
An estimated 10.7 million people were coinfected with M. tuberculosis and HIV in 1997 
[reviewed in [11, 12]].  From those 10.7 million coinfected individuals, approximately 640,000 
will develop tuberculosis disease.  A majority of the tuberculosis/HIV coinfected patients are 
found in sub-Saharan Africa and southeast Asia.  An estimated 60,000 reside in North America.  
Treating HIV in the presence of M. tuberculosis infection can be somewhat complicated due to 
significant interactions between the rifamycins and the antiretroviral protease inhibitors and non-
nucleoside reverse transcriptase inhibitors.  In addition HIV infection can change the progression 
of tuberculosis disease.  Extrapulmonary tuberculosis, particularly in the lymph node is more 
common in HIV-positive individual than HIV-negative individuals.  Although analysis of chest 
radiographs do not indicate any abnormalities in HIV-positive individuals with >200 CD4+ 
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 cells/µl, HIV-positive individuals with < 200 CD4+ cells/µl do having increased mediastinal 
adenopathy (which is also common in children with primary tuberculosis). M.tuberculosis 
infection also appears to change the progression of HIV infection because M. tuberculosis 
infection leads to induction of proinflammatory cytokines, including TNF.  TNF can upregulate 
intracellular retroviral replication enhancing HIV infection.   
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2.0 Animal Models of Tuberculosis 
Current animal models used to study M. tuberculosis include mouse, guinea pig, rabbit, 
and nonhuman primate models.  All of these models have some features in common with human 
tuberculosis, including infection by depositing a few virulent bacilli directly into the lung, 
development of a granuloma (inflammatory lesion), and onset of a strong cell mediated immune 
response.  However, there are differences in each animal species’ ability to control infection, 
limit dissemination, and develop persistent infection. 
The use of these animal models could not have been possible without the development of 
microbiology and engineering techniques to work with M. tuberculosis.  These include growth of 
M. tuberculosis in liquid media, the improved methods for storing the bacillus and the ability to 
enumerate bacilli on solid media. Aerosol exposure chambers allow reproducible low dose 
infection via the physiologically relevant respiratory route.   
2.1 Monkey 
Nonhuman primates have been used as models for tuberculosis infection for years.  In the 
1970s these animals were used to address the efficacy of BCG vaccination, ideal route of 
administration, and the differences between strains of BCG [13-15].  The nonhuman primate 
model also served as a good model for testing new drugs as they became available, serving as a 
good intermediate step between testing drugs in the mouse model and in man [16].  The model 
was used to evaluate single and multiple drug regiments using antituberculosis drugs including 
isoniazid, streptomycin, p-amino-salicylic acid, cycloserine, ethambutol and others.  Following 
these studies the use of nonhuman primates declined due to the high cost and space required for 
the studies.  More recently, interest in using the primates has reemerged as the research has 
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 indicated that infection of nonhuman primates leads to disease that closely resembles human 
disease [17].  Both primary and latent disease can be modeled in macaques, and there is an 
extensive array of reagents for immunologic studies in monkeys [17].  Difficulties in the use of 
these animals for tuberculosis research include the requirement for BSL3 primate space, out bred 
populations, and cost. 
2.2 Rabbit 
The rabbit is one of the few animal models able to form liquefied necrotic or cavitary 
granulomas in response to M. tuberculosis.  Cavitation occasionally occurs in human 
tuberculosis and leads to the release of massive numbers of bacilli for dissemination.  
Interestingly, rabbits are much more susceptive to M. bovis than to M. tuberculosis.  A 
disadvantage of rabbit models of tuberculosis is that the cost is relatively high and they require 
more biosafety level 3 (BSL3) space than guinea pig or mouse models.  Another disadvantage is 
that there are limited reagents available for the immunological studies.   
2.3 Guinea Pig 
In contrast to mice and humans, the guinea pig is highly susceptible to M. tuberculosis 
infection and develops progressive pulmonary infection [18].  Even a single virulent tubercle 
bacillus can lead to progressive infection and death.  In this model, there is extremely high 
extrapulmonary dissemination.  These animals can be protected to some degree from 
tuberculosis with BCG vaccination, and they do develop granulomas similar to humans (except 
for the lack of cavitation).  A drawback of this model for immunologic research is the scarcity of 
immunological reagents.  Current efforts are being made in cloning and developing cytokine and 
chemokine reagents for use in this model [19-22].  
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 2.4 Mouse 
Immunological and microbiologic studies of M. tuberculosis have advanced most 
dramatically in the mouse models of tuberculosis, but as with all models, they have limitations 
[reviewed in [18, 23]].   The mouse models of tuberculosis are cost and space efficient.  Similar 
to humans, the mouse is capable of generating a strong adaptive immune response to M. 
tuberculosis and can control low dose inocula.  The mouse model of tuberculosis was used by 
Robert Koch to test his famous set of postulates on field mice inoculated with M. tuberculosis 
[24].  Over the last century, the model has evolved and played a key role in the discovery of 
streptomycin and other anti-mycobacterial drugs.  Following drug discoveries, the mouse 
became a model of vaccine study with BCG immunization.  Furthermore, it was the mouse 
model that generated data indicating a cell mediated immune response is initiated in response to 
M. tuberculosis and that control was not primarily mediated by the humoral immune response.  
Another advantage of the mouse model is the availability of immunological reagents.  Genetic 
manipulation has revolutionized the use of the mouse as a model for disease.  Both transgenic 
knockout and over-expression systems allow for in depth analyses of mechanisms by which the 
mouse controls M. tuberculosis infection.  The use of monoclonal antibodies to measure cytokine 
production, block functioning proteins, and characterize the cell populations in response to M. 
tuberculosis infection has been instrumental in advances made in immunological research.    
There are a variety of strains available for analysis of M. tuberculosis infection in mice.  
The most commonly used is the C57Bl/6 strain, which is often described as being relatively 
resistant to tuberculosis [mean survival time(MST)=315d] [25].  Other strains, such as the 
BALB/c mouse, are also considered resistant to infection administered via aerosols (MST, 245d).  
On the other hand, more susceptible mouse strains include the CBA, C3H, and DBA/2J strains 
(MST, 110d).   
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 A clear disadvantage of the mouse model is the relatively high bacterial burden in the 
lungs.  The bacterial burden in mice rises almost uninhibited during the first 3 weeks after 
infection, and the number of bacilli then reaches a plateau between 105 and 106 (Figure 2).  
Despite the magnitude of the bacterial burden, the mice survive for approximately a year.  
Immunocompromising conditions or age can spark reactivation with a rise in bacterial burden.  A 
typical life-ending burden in the mouse is >108 CFU/lung, but can reach 109 CFU/lung.  Our 
studies, some of which will be described in this thesis, indicate that the peak of the immune 
response in C57Bl/6 mice is actually more robust than necessary to control infection.  Another 
disadvantage is that although mononuclear infiltrates form in the lungs of infected mice, they 
rarely develop necrotic or caseous granulomas, and the structure only slightly resembles that of a 
human pulmonary granuloma [26].   
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Figure 2.  Bacterial burden in the lungs of wild type C57Bl/6 mice. 
C57Bl/6 mice infected with 50-100 colony forming units through aerosols can control bacterial burden by 
approximately 4 weeks post infection.  At this time point the mycobacterial burden reaches a plateau at about 106 
colony forming units. (These data were generated in our laboratory, unpublished). 
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The mouse model has been modified to study latent tuberculosis.  The definition of 
murine latency and human latency are the same, but there are differences in latency in these two 
species [reviewed in [27]].  Latency can be defined as a stable M. tuberculosis burden in the 
lungs without clinical signs or histological changes.  In the human, the bacterial numbers are 
believed to be very low or almost undetectable during latency, whereas, the infection stabilizes at 
~106 CFU/lung in the mouse.  Therefore, the “latent murine model” has also been referred to as 
“chronic persistent tuberculosis”, for there is clearly an active immune response employed to 
maintain control of the bacteria, resulting in a chronic infection.   
Other models have been developed in mice to more closely resemble the human disease, 
at least in terms of bacterial numbers, such as the Cornell model [28-30].  This model relies on 
the use of anti-mycobacterial drugs to control the initial infection.  Unfortunately, there is no 
standard protocol for this model.  When this model was first described in the 1950s, the 
chemotherapy was initiated just 20 minutes post inoculum.  Since that time, the dose and strain 
of M. tuberculosis, the time of initiation of chemotherapy, and the length, type, and dose of 
chemotherapy have varied from experiment to experiment.   For immunological studies the 
Cornell model has proven to be inconsistent, and if chemotherapy is initiated early after 
infection, the antibiotics rather than the immune response is primarily responsible for controlling 
infection.  Despite the difficulties establishing a latent tuberculosis murine model, studies of 
chronic persistent infection in mice have generated insights to immune responses during this 
stage of infection [6]. 
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 3.0 Initiation of Infection 
The initiation of M. tuberculosis infection in mice and humans occurs through the 
respiratory tract.  The aerosol droplets containing M. tuberculosis must be <5µm for the bacillus 
to enter the alveolar space and infect alveolar macrophages.  After initial infection, dendritic 
cells and monocyte-derived macrophages can take up the bacillus.  The M. tuberculosis bacillus 
can be taken up by the macrophage through many receptors.  These include the scavenger 
receptor, the mannose receptor, the complement receptors 1, 3 and 4, and the most recently 
described CD44 receptor on macrophages [31-34].  In transgenic knockout models of these 
receptors, infection may use redundant methods of receptor attachment, for when one receptor is 
missing, another is utilized, making it difficult to confirm roles in internalization for these 
receptors [32, 35-37].   Phagocytic uptake via the complement receptor, CR3, can occur with 
both opsonized and nonopsonized bacillus [38, 39].  However, the best characterized mechanism 
for nonopsonized bacillus in mice and humans is the mannose receptor [32, 40].  Internalization 
of M. tuberculosis by human DCs can be mediated by DC-SIGN [41].  Although it is clear that 
M. tuberculosis has a tropism for phagocytic cells, M. tuberculosis also interacts with epithelial 
cells, possibly through its antigen 85, a fibronectin binding protein [42].   
 In mice whose alveolar macrophages were depleted by dichloromethylene diphosphonate 
liposomal treatment, there was increased survival after pulmonary challenge and 9.7 fold fewer 
M. tuberculosis in the lung and 2.7 fold less in the liver [43].  In addition, the cellular infiltrate in 
these mice was more diffuse and overall Th1 and Th2 cytokine production was reduced.  The 
early replication of M. tuberculosis in the lung was not affected, suggesting that initial uptake of 
M. tuberculosis by alveolar macrophages was not required for establishing infection, but rather 
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 that later in the infection the alveolar macrophages may play a role in the maintaining a 
pulmonary infection. 
Initial uptake can lead to killing of M. tuberculosis through phagolysosomal fusion and 
acidification, but this process is dependent on the microenvironment of the macrophage.  The 
live bacillus can inhibit phagolysosomal fusion by recruiting a host tryptophan aspartate 
containing coat protein (TACO), which prevents maturation of the phagosome [44].  TACO is 
released during normal phagosome maturation into lysosomes.  With retention of TACO on the 
phagosome, the M. tuberculosis can survive and replicate.  In addition to retention of TACO, the 
M. tuberculosis containing phagosome possibly accumulates Rab5 and excludes Rab7 indicating 
that the phagosome is arrested at the early endosomal stage [reviewed in [45]]. 
M. tuberculosis does not completely go under the immune radar prior to the cell mediated 
immune response.  There is an innate immune response to the bacillus.  M. tuberculosis and 
other bacteria have pathogen associated molecular patterns (PAMPs) that can be recognized by 
various receptors, initiating immune responses.  The M. tuberculosis bacillus is recognized by 
toll-like receptors (TLRs), the mannose receptor, complement receptors, and the 
lipopolysaccaride (LPS) receptor.  Both viable and dead M. tuberculosis can activate murine 
macrophages expressing TLR2 and TLR4 [reviewed in [46, 47]].  The LPS receptor, CD14, 
enhances the macrophage’s ability to respond to lipoarabinomannan (LAM), a mycobacterial cell 
surface molecule [48].  There is evidence that mycobacterial lipoproteins, such as 19kDa protein, 
are recognized by TLR2. The 19kDa protein can inhibit MHC Class II expression and processing 
of soluble antigens through TLR-2 signaling [49-51].  In addition, the 19kDa protein can induce 
macrophage apoptosis through TLR2 [52].  Interaction of the bacillus with TLR2 also leads to 
production of IL-12, IL-8, IL-23 and TNF [47, 53-55], cytokines essential for control of 
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 infection, while TLR4 ligation supported the production of IL-12 and CXCL10.  Whether TLR2 
and TLR4 are required for control of infection, or if their roles are redundant was addressed in 
transgenic knockout models.  TLR2 and TLR4 deficient mice controlled acute infection similar 
to wild type mice, when a low dose aerosol route was utilized [56].  When the dose was 
increased 20-fold, these knockout mice both exhibit increased susceptibility to infection.  In 
addition, during chronic infection TLR4 -/- mice succumbed to low dose aerosol infection by 5-7 
months post infection exhibiting impaired macrophage recruitment and proinflammatory 
cytokine responses [57].  These data suggest a role for TLR4 in the adaptive immune response 
during chronic infection, which is somewhat surprising considering the general belief that toll-
like receptors’ major role is the initiation of the immune response. 
 Early after infection there is a neutrophilic infiltrate in the lungs, which may be important 
for early control of infection.  When neutrophil depleted mice were infected with M. 
tuberculosis, the bacterial burden was significantly higher by one-week post infection in the 
liver, lung and spleen [58].  In addition the mice exhibited reduced IFNγ and NOS2 mRNA 
expression. 
 The bacillus disseminates from the lungs at least in part through lymphatic drainage to 
the mediastinal lymph nodes.  This dissemination occurs in an aerosol infected mouse 9-11 days 
after infection and M. tuberculosis specific T lymphocytes generated in the lymph nodes 2-3 
days later [59].  The dissemination of infection to the periphery organs, such as the spleen or 
liver occurs 11-14 days post infection and again the generation of M. tuberculosis specific 
lymphocytes follows.  Dissemination appears to help initiate the cell mediated immune response 
in a timely manner, for when comparing C57Bl/6 mice to more susceptible C3H mice, 
dissemination occurred earlier in the C57Bl/6 strain [59]. 
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4.0 Acquired Immune Response 
M. tuberculosis infection is controlled primarily through the cell mediated immune (CMI) 
response. T cells are primed and activated within the lymphatics and the protective response is 
mediated within the lungs in the granuloma.  This response involves many cell types including 
dendritic cells, macrophages, CD4+ and CD8+ T lymphocytes, and B lymphocytes [26, 60].  
Although each of these cell types clearly is induced in response to infection, their functions 
during M. tuberculosis infection are still being defined.  The chart below illustrates susceptibility 
of many transgenic knockout mice with M. tuberculosis infection.  In addition it summarizes the 
cellular infiltrates found in the mice, since we have demonstrated that even resistant mice can 
have altered cell infiltration compared to wild type mice.   
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 Table 1.  Susceptibility chart on transgenic knockout mice infected with M. tuberculosis.  
The table below describes the mean survival time and cellular infiltrate as described in the literature or in current 
studies.  All infections were performed with a low dose aerosol infection, unless otherwise noted.  NR = not 
reported, ND = not determined 
 
Strain of Mice Mean Survival Time 
(Aerosol) 
Cellular Infiltrate in Lung Reference 
C57Bl/6 310 d Organized [23] 
TNFRp55-/- 25 d Dissorganized, neutrophilic Section 7.0, 
[61] 
CCR2-/-  21 d (high dose) Dissorganized, few Mφ, 
neutrophilic 
[62] 
CCR2-/-  >200 d (low dose) Organized, fewer Mφ [63] 
CCR5-/- >200 d Organized, more lymphocytic Section 9.0 
CXCL10-/- >90 d Organized unpublished 
GKO 30 d Organized, more granulocytes [64] 
IL-10-/- >200 d Organized, more activated mφ Appendix A, 
[65] 
IL12p40-/- 45 d NR, Fewer lymphocytes  [66] 
IL12p35-/- ND, but >CFU than WT 
@ 55d 
NR, Fewer lymphocytes [67] 
IL-6-/- 59 d (for i.v. infection) ND [68] 
CD4-/- 45 d Delayed, Some organized, 
smaller  
[7] 
β2M-/- 232 d Organized, larger infiltrates [69] 
BKO >200 d Organized, smaller [70] 
NOS2-/- >180 d, but 1 log >CFU 
than WT 
Diffuse, more neutrophilic [71] 
CXCR3-/- >140 d Transiently fewer, smaller but 
organized 
[72] 
CCL2-/- > 200 d Organized, fewer Mφ [73] 
 
4.1 Granuloma Formation 
Granuloma formation is the hallmark of M. tuberculosis infection. Granulomas form in 
response to chronic local antigenic stimulation, and can be observed in other infectious diseases, 
including schistosomiasis, leprosy, and leishmaniasis [74-78]. Granuloma structure and 
composition varies depending on the organism.  A tuberculous granuloma is observed 
concomitant with a highly activated cell mediated immune response, which generally mediates 
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 control of mycobacterial numbers in the lungs. This is an attempt by the host to contain the 
infection, however the resulting pathology can cause complications for the host.   
 The granuloma functions to control M. tuberculosis infection by orchestrating 
communication between immune cells (Figure 3).  It creates a local environment for the cells to 
interact leading to an effective immune response where cytokine production, macrophage 
activation and CD8 T cell effector functions lead to killing of M. tuberculosis.  The granuloma 
also physically contains the bacilli, walling off and preventing spread of the infection. These 
actions lead to inhibition of growth or death of M. tuberculosis, in part by enhancing macrophage 
activation and creating an oxygen and nutrient deprived environment.   
 
Figure 3.  Granuloma formation in the lungs of M. tuberculosis infected mice.   
This model of granuloma formation was created based on the literature and our studies.  Macrophages after infection 
with M. tuberculosis produce TNF and many chemokines.  These chemokines are from both the C-C and C-X-C 
chemokine families of inducible chemokines.   The receptors for these chemokines include CCR2, CCR5, CXCR3, 
among others, which are present on many of the immune cells that migrated to the lungs during M. tuberculosis 
infection and ultimately play a role in the granuloma. 
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 The granuloma is composed of many different cells, including macrophages, dendritic 
cells, CD4 and CD8 T lymphocytes, and B lymphocytes [26, 60]. The macrophages in human 
infection can differentiate into multinucleated giant cells.  Occasionally, such giant cells can be 
observed in murine granulomas, but usually under conditions of severe inflammation. In human 
granulomas, the macrophages are centrally located with the lymphocytes surrounding and 
infiltrating the macrophage area.  Some of the macrophages are infected and many have an 
activated appearance.  Necrosis can occur in granulomas, beginning in the center of the structure, 
which may progress to caseous or necrosis in human tissue.   The caseous material is usually 
solid, but if the infection is not controlled, can liquify and support extracellular replication of M. 
tuberculosis. Caseous granulomas can progress to form cavities within the lung, leading to 
erosion of the granuloma into a bronchus, and the subsequent release of bacteria into the airways. 
Solid granulomas without obvious necrosis are also observed.  These granulomas may be 
controlling or clearing the infection, or may be simply observed prior to undergoing necrosis. 
Fibrosis of a granuloma seems to occur as the granuloma controls the infection and the 
inflammatory process is limited.  In a latently infected person, one or more granulomas 
controlling the infection can sometimes be observed; these granulomas can also be calcified.   
 In murine models of tuberculosis, the granuloma is arranged differently but performs the 
same functions of limiting bacterial replication and spread of infection, as well as localizing the 
inflammatory and immune response to the site of infection within the lung.  Rather than the 
macrophages being centrally located, they are arranged in sheets in the lungs, adjacent to loose 
aggregates of lymphocytes. As infection progresses, many macrophages appear foamy, an 
indication of activation.  Lymphocytic infiltrate is observed around perivascular spaces early 
after aerosol infection; these cells migrate further into the lung parenchyma as the infection 
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 progresses.  The aggregates of T lymphocytes with macrophages (i.e. granuloma formation) 
begin to form by 2-3 weeks post infection, but are larger and more organized by 4 to 5 weeks 
post infection.  CD4, CD8 and γδ T cells are present in these aggregates.  B lymphocytes also 
migrate to the lung at a similar time.  The aggregates of B cells form tighter clusters as the 
infection progresses, and can be distinguished from the T lymphocytes because the cells are 
more tightly packed.  There is also an influx of neutrophils in the lung early after infection, 
which peaks ~2 to 3 weeks post-infection in mice that control infection and then decreases to 
very low levels.  The total numbers of T and B cells stabilize by 5 to 6 weeks post infection and 
granulomas are well established. If bacterial numbers are not controlled by the immune response, 
infiltration of cells continues and the cellular aggregates increase, resulting in much of the lung 
filled with inflammatory cells, limiting airway space. If mice are immunocompromised (e.g. 
IFN-γ deficient mice) and progress to high bacterial burdens, necrosis of the granulomas is often 
observed, with extensive neutrophil infiltration. Necrosis in granulomas of mice is almost always 
associated with high M. tuberculosis numbers; necrosis is rarely observed in wild type mice that 
are controlling the infection, even in long-term infections. This may be a different situation than 
that of humans, where it is believed that the immune response contributes to necrosis within the 
granuloma.  
4.2 Cellular Interactions during the protective immune response 
4.21 Dendritic Cells 
Dendritic cells are a key link between innate and adaptive immunity.  As potent antigen 
presenting cells and potent responders to PAMPS, dendritic cells often influence the strength and 
type of adaptive immune response [79].   M. tuberculosis infection of bone marrow derived 
dendritic cells results in the upregulation of cell surface molecules, such as ICAM, B7.1, and 
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 B7.2.  In addition, infection of murine DCs leads to increased expression of inflammatory 
cytokines, IL-12, TNF, IL-1β, and IL-1α [80-82].  These cytokines initiate Th1 responses in T 
lymphocytes, stimulating the production of IFNγ and other cytokines.  In addition, infected 
human dendritic cells produce chemokines, such as CCL3, CCL4, CXCL9 and CXCL10 [83], 
which appear to recruit activated NK and T lymphocytes.  Beyond initiation of the immune 
response, the DCs may play a role in adaptive immunity, especially in chronic infections such as 
M. tuberculosis.  Although murine DCs do produce reactive nitrogen intermediates (RNI) and 
reactive oxygen intermediates, they do not actively kill the M. tuberculosis bacillus (K. Bodnar 
and J.L.Flynn, unpublished).  Rather, they produce more peroxynitrite (K. Bodnar, unpublished), 
a form of RNI, which is nontoxic to pathogenic mycobacterium [84].   In addition, a bacillus-
containing phagosome (or vesicle) within activated DCs is structurally different than a 
phagosome containing M. tuberculosis in an activated macrophage (K. Bodnar, unpublished).  
Within the activated macrophage, some of the vesicles containing M. tuberculosis form multiple 
membranes around the bacillus.  Studies in human DCs support the findings in the murine 
system [85].  The mycobacterial vacuoles of infected human DCs neither acidify nor fuse with 
lysosomes, explaining why the mycobacteria are not killed.  In addition the lack of 
communication between these vacuoles and the normal host cell recycling machinery may 
indicate why the bacteria also do not multiply.   M. tuberculosis survival within the dendritic 
cell, possibly in a non-replicating state, may be beneficial for the immune response, providing a 
long term source of antigen for presentation to lymphocytes.  Dendritic cells have been described 
in the lung and within granulomas of both mice and humans [60, 86].  In the mouse model the 
CD11c+ dendritic cells in the lungs of infected mice appear to be of mixed phenotype, some 
mature, while most immature [60].  
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 4.22 Macrophages 
 The role of macrophages in the CMI response is no less complicated.  With many 
different states of macrophages (activated and unactivated), and types of macrophages 
(residential, alveolar and newly recruited monocytes), it can be difficult to clearly define 
different macrophage responses to M. tuberculosis infection.  Macrophages, as described earlier, 
are a first line of defense against infection, but their role in the CMI response is a key to control 
of infection.  Macrophages can be activated by stimulation with inflammatory cytokines, such as 
IFNγ, but IFNγ alone cannot stimulate a macrophage to produce RNIs and ROIs.  Another signal 
such as TNF or LPS or another bacterial product is required.  Activated macrophages are capable 
of bacteriocidal activity on M. tuberculosis, presumably within the phagolysosome, where the 
acidic vesicle contains hydrolases, ROI, and RNI.  The importance of RNI to control of infection 
is a highly debated point.  In the murine system, RNI appears essential for control of infection 
[87].  On the other hand, in the human system, a role has not clearly been defined.   Immature 
macrophages, or newly recruited monocytes, appear to be less effective as antimicrobial forces, 
and may serve as a preferred host for the M. tuberculosis bacillus.  Macrophage 
antimycobacterial function may also be stimulated by GM-CSF and IL12.  On the other hand, 
IL-6 and IL-1 do not appear to have a significant affect on the mycobacterial growth.  Recent 
evidence indicates that this may be due to a block in the IL-6 signaling via the 19Ka M. 
tuberculosis protein [49, 88]. 
The role of macrophages in control does not lie solely within the phagosome, but also in 
the context of macrophage- T cell interaction.  Macrophages, like dendritic cells, also present 
antigen in the context of major histocompatibility class I (MHC), class II, and non classical 
molecules to T lymphocytes.  But recent data has shown that macrophages are not as effective as 
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 dendritic cells in priming naïve T cells to develop a Th1 phenotype. The inability of 
macrophages to prime Th1 cells has been attributed to the production of IL-10 by macrophages 
and minimal IL-12 production [80].  The presentation of antigen by macrophages in the context 
of MHC I may be a major factor in the ability of CD8+ lymphocytes to contribute to host defense 
through CTL activity. 
4.23 CD4+ T lymphocytes 
 The continual interaction between T lymphocytes and antigen presenting cells allows for 
surveillance and containment of infection (Figure 4).  In an oversimplified model, the 
macrophage produces stimulatory cytokines and presents antigen to activate the T lymphocytes, 
and T lymphocytes produce IFNγ and TNFα to activate the macrophages.  CD4 T lymphocytes 
play a key role in IFNγ production and control of M. tuberculosis. CD4-/- mice are unable to 
control M. tuberculosis infection.  Interestingly, eventually the CD8 T lymphocytes in the CD4-/- 
mice produce enough IFNγ to make up for the deficiency in CD4 lymphocytes, but the mice still 
succumb to infection [7].  Therefore, CD4 lymphocytes may perform an additional function in 
the CMI response that cannot be compensated for by other cells.  This was also evident in 
chronic studies where CD4+ T lymphocytes were depleted through antibody administration.  The 
CD4 T cell-depleted mice were unable to control infection, despite having similar levels of IFNγ 
compared to control mice [8].   
There is increasing evidence that CD1 restricted CD4 lymphocytes may play a role in 
lipid antigen specific responses during infection [89].  In healthy human subjects with previous 
exposure to M. tuberculosis, CD1-restricted M. tuberculosis specific T cells comprise a 
significant portion of their circulating CD4+ blood.  Interestingly, patients with active TB had 
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 low CD1 specific proliferative responses until after two weeks of chemotherapy when their lipid 
specific proliferative responses increased significantly.   
CD4 cells may be very important for stimulation of dendritic cells and cross priming of 
CD8 lymphocytes, as evidenced in many viral models.  Studies addressing this hypothesis are 
underway.  CD4 cells also can be cytolytic, acting on infected cells through the Fas – FasL 
interaction.  Antibody blockade of CD95- CD95L interaction of CD4+ cells from healthy 
tuberculin skin test-positive persons with autologous monocytes decreased cytotoxicity by 25% 
[90].   Mice deficient in CD95 signaling were able to control acute infection similar to wild type 
mice, but entering the chronic stage of infection, the CD95L-/- and CD95-/- mice were gradually 
unable to control the bacterial burden [91]. 
4.24 CD8+ T lymphocytes 
 There is growing support for a role for CD8 lymphocytes in the CMI response to M. 
tuberculosis.    MHC Class I molecule appears to be important for the control of M. tuberculosis, 
for mice deficient in beta-2-microglobulin (β2M-/-) are more susceptible to M. tuberculosis 
infection [69].  Use of this model to study CD8 T cell responses does not rule out the possibility 
that the increased susceptibility was due to a lack of non-classical MHC Class Ib, but the 
additional finding that TAP deficient mice [92], which also lack CD8+ lymphocytes, exhibited 
increased susceptibility to infection supports the idea that MHC Class I restricted CD8 
lymphocytes are required to control infection.  Vγ9/Vδ2 T cell lines generated from the 
peripheral blood mononuclear cells (PBMCs) of PPD+ healthy individuals can kill M. 
tuberculosis infected macrophages both by a perforin and granulysin dependent mechanisms 
[93]. More recently it has been shown that CD8 lymphocyte precursors can be found in the lungs 
and lymph nodes of M. tuberculosis infected mice.  These precursors increase in frequency 
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 during the first 4 weeks post aerosol infection and then their frequency wanes (V. Lazarevic, 
unpublished).  In support of CD8 lymphocytes acting as cytotoxic cells, perforin can be detected 
in cells and tissues of M. tuberculosis infected mice [94] and T lymphocytes, isolated from 
infected mice and cultured short term with M. tuberculosis infected dendritic cells, can lyse 
target M. tuberculosis infected cells and produce IFNγ [95].   
4.25 B lymphocytes 
 Following M. tuberculosis infection there is a considerable B lymphocyte infiltration in 
the lungs and the cells are located within the granuloma (unpublished, Flynn).  Low – dose 
aerosol infection of B cell knockout mice (BKO) with M. tuberculosis led to altered 
dissemination and granuloma formation.  The BKO mice had similar numbers of bacteria in their 
lungs, but the dissemination to peripheral organs was delayed and the pulmonary lesions were 
less severe.  These differences have been linked to absence of the cells in the mice, not due to 
lack of antibody response [70].  During chronic infection, the absence of B lymphocytes did not 
appear to affect the M. tuberculosis infection [96] further indicating that these cells may be 
present as a reaction to the inflammation, but their presence is neither an advantage nor 
disadvantage for the host.  On the other hand, when BKO mice were infected i.v. with a high 
dose of virulent H37Rv M. tuberculosis, the mice exhibited increased bacterial load in their lungs 
by 4-6 weeks post infection compared to wild type mice [97].   
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Figure 4.  Cell mediated immune response to M. tuberculosis.   
M. tuberculosis (red circles) infection of macrophages and dendritic cells (APC) leads to the presentation of antigen 
in the context of MHC-Class I and –Class II (MHC).  Subsequently in the lymph nodes both CD4+ and CD8+ cells 
are primed and activated through ligation of their T cell receptors (TCR) interacting with MHC presenting M. 
tuberculosis antigens.  These cells then migrate to the lungs where they are activated.  They produce cytokines (IFN, 
TNF) and interact through macrophages (Mφ) to initiate expression of reactive nitrogen intermediates (including 
NO), resulting in the killing of the bacillus.  In addition CD8 lymphocytes act as cytotoxic T lymphocytes (CTL) by 
lysing the macrophages harboring the bacillus or by direct killing mechanisms, such as granulysin. 
4.3 Cytokine mediated actions 
It is evident that the communication between immune cells is not only through cell-cell 
interaction, but also through cytokine signaling.  In this section, the roles of both pro-
inflammatory and anti-inflammatory cytokines will be addressed in more detail.   
 It has been demonstrated both experimentally and clinically that IFNγ is an essential 
cytokine for the development of protective immunity against M. tuberculosis infection.  IFNγ 
deficient mice (GKO) exhibit increased susceptibility to disease [Table 1,[64, 98]].  Infection of 
GKO mice led to florid bacterial growth and tissue destruction.  Furthermore, patients with 
defective receptors for IFNγ and IL-12 are more susceptible to M. tuberculosis and other less 
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 pathogenic mycobacteria [99].  GKO mice do generate antigen-specific T lymphocytes, but lack 
the ability to induce NOS2 in macrophages [100].  The cellular infiltrate in the lungs following 
aerogenic infection consisted of >50% granulocytes with many neutrophils and even eosinophils 
[100].   
 IL-12 is a key cytokine involved in differentiation of T cell responses and initiation of 
Th1 cytokine responses.  The IL-12p70 molecule is a heterodimer, consisting of a p40 and p35 
subunit acting through the IL-12R.  IL-12 can also form a homodimer of p40 subunits that 
appears to act as an antagonist to IL-12p70.  More recently the p40 subunit was found to have 
some IL-12 like activities.  When IL-12p40-/- mice and IL-12p35-/- mice were infected with M. 
tuberculosis, p40-/- mice were more susceptible to disease than p35-/- mice (which were still 
more susceptible to disease than control, wild type mice) [Table 1,[67]].  The p35-/- mice were 
able to generate antigen specific responses.  This finding indicates that the p40 subunit, which is 
also a subunit for IL-23, has functions that are independent of p35.  
 Another targeted cytokine deletion that leads to profound susceptibility in mice when 
infected with M. tuberculosis is disruption of the TNF gene or its p55 subunit receptor [101-
103].  When infected via aerosol or intravenous routes, TNF deficient mice succumb to infection 
with a mean survival time of approximately 28 days.  TNF deficient mice lack granuloma 
structure and have a large influx of neutrophils as the bacterial burdens increase.  These mice are 
unable to activate macrophages and the production of NOS2 is reduced.  Clearly, TNF’s effects 
on tissue can be both beneficial and detrimental, and TNF’s involvement in the host response is 
on many levels.  The roles of TNF on the host response are described in more detail in chapter 1.   
Recently, therapies have been developed that inhibit TNF signaling, in an effort to reduce 
inflammation during such chronic diseases as rheumatoid arthritis or Crohn’s disease.  Both a 
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 humanized anti-TNF neutralizing antibody (Infliximab) and an antibody – TNF receptor fusion 
protein (Etanercept) have been implemented for this purpose.  Unfortunately, use of these drugs 
increased the risk of reactivation of tuberculosis in latently infected (PPD+) individuals [104].  
The incidence of tuberculosis was higher in patients prescribed Infliximab than Etanercept [105].  
The stronger correlation between Infliximab and tuberculosis may be due the use of this 
treatment in Europe (where a higher percentage of the population has latent tuberculosis), or it 
may be a reflection of the different binding capability of the drugs.  Infliximab strongly binds 
monomeric, trimeric and transmembrane forms of TNF, whereas Etanercept binds strongly to 
trimeric forms and weakly to monomeric and transmembrane forms of TNF.  There is also 
evidence that Infliximab treatment induces drug-mediated apoptosis and monocytopenia. 
The patient population receiving Infliximab treatment not only had a higher incidence of 
tuberculosis then the general population, but they also had a higher incidence of extrapulmonary 
and disseminated disease.  Studies in our murine model of tuberculosis have recapitulated these 
findings [106].  Although the mechanisms underlying the TNF dependent control of acute and 
latent tuberculosis has not been clearly elucidated, TNF appears to modulate cell migration in the 
lungs.  A major focus of this thesis is the role of TNF in chemokine expression and granuloma 
formation (described in Section 7.0 Chapter 1  TNF-alpha influences chemokine expression of 
macrophages in vitro and CD11b+ cells in vivo during M. tuberculosis infection, affecting cell 
migration and granuloma formation).   
 In addition to inflammatory cytokine production as a result of M. tuberculosis infection, 
expression of anti-inflammatory cytokines such as IL-10 or TGF-β increases in some infected 
populations of humans and mice.  Expression of IL-10 can be detrimental depending on when it 
is expressed and how much is expressed.  In the case of IL-10 transgenic mice, overexpression of 
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 IL-10 can induce reactivation in chronically infected mice and can lead to increased 
susceptibility to acute infection with BCG [107, 108].  IL-10 -/- mice were reported to have 
increased resistance to mycobacterial infection with M. avium and BCG [109, 110].  However, in 
the case of M. tuberculosis infection, published results indicate that either there are no 
differences in control of bacterial growth or the differences are seen early after infection and 
over time the IL-10-/- mice have similar disease progression [Table 1,[65, 109]].  The interactive 
role of IL-10 and TNF in granuloma formation will be discussed in further detail in the appendix 
of this thesis (see Appendix A.0 IL-10 expression during aerosol M. tuberculosis infection is a 
result of increased bacterial burden and does not lead to immunosuppression). 
4.4 Cytokines and cells involved in granuloma formation 
Genetically engineered knockout mice have provided clues to the roles of immune cells 
in granuloma formation.  CD4 T cell-deficient mice, which are susceptible to M. tuberculosis 
infection, experience a delay in the formation of the granulomas compared to wild type mice [7], 
and both disorganized and organized granulomas can be found in their lungs.  Mice deficient in 
CD8 T cells also form granulomas in the lungs, but do not control infection as well as wild type 
mice [69, 111].  Interestingly, data generated using γδ T cell deficient (δ-/-) mice suggest that 
these T cells may play a role in granuloma formation [112].  The δ-/- mice had larger, more 
diffuse granulomas in the lungs following low dose aerosol infection, compared to wild type 
mice, but with high dose aerosol infection the δ-/- mice had a largely neutrophilic infiltrate.  
Severe combined immunodeficient (SCID) mice when infected with an avirulent M. bovis 
vaccine strain, BCG, do form epithelioid macrophage aggregates in the liver and spleen, but less 
so in the lung [113]. B-cell deficient mice have smaller, more diffuse granulomas than wild-type 
mice following aerosol infection, but successfully control infection in the lung [70, 96]. 
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 However, in the absence of B cells, the pathology of the lungs is altered significantly, and may 
point to a role for these cells in granuloma formation or maintenance, as discussed above.  
Interestingly, spread of the infection from the lungs to the spleen is reduced in B cell-deficient 
mice [70].  IFN-γ has been mentioned as being important in granuloma formation, however 
immune cells migrate to the lungs and aggregate to form granulomas in IFN-γ-/- mice following 
M. tuberculosis infection [64, 98].  Due to the lack of IFN-γ and subsequent poor macrophage 
activation, these granulomas do not function to control the infection, and quickly become 
necrotic.  In murine models of infection where TNF is absent granuloma formation is 
substantially impaired, pointing to an important role for this cytokine in the signals that direct 
granuloma formation [101, 103].  This will be addressed to a greater extent later in the thesis.  
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 5.0 Chemokines  
Cellular trafficking and recirculation is a multi-step process including rolling, adhesion, 
and migration across endothelium into tissues [reviewed in [114]].  Once inside tissues, the cells 
continue to migrate through more locally directed mechanisms.  These processes are directed by 
adhesin molecules, both integrins and selectins, and chemokines and chemokine receptors. 
Chemokines are small 8-10 kDa chemotactic cytokines, which bind to pertussis toxin-sensitive 
G-protein coupled receptors, inducing actin dependent processes such as membrane ruffling, 
pseudopod formation and assembly of adhesion complexes.   Chemokines are a diverse class of 
molecules acting both as constitutive signals functioning to form secondary lymphoid tissues, 
and as inducible signals in response to physiological stress, such as inflammatory stimuli 
including infection.  
The pattern of chemokine receptor expression dictates, to some extent, the localization of 
cells participating in the immune system. Many immune cells switch from constitutively 
expressed receptors to inflammatory receptors as a consequence of cell activation and 
polarization. For example, immature dendritic cells residing within tissues express CCR5 and 
CCR1[115].  Upon uptake of antigen and maturation, dendritic cells downregulate CCR5 and 
CCR1, and upregulate CXCR4 and CCR7, causing migration of these antigen presenting cells to 
the lymphoid tissues, such as lymph nodes, where they can encounter and prime naive T cells.  
The chemokines that bind to CXCR4 and CCR7, CXCL12 (SDF-1α/β), CCL19 (MIP3β) and 
CCL21 (SLC), are expressed primarily in lymphoid tissues [reviewed in [115]].    Naïve T 
lymphocytes express a different repertoire of receptors (CXCR4, CCR7) than activated T 
lymphocytes (CCR1, CCR2, CCR5 and CXCR3); the chemokine receptor profile influences 
where the cells reside or migrate within lymphoid or non-lymphoid tissue.  Activated T cells will 
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 generally migrate to sites of inflammation or infection rather than back into the lymphoid tissue.  
Memory cells also have different chemokine receptors, which likely play a role in where various 
subsets of memory cells reside following resolution of infection [116, 117].    
Characterization of chemokine expression has been performed by conventional 
techniques such as RNA expression analysis to assess gene expression and ELISA to detect 
protein.  Due to high homology between chemokines in many species, it has been difficult to 
develop useful monoclonal antibodies for studies, particularly in the murine model.  Polyclonal 
antibodies exist, but very few monoclonal antibodies are available for flow cytometric analysis in 
murine models, limiting the studies that can be performed in situ or ex vivo.  There is a larger 
collection of monoclonal antibodies available for human or nonhuman primate studies.  Cell 
migration assays using transwell inserts or Bowden chambers have also allowed basic migration 
properties to be evaluated, but these systems are simplistic compared to the multi-factorial 
processes occurring in vivo, and cell lines, rather than primary cells from different tissues, are 
usually used for these studies. 
The number of chemokines identified has been expanding at a rapid rate in the past few 
years.  There appears to be redundancy in the expression of both chemokines and their receptors, 
since most receptors bind multiple chemokines, and specific chemokines can bind to more than 
one receptor. Often, more than one ligand for a chemokine receptor can be expressed at the site 
of infection, suggesting that both chemokines have a function, or that signals such as infection or 
inflammation induce a number of different chemokines. A particular chemokine receptor can be 
found on many different types of cells. For example, T lymphocytes, monocytes, macrophages, 
basophils and immature dendritic cells express CCR2 [118]. In addition, expression of inducible 
chemokines from a number of different cell types can be observed. Monocytes, endothelial cells, 
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 epithelial cells, fibroblasts and keratinocytes can produce CXCL10, an IFN-γ-inducible 
chemokine [119].  The various signals for induction of chemokine production by different types 
of cells are still being determined.   The true extent of redundancy in vivo, and the possible 
reasons for such apparent duplication of function, remains to be determined; it may simply be 
that our current understanding of the roles or induction of expression of each chemokine in a 
complex and interactive system is incomplete.  However, results from CXCL9-/- mice, in which 
an IFN-γ inducible chemokine that recruits activated T cells via CXCR3 was not present, 
indicated that the absence of this chemokine had no discernible effect on control of a number of 
different bacterial and viral pathogens, despite the requirement for IFN-γ in control of these 
pathogens [120]. One can speculate that CXCR3 is not important for directing activated T cells 
to the site of infection, that another CXCR3 ligand [such as CXCL10 (IP-10)] is also expressed 
at the site of infection (which is often the case), or that other chemokine receptors can also direct 
activated T cells equally well to infected tissues. Surprising results from this same study were 
that CXCL9 was important for antibody responses to Francisella tularensis, and that activated B 
cells expressed CXCR3 [120].  Genetically engineered mouse models are likely to enlighten us 
about the roles these chemokines and receptors can play in induction of immune responses and 
control of infection. 
The expression of chemokines is highly regulated.  Studies are underway addressing 
signals required for post-transcriptional processing and secretion of the small molecular weight 
proteins.  Several genes encoding chemokines are controlled by NF-κB, NF-IL6, activator 
protein 1 (AP-1) and Sp1 [reviewed in [121]].  Hydrogen peroxide (H2O2) not only gives rise to 
NF-kB signaling pathways, it also appears to production of mRNA encoding MIP1a and IL-8 in 
human cell lines [122].  In addition studies in the murine macrophage cell line B10R indicate 
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 that H2O2 increases expression of CCL3, CCL4, CXCL2 and CCL2 [123].  H2O2 dependent 
induction of chemokines is dependent on both ERK and cAMP-dependent pathways.  H2O2 
dependent upregulation of CCL3, CCL4 and CXCL2 is at the level of gene transcription 
activation, but the expression of CCL2 is increased through both gene transcription activation 
and mRNA stabilization, indicating that there is differential post-transcriptional regulation of 
chemokines expression.  Another type of post-transcriptional regulation that has been uncovered 
is regulation of the secretion of the chemokines.  CCL5 secretion from memory T cells appears 
to be dependent on TCR stimulation [124]. These CD8+ memory T cells carry high levels of 
CCL5 mRNA but do not contain or secrete the protein unless the cells undergo TCR 
engagement. 
5.1 Chemokines and M. tuberculosis  
 There have been a variety of studies aimed at characterizing expression of chemokines in 
response to M. tuberculosis in vitro and in vivo, in human and murine systems.  However, 
synthesizing an understanding of cell infiltration and granuloma formation using results from 
these descriptive studies has proved difficult.  This is in part due to lack of appropriate reagents 
for study, but also to the complexity of the system for migration of cells into tissues in response 
to infection.  In addition chemokines also play roles in other activities of cells, such as induction 
of apoptosis or proliferation [reviewed in [114]]. Table 2 lists the major chemokines that will be 
discussed in this thesis (Table 2). 
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 Table 2.  Chemokine Nomenclature.  
Systematic Name Mouse Ligand Receptor 
CCL2 JE, MCP-1 CCR2 
CCL3 MIP-1α CCR1, CCR5 
CCL4 MIP-1β CCR5 
CCL5 RANTES CCR1, CCR3, CCR5 
CCL7 MCP 3 (Human), MARC CCR1, CCR2, CCR3 
CCL8 MCP-2 CCR3 
CCL11 Eotaxin CCR3 
CCL12 MCP-5 CCR2 
CXCL1 GRO-α CXCR2 
CXCL2 MIP-2 CXCR2, CXCL1 
CXCL8 IL-8 CXCR1, CXCR2 
CXCL9 MIG CXCR3 
CXCL10 CRG-2, IP-10 CXCR3 
CXCL11 I-TAC CXCR3 
 
5.2 Induction of chemokine expression by M. tuberculosis 
 
M. tuberculosis is a strong inducer of chemokine expression. Studies to date have 
primarily focused on the pattern of expression of inducible chemokines following M. 
tuberculosis infection of macrophages in vitro.  M. tuberculosis induces a rapid expression of 
many chemokines in murine macrophages, detectable as early as 2 hours post infection.  In vitro, 
expression usually peaks 12 to 30 hours post-infection [125].  Human macrophages produced 
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 chemokines CCL2, CCL3, CCL4, and CCL5 in response to virulent strains of M. tuberculosis 
[126, 127]. Responses were attenuated with infection using an avirulent strain of M. tuberculosis 
(H37Ra) for CCL3, but not CCL4 or CCL5 [127], indicating that the PAMPs or antigens that 
stimulate the production of these chemokines may be different.  Lymph node tissue and CD14+ 
blood monocytes isolated from tuberculosis patients expressed more CCL2 than those from 
control subjects [128].  In addition human alveolar macrophages produced significantly more 
CCL3, CCL2 and CCL5 than blood monocytes upon infection with M. tuberculosis [126].  These 
results suggest that the chemokines interacting with CCR1, CCR2, and CCR5 might play a role 
in the trafficking of cells bearing these receptors to the site of infection.  However, direct 
evidence for such a role for all these chemokines in tuberculosis remains elusive. 
Expression of CCL2, CCL3, CCL7, CCL12, CXCL2, and CXCL10 in response to M. 
tuberculosis infection of mice has been reported [62, 63, 125]. CCL4, CCL5, and CXCL9 are 
also expressed by murine macrophages following infection with virulent Erdman strain of M. 
tuberculosis (see Section 7.0).  These results support that M. tuberculosis is a strong inducer of 
chemokines.  The cell wall components of mycobacteria may be crucial to this induction, as it 
was reported that infection of murine macrophages with delipidated M. tuberculosis strain 
Erdman significantly reduced production of CCL3 [129].  In addition, different strains of M. 
tuberculosis can induce different levels of chemokines in the tissues of infected mice[125], 
although in this study, the control of infection was similar for the strains tested. 
 Macrophages are not the only cells in the lungs responding to M. tuberculosis by 
producing chemokines.  Expression of CXCL8 and CCL2 mRNA, but not CCL3, CCL4, or 
CCL5 was detected in human alveolar epithelial cell line A549 in response to virulent strains of 
M. tuberculosis [128].  M. avium and heat-killed M. tuberculosis could not elicit the same 
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 responses in these cells. Murine pleural mesothelial cells stimulated with BCG and rIFNγ 
induced CCL4 and CCL2 expression in a dose dependent manner [130].  This production could 
be inhibited by IL-4. Granulocytes from the blood of patients with active tuberculosis produced 
CXCL8 and CXCL1 in response to LAM from M. tuberculosis. Human bronchial epithelial cells 
produce the CXCR3 ligands (CXCL9, 10 and 11) [131] and this expression is upregulated by 
IFN-γ.  CXCL10 was expressed at higher levels in the bronchial epithelium of tuberculosis 
patients, compared to control subjects [132].  These studies imply that cells other than 
macrophages or monocytes participate in recruiting cells by producing chemokines in response 
to mycobacteria.   
The expression of chemokines in vivo has been characterized to a limited degree.  Studies 
performed using bronchoalveolar lavage (BAL) fluid indicate that there are elevated levels of 
CCL2, CCL5, CCL7, CCL12, CXCL8 and CXCL10 in tuberculosis patients compared to 
uninfected controls [126, 133, 134]. Increased expression of CCL5 correlated with higher 
numbers of cells in BAL fluid [134].  Although the production of many chemokines has not been 
examined, CCL11 (Eotaxin) [133] and CCL3 [126] were not detected in human BAL fluid. 
With the emergence of HIV/M. tuberculosis co-infection, a number of studies have 
addressed the ability of M. tuberculosis to enhance HIV infection. PBMC from HIV+ patients 
with tuberculosis produced more HIV than those from patients without tuberculosis, even with 
similar numbers of CD4+ lymphocytes [135].  The increase of CCR5 and CXCR4 (HIV co-
receptors) expression on monocytes in response to M. tuberculosis was hypothesized to result in 
increased productivity of HIV infection. Stimulation of whole blood with M. tuberculosis LAM 
upregulated expression of CCR5 and CXCR4 [136]. In addition, HIV infection reduced 
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 production of CCL3 and CCL5 from PBMC [135], freeing up more receptors for HIV to bind 
and possibly interfering with recruitment of cells to fight infection.   
5.3 Difficulties in studying chemokines and infectious disease  
 The M. tuberculosis infection studies performed on genetically engineered mice suggest 
that redundancy in the chemokine system may be real.  In CCR2-/- mice the number of 
macrophages migrating to the lung after 3 weeks of infection increased significantly compared to 
two weeks post-infection.  At the 3 week time point, a number of chemokines are expressed in 
response to both higher M. tuberculosis burden and expression of inflammatory cytokines.  At 
this time, other chemokines signaling through CCR1 or CCR5 (or other receptors) may stimulate 
the migration of monocytes to the lungs.  In the absence of CCR2 or CCR5, many immune cells 
still migrate to the lungs and form granulomas [62, 63], and data not shown). These results may 
indicate that these receptors are not essential for migration of cells to the lungs or within the 
lungs (e.g., for granuloma formation), or that other signals and interactions with adhesins may be 
more important.  The breadth of the chemokine response induced following M. tuberculosis 
makes it difficult to pinpoint which subset is important at which time during infection. 
 Many cytokines and infectious disease products regulate chemokines.  There is evidence 
that IFN-γ, TNF and M. tuberculosis itself induces expression of chemokines in vitro and in 
vivo.  In models of infection when bacterial burdens are different (such as when comparing 
immunodeficient mice with wild type mice), drawing conclusions about chemokine expression 
can be very difficult. Higher expression of chemokines could be due to increased numbers of M. 
tuberculosis bacilli, instead of resulting from a specific immunodeficiency (for example, in a 
cytokine knockout mouse).  Alternatively, higher chemokine levels could alter the anti-
mycobacterial response, resulting in higher bacterial burdens.   
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  Interpreting differential chemokine expression in M. tuberculosis infection, particularly 
in vivo, is challenging.  Because chemokines act in a gradient, higher chemokine expression does 
not necessarily mean that more cells will migrate in response to that signal.  Too much 
chemokine can saturate a receptor and desensitize the cell to the migration signal.  Specifically 
with studies on chemokines in M. tuberculosis infection, the expression of chemokines is likely 
very different within the granuloma compared to the whole lung, if chemokines participate in the 
formation and maintenance of the granuloma. Indeed, in our studies designed to procure pure 
granulomatous tissues for the analysis of host gene expression using an approach that 
incorporates laser capture microdissection and real-time PCR technology, results showed that the 
relative levels of expression of certain immunologic genes (including chemokines and 
chemokine receptor genes) determined using microdissected tissue-derived RNA may differ 
significantly from that obtained when total lung RNA was used for analysis [137]. These data 
suggest the conventional use of whole infected lungs to study granuloma-specific gene 
expression can yield data that may not genuinely reflect intra-lesional events. In addition, BAL 
fluid as a source of cells or chemokines is unlikely to reflect the site of infection within the 
lungs.  Therefore, such studies need to be interpreted cautiously.  
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6.0 Statement of the problem 
 The goal of this study was to address the hypothesis that TNF influences chemokine 
expression in the lung during tuberculosis, thereby playing a major role in orchestrating 
granuloma formation.  The signals required for the complex process of granuloma formation in 
response to M. tuberculosis infection are not well understood, although this structure is important 
in containing the infection in the tissues. Although tumor necrosis factor–alpha (TNF) is required 
for control of M. tuberculosis, the mechanisms underlying its requirement have not been well 
defined.  In models of chronic or latent tuberculosis, TNF was required for maintenance of 
macrophage activation, granuloma formation and ultimately, control of disease. One mechanism 
of TNF control could be its regulation of chemokine expression.  Chemokines, or chemotactic 
cytokines, are compelling candidates for influencing cell migration and granuloma formation in 
tuberculosis.  As part of our work on TNF and granuloma formation, we characterized 
chemokine expression in the lungs following M. tuberculosis infection and evaluated the 
immune response and granuloma formation in the absence of select groups of chemokines or 
chemokine receptors.  
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 7.0 Chapter 1  TNF-alpha influences chemokine expression of macrophages in vitro and 
CD11b+ cells in vivo during M. tuberculosis infection, affecting cell migration and 
granuloma formation 
This chapter has been submitted to Journal of Immunology.  The chapter in this form is more 
inclusive that the submitted paper and includes additional data that was not shown in the 
submitted paper. 
7.1  Introduction 
 Tuberculosis in immunocompromised hosts elucidated the protective immune responses 
to M. tuberculosis.  In recent years, the use of anti-inflammatory drugs targeting tumor necrosis 
factor alpha (TNF), such as Infliximab (Remicade) and Enbrel (Etanercept), for treatment of 
chronic inflammatory diseases, has highlighted the importance of TNF in controlling M. 
tuberculosis, since there is an increased risk of reactivation tuberculosis in patients treated with 
these drugs [104, 105].  
 TNF has many potential effects within the lungs of an infected individual.  In vitro, TNF 
has been reported to affect apoptosis of infected macrophages [138, 139], secondary signaling to 
macrophages for nitric oxide production [reviewed in [140]], and regulate activity of other 
inflammatory cytokines (such as IL-12) [141].  In vivo, pathology, control of bacterial numbers, 
and chemokine expression (in the liver) have been shown to be affected by TNF [142].  The role 
of TNF within the lungs in chemokine expression following M. tuberculosis infection has not 
been explored.   
Antibody mediated neutralization of TNF in chronically infected mice led to severe 
pathology with the loss of granuloma structure [106].  Bacterial loads in the TNF-neutralized, 
chronically infected mice increased initially, but stabilized at a level below that generally 
considered fatal in C57BL/6 mice.  Nonetheless, TNF-neutralized mice succumbed quickly.  
Granuloma structural deficiencies and uncontrolled infection in mice lacking TNF have been 
reported by our group and others, in both acute and chronic infection [101, 103, 106, 142], 
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 however the mechanisms by which TNF controls granuloma development and maintenance have 
yet to be elucidated.  Studies in the liver of M. smegmatis and M. tuberculosis intravenously 
infected mice showed that gene expression of a subset of chemokines was reduced in TNF 
deficient mice [143], but these studies do not reveal the localized chemokine expression patterns 
in the lungs- the primary site of M. tuberculosis infection and control.   
 We hypothesized that TNF influences macrophage chemokine expression and these 
localized differences in expression lead to changes in granuloma formation.  Our results 
described here demonstrate for the first time that TNF affects chemokine gene and protein 
expression by M. tuberculosis-infected macrophages, both in vivo and in vitro. We also 
demonstrate that during the early phases of acute infection TNF deficient mice have similar 
numbers and types of immune cells migrating to the lungs, indicating that the lack of granuloma 
formation is a result of a migration defect within the lung tissue, rather than a defect in the 
migration of cells to the lungs.  These data support that TNF affects the expression of many 
chemokines at the level of macrophage gene expression, suggesting that differences in localized 
chemokine gradients may result in disorganized cellular infiltrate within the lungs. 
7.2  Materials and Methods 
Animals.  C57BL/6 female mice (Charles River, Rockland, Mass.) and TNFRp55-/- (breeding 
pairs from Dr. Tak Mak, [144] 8-14 weeks old were used in all experiments.  TNFRp55-/- mice 
were bred in an SPF facility at the University of Pittsburgh and transferred to the Biosafety Level 
3 animal facility at 7-8 weeks of age.  All infected mice were maintained in the BSL3 animal 
laboratories and routinely monitored for murine pathogens by means of serological and 
histological examinations.  The University Institutional Animal Care and Use Committee 
approved all animal protocols employed in this study. 
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 Chemicals, antibodies and reagents.  All chemicals were purchased from Sigma Chemical Co. 
(St. Louis, MO.) unless otherwise noted.  Middlebrook 7H9 liquid medium and 7H10 agar were 
obtained from Difco Laboratories (Detroit, MI).  Antibodies used in flow cytometric analyses 
were obtained from Pharmingen (San Diego, CA).  The cell lines, MP6XT-22 (anti-TNF) and 
was obtained from DNAX and used to generate ascites (Harlan Bioproducts, Indianapolis,IN).  
Antibodies were purified endotoxin free from ascites fluid as previously described [106] and 
mice were treated with antibody intravenously every three days (0.5mg/dose) starting 4 months 
post infection.  Control mice received normal rat IgG (Jackson Immunoresearch Laboratories 
Inc.,West Grove, PA) with the same dosing regiment. 
Mycobacteria and infection of mice.  To prepare bacterial stock, M. tuberculosis strain Erdman 
(Trudeau Institute, Saranac Lake, N.Y.) was used to infect mice, and then bacteria were 
harvested from their lungs, expanded in 7H9 liquid medium and stored in aliquots at -80°C.  
Mice were infected via the aerosol route using a nose-only exposure unit (InTox Products, 
Albuquerque, N.M.), and exposed to M. tuberculosis (1 x 107 CFU/ml in the nebulizer chamber) 
for 20 minutes, followed by 5 minutes of air. This resulted in reproducible delivery of 50-100 
viable CFU of M. tuberculosis as described previously [94], which was confirmed by CFU 
determination on the lungs of 2-3 mice 1 day post-infection.   In acute experiments where a 
higher inoculum was used, the concentration of M. tuberculosis in the nebulizer was increased, 
and day 1 CFU were determined in the lungs.  The tissue bacillary load was quantified by plating 
serial dilutions of the lung, liver, and spleen homogenates onto 7H10 agar as described 
previously [30]. 
Bone marrow derived macrophages.  Macrophages were derived from C57Bl/6 bone marrow 
based on adherence.  The mice were euthanized and bone marrow was flushed out of the femur 
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 and tibia bones with DMEM as previously described [82].  The bone marrow suspension was 
washed twice with 2% FBS in PBS and the cells were counted.  2x106 cells were plated on non-
tissue culture treated petri dishes (Labtek) in 25 ml macrophage media (25% L cell supernatant, 
20% FBS, 1% L-glutamine, 1% sodium pyruvate, and 1% nonessential amino acids).  After 4 
days in culture the cells were fed with 10 ml fresh macrophage media.  On day 6 macrophages 
were infected with M. tuberculosis (MOI of 4).  Four hours post infection the supernatant was 
removed, cells were washed and fresh media was added.   
Flow cytometric analysis of lung cells. To determine cellular infiltrate in the lung, at 10-day 
intervals lungs were removed for flow cytometric analysis.  Lungs were subjected to a short 
period (20 minutes) of digestion with 1 mg/ml collagenase A and 25 Units/ml DNAse (both from 
Boehringer Mannheim, Mannheim, Germany) at 37°C.  The suspension was pushed through a 
cell strainer as previously described [63].  Red blood cells were lysed with red blood cell lysis 
buffer (NH4Cl/Tris Solution) and the single cell suspension was counted.  The samples were 
stained with 0.2 µg anti-CD4, anti-CD8, anti-CD69, or 0.15 µg anti-Gr1 and 0.2 µg anti-CD11b 
in FACS buffer (0.1% NaAzide, 0.1% BSA, 20% mouse serum).  Following washes, the cells 
were fixed in 4% PFA for 1 hour and collected on a FACS Caliber (Beckon Dickinson).  
Analysis was performed on Cell Quest software (BD-Pharmingen, San Diego, CA). 
Histopathology.  Tissue samples for histological studies were fixed in 10% normal buffered 
formalin followed by paraffin embedment.  For histopathological studies 5- to 6- µm sections 
were stained with Harris’ hematoxylin and eosin.   
Ex vivo CD11b+ isolation.  To isolate CD11b+ cells from the lungs of C57Bl/6 mice, a 
Magnetic Cell Sorting (MACS) column isolation protocol (Miltenyi Biotech, Auburn, CA) was 
followed.  The lungs were removed, rinsed in T cell media and pushed through a 70µm cell 
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 strainer (Fisher, Pittsburgh, PA) using the end of a 5 ml syringe.  Following red blood cell lysis 
and washing, the cells were labeled with CD11b Microbeads in MACs buffer (2mM EDTA and 
0.5% SDS in PBS) for 15 minutes at 8°C.  The cells were washed with MACS buffer and then 
resuspended in 0.5ml of buffer.  The cells were poured over a 40µm cell strainer and then 
applied to a prewashed MS+ column.  After initial flow through, the column was washed 3 times 
with 0.5ml buffer.  The column was then removed from the magnet and the CD11b+ cells were 
eluted from the column with 1 ml of buffer.  The cells were spun down and resuspended in 1ml 
of TRIZOL and the RNA was isolated. 
RNA Isolation.  RNA was isolated from the lung or cells using the TRIZOL isolation protocol 
with slight modifications.  The lung was homogenized in 3ml (cells were lysed in 1ml TRIZOL/ 
2x106 cells) of TRIZOL reagent and then two chloroform extractions were performed.  
Following an isopropanol precipitation, the RNA was washed with 70% ethanol and treated with 
RNase Inhibitor (Applied Biosystems, Foster City, CA) for 45 minutes.  Following complete 
resuspension of the RNA at 65° C for 15 minutes the RNA was cleaned and DNase digested 
using the Qiagen RNA isolation kit, as directed by the manufacturer (Qiagen Inc., Valencia, 
CA).   
RNA expression of chemokines in lung granulomas isolated by Laser Capture Microdissection   
 
Histologically distinct cell populations were procured for subsequent gene expression analysis in 
a precise and reliable manner using the Laser Capture Microdissection (LCM) [145].   Lung 
tissue for LCM was fixed in 10% normal buffered-formalin for 8 hours at room temperature, 
transferred to 70% ethanol overnight at 4ºC and paraffin-embedded the next day.  Tissue sections 
(8 µm) were de-paraffinized, rehydrated, stained and dehydrated by serially immersion in xylene, 
100% ethanol, 95% ethanol, 70% ethanol, Mayer’s hematoxylin (Sigma, St. Louis, MO), eosin 
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 (Sigma, St. Louis, MO), 70% ethanol, 95% ethanol, 100% ethanol, xylene and then placed in a 
vacuum oven with dessicant for 15 minutes.  Using the Pix-Cell II (Arcturus, Mountain View, 
CA), cells from microscopically visualized granulomas were transferred onto a thermoplastic cap 
via laser beam (30 µm beam at 40mW power).   Four to six tissue sections were used for LCM 
per animal to yield approximately one to two caps full of tissue. RNA extraction was performed 
using Proteinase K and Trizol (Invitrogen, Carlsbad, CA) by methods previously described 
[137].  The RNA pellet was further purified with a RNAse free DNAse kit (Qiagen, Valencia, 
CA) using the manufacturer’s instructions. RNA samples were stored at -80ºC until cDNA 
synthesis. 
Real time RT-PCR.  The RNA was reverse transcribed using Superscript II enzyme, as directed 
by the manufacturer (Invitrogen, Carlsbad, CA).  For Real time RT-PCR we used the 
comparative Ct method [146].  HPRT served as the endogenous control, and uninfected lung or 
macrophages as the calibrator.  Each primer and probe set was tested for efficiency (results 
efficient >97% for all primer/probe sets).  All samples were run in triplicate and with “no reverse 
transcriptase” controls on an ABI Prism Sequence Detector 7700.  Relative gene expression was 
calculated as 2 ^-∆∆Ct, where ∆Ct = Ct (gene of interest)- Ct (endogenous control) and the 
∆∆Ct= ∆Ct (sample) - ∆Ct (calibrator).  Results are expressed as relative gene expression to 
uninfected samples. The primer and probe concentrations were used as suggested by Applied 
Biosystems (Foster City, CA) with the final concentration of each primer at 400nM and probe at 
250nM.  The primers (Gibco BRL, Grand Island, NY) and probes (Applied Biosystems) used in 
this assay were designed using Applied Biosystems Primer Express Software and the sequences 
are in Table 3. 
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 Table 3.  Primers and Probes used in the Taqman Real time RT-PCR assay.   
Primers are probes were designed using the Primer Express Software.  Sequences used for primer and probe 
synthesis are found in the table. 
Gene Forward Primer 
(5’ to 3’) 
Reverse Primer 
(5’ to 3’) 
Taqman Probe (5’ 
6-FAM, 3’ TAMRA 
labeled) 
CXCL9 TGG AGC AGT GTG GAG 
TTC GA 
TCG GCT GGT GCT GAT 
GC 
CCC TAG TGA TAA GGA 
ATG CAC GAT GCT CC 
CXCL10 AGA GCA GCA CTT GGG 
TTC 
ACG GCA GCA CTT GGG 
TTC 
CGG AAG CCT CCC CAT 
CAG CAC C 
CXCL11 GGG CGC TGT CTT TGC 
ATC 
AAG CTT TCT CGA TCT 
CTG CCA T 
CCC CGG GAT GAA AGC 
CGT CAA 
CCL2 CTT CCT CCA CCA CCA 
TGC A 
CCA GCC GGC AAC TGT 
GA 
CCC TGT CAT GCT TCT 
GGG CCT GC 
CCL3 ACC AAG TCT TCT CAG 
CGC CAT 
TTC CGG CTG TAG GAG 
AAG CA 
TGG AGC TGA CAC CCC 
GAC TGC C 
CCL4 CCC GAG CAA CAC CAT 
GAA G 
AGA AGG CAG CCA CGA 
GCA 
TCT GCG TGT CTG CCC 
TCT CTC TCC TC 
CCL5 CTG CAG CCG CCC TCT G GAC TGC AAG ATT GGA 
GCA CTT G 
CTC CCT GCT CGT TTG 
CCT ACC TCT CC 
CCL12 GGA GGA TCA CAA GCA 
GCC AGT 
TCA GCA CAG ATC TCC 
TTA TCC AGT AT 
TCC CCG GGA AGC TGT 
GAT CTT CAG 
HPRT TTA CCT CAC TGC TTT 
CCG GAG 
AAA AGC GGT CTG AGG 
AGG AAG 
TAG CAC CTC CTC CGC C 
TNF TGA TCC GAG ACG TGG 
AA 
ACC GCC TGG AGT TCT 
GGA A 
TGG CAG AAG AGG CAC 
TCC CCC AA 
 
Protein Determination.   
Immunoassay.  The quantity of CXCL9 and CXCL10 in the macrophage culture supernatants 
was determined with the Quantikine mouse CXCL9 and CXCL10 immunoassays (R&D 
Systems, Minneapolis, MN).  These kits were used exactly as suggested by the manufacturer.  
The readout was performed using the Emax precision microplate reader (Molecular Devices, 
Sunnydale, CA). 
SearchLight Proteome Arrays.  To determine the protein concentration of TNF, IL-10, CCL2, 
CCL3, CCL5, CCL12, CXCL2, a multiplex sample testing service was utilized.  Supernatants 
from uninfected and infected macrophages were filter sterilized and sent to Pierce Biotechnology 
(Boston, MA) for quantitative measurement using multiplexed sandwich ELISAs. 
In situ hybridization.   
Cloning.  The pGEM-T Easy Vector System (Promega, Madison, WI) was used to clone CCL5, 
CXCL9, and CXCL10 PCR products.  Primers were designed to amplify CCL5, CXCL9 and 
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 CXCL10 with restriction enzyme sites specific for the pGEM-T vector cloning sites.  These 
primers were used to amplify murine cDNA using the Applied Biosystems Thermocycler.  
Following amplification, the product was purified using QIAquick Nucleotide Removal Kit 
(Qiagen, Valencia, CA).  The ends were digested and the product was ligated to prepared pGEM-
T vectors.  Competent E. coli (JM109) was transformed with the ligation reactions, using the 
suggested protocol (Promega).  Transformed bacteria were selected based on resistance to 
ampicillin and interruption of the LacZ promoter, and the selected colonies were grown up in 
LB+AMP liquid media.  The plasmid DNA was purified from this culture by the Qiagen 
Midiprep protocol (Qiagen).  Following verification of the insert, the plasmids were linearized 
and used to generate probes.     
Probe generation.  Labeled RNA probes were synthesized by in vitro transcription of DNA 
cloned downstream of T7 or SP6 RNA polymerase in the pGEM-T vector using 35S-UTP as 
substrate.  The MAXIscript In vitro Transcription Kit (Ambion, Austin, TX) was used for this 
protocol, with slight modification.  In short, linearized plasmid was incubated with the reaction 
mix (buffer, dATP, dCTP, dGTP 35S-UTP)+ either T7 or SP6 polymerase.  The reaction was 
incubated at 37°C for 3 h, 1µl DNase was added for an additional 20 minutes at 37°C.  
Following a 5 minute incubation at 65°C, the probes were brought up to 50µl and purified using 
the ‘mini Quick Spin RNA Column’ as directed by the manufacturer (Roche, Indianapolis, IN).  
Probes were stored at -80°C. 
Tissue and slide preparation.  Lungs were fixed in 4% paraformaldehyde at 40°C for 5 hours, 
washed in two overnight incubations of PBS followed by treatment in a sucrose gradient and 
then snap frozen and stored at -80°C.  14µm cryosections were cut and the slides were post fixed 
in 4% paraformaldehyde for 20 minutes, dehydrated in an ethanol gradient (70% EtOH 20 
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 minutes, 80% EtOH 5 minutes, then 95% EtOH 5 minutes).  After air drying the slides, antigen 
retrieval was performed in 0.01M sodium citrate with warming in the microwave.  After the 
slides were cooled, the tissues were acetylated twice in 0.25% acetic anhydride- 0.1M 
Triethanolamine solution.  Following treatment in another EtOH dehydration gradient, the slides 
were air dried and ready for hybridization.   
Hybridization and washes.  Tissue was hybridized to the 35S-labelled probes as previously 
described [147].  In short, 5x104 cpm/µl sense or anti sense probe was hybridized to the tissue 
under siliconized coverslips (5x104 cpm/µl sense or anti sense probe in 1x hybridization buffer 
containing 10% dextran sulfate formamide, 0.6M NaCl, yeast tRNA [100µg/ml], and 0.4M DTT) 
overnight at 50°C.  Coverslips were removed and slides were washed in a series of SSC buffers: 
5XSSC+0.1mM DDT 42°C for 30 minutes; 2XSSC/50% formamide+0.1mM DTT 60°C for 20 
minutes; ribowash solution (0.1M Tris, 0.05M EDTA, 0.4M NaCl) 37°C for 10 minutes; 
ribowash solution at 37°C for 10 minutes; ribowash solution+ 6.25U of an RNAse A+T1 mix 
37°C for 30 minutes; ribowash solution 37°C for 10 minutes; 2xSSC 37°C for 10 minutes; 
0.2XSSC 37°C for 10 minutes. Slides were then dehydrated in 0.3M ammonium acetate+ EtOH 
gradient.  After the slides were completely dried, they were dipped in prewarmed radiography 
emulsion (Kodak) and dried.  Slides were wrapped in a dark box for one week.  Development 
was in D19 developer followed by fixation in Rapid Fix.  Slides were counterstained in 
hematoxylin. 
Statistical Analysis.  3-4 mice per group per time point were used for all studies.  Statistical 
analysis was performed on the data utilizing Prism Software for an unpaired t-test.  For bacterial 
numbers and cell numbers, log transformation was performed prior to statistical analysis to 
normalize the data. P values <0.05 were considered significant. 
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 7.3  Results 
Susceptibility to tuberculosis without TNF 
 
 It is well established that mice deficient in TNF have increased susceptibility to M. 
tuberculosis infection [reviewed in [6]].   Following acute low dose aerosol infection, TNFRp55-
/- mice and TNF- neutralized mice (MP6-XT22 treated) had significantly higher bacterial 
burdens than control mice by 18-21 days post infection (Figure 5A and data not shown).  The 
mice succumbed by 28 days post infection.   
 Following TNF neutralization of chronically infected mice, the bacterial burden increased 
by 8 days post antibody treatment (Figure 5B), but was not significantly different until 18 days 
post antibody treatment.  We previously reported that the mean survival time for chronically 
infected TNF-neutralized mice was 44 days, when infection was initiated by intravenous 
infection with moderate doses of M. tuberculosis [106]. However, using low dose inoculum 
delivered via aerosol to set up the chronic infection, neutralization of TNF resulted in faster 
progression of disease with a mean survival time of 22 days after initiation of antibody treatment 
(Figure 5C).  In the following experiments, we analyzed the effects of TNF deficiency in acute 
and chronic models of infection, using aerosol delivery for all studies. 
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Figure 5.  Deficiencies in TNF signaling led to rapid disease progression.   
A.  Serial dilutions of lung homogenates were plated throughout infection to determine the colony forming units.  
Colony forming units of TNFRp55-/- mice (open triangles) were significantly higher than wild type mice (closed 
circles) by day 21 post aerosol infection (**p=0.021). B.  MP6-XT22 treatment of C57BL/6 wild type mice 4 
months post infection led to an increase in bacterial numbers in the lungs (* p=0.04).  MP6XT-22 treated mice: open 
squares, IgG treated mice: closed triangles.  C. MP6XT-22 treatment led to rapid reactivation of disease and mice 
began to succumb to infection only 15 days after anti-TNF Ab treatment.  The mean survival time for MP6XT-22 
treated mice (when treatment began 4 months post aerosol infection) was 22 days.  Each time point represents the 
mean of 4 mice.  The graphs shown are representative of data from 1 of 4 independent experiments. 
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Cell infiltration during acute infection 
 During acute mycobacterial infections TNF deficient mice do not form proper 
granulomas [101-103].  The cell populations migrating into the lungs were assessed by flow 
cytometry. No defects in appearance of T lymphocytes and macrophages in the lungs early after 
infection were observed in TNF deficient mice compared to controls (Figure 7).  By 21 days post 
infection, when bacterial burdens were already significantly higher in TNFRp55-/- mice, the 
number of CD8+ T lymphocytes was reduced and the number of neutrophils was significantly 
higher.  The increased neutrophilic infiltrate was likely a result of the increased mycobacterial 
burden in these mice.  
Histological analysis of the lung infiltrate indicated that although the cells were migrating 
into the lungs, they were not forming an organized granuloma structure, as previously reported 
[[101, 103], and Figure 6].  These data indicate that TNF is not required for migration of cells 
into the lung following infection, but rather may influence migration within the lung.   
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Figure 6.  Lung pathology in M. tuberculosis infected TNFRp55-/- mice and wild type mice. 
Following low dose aerosol infection, mice were sacrificed at indicated time points and a lobe of their lung was 
fixed in 10% formalin and then embedded, sectioned and H & E stained.  TNFRp55-/- mice do have cellular 
migration into the lungs, but the cellular infiltrates are not organized and have higher granulocyte numbers by 20 
days post infection. 
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Figure 7.  Immune cells migrate into the lungs in TNFRp55-/- mice.   
Flow cytometric analysis of the lung was used to quantify the numbers of CD4+ and CD8+ lymphocytes, 
macrophages (CD11b+ Gr1-) and neutrophils (CD11b+ Gr1+) present in the lungs post aerosol infection.  There 
were similar numbers of CD4+ lymphocytes and CD8+ lymphocytes in the lungs up to 16 days post infection.  At 
21 days post infection the number of CD8+ lymphocytes decreased.   The number of macrophages migrating into 
the lungs of the TNFRp55-/- mice was similar to WT mice throughout the length of the experiment.  The number of 
neutrophils increased in the TNFRp55-/- mice when bacterial burdens increased.  Each time point represents 3-4 
mice.  These graphs are representative of 3 independent experiments. 
 
Cell populations in the lung following anti-TNF treatment in chronically infected mice  
 
 The cell populations in the lungs of anti-TNF Ab treated and IgG control mice were not 
significantly different until the bacterial burdens significantly increased in the anti-TNF Ab-
treated mice (Figure 8).  There was variability among the mice during the chronic stage of 
infection (see error bars for day 0 time points, Figure 8), and mice in the TNF-neutralized group 
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 succumbed to reactivation over the course of 10 days, beginning at day 12.  Histological changes 
in the granuloma structure were observed as early as 9 days post anti-TNF Ab treatment 
(representative sections at 12 days shown in Figure 9). By 18 days of antibody treatment all 
surviving anti-TNF treated mice had diffuse cellular infiltrates in their lungs accompanied by 
edema within alveolar spaces.  
 These data indicate that TNF plays either a direct or indirect role in controlling migration 
of immune cells within the lungs and maintaining granuloma structure.  A possible mechanism 
for control of migration of cells is through effects on chemokine expression.   
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Figure 8.  As bacterial burdens increased in MP6XT-22 treated mice, the numbers of cells migrating into the 
lung increased significantly.   
MP6XT22 treatment began 4 months post aerosol infection.  Following the initiation of MP6XT22 treatment, flow 
cytometric analysis of cellular infiltrate to the lungs revealed that as disease progressed the numbers of CD4+ and 
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 CD8+ lymphocytes and macrophages increased, but the numbers of these cells in the IgG treated mice were stable.  
The number of neutrophils in the lungs of MP6 and IgG treated mice did not significantly change after antibody 
treatment began.  Each time point represents 4 mice/group.  This experiment was repeated twice with similar results. 
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Figure 9.  Neutralization of TNF in chronically infected mice leads to severe lung pathology.   
MP6XT-22 treatment of mice led to disorganized cellular infiltration and fluid in the alveolar spaces of the lungs by 
12 days post antibody treatment (middle panel). IgG treated mice (right panel) at day 12 post antibody treatment still 
exhibited organized granuloma formation, with clusters of lymphocytes and macrophages. (100x magnification). 
Sections shown here are representative of 4 mice/ group.  This experiment was repeated with similar results 4 times.    
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 TNF affects chemokine expression in M. tuberculosis infected macrophages 
 Effects of TNF on M. tuberculosis-induced chemokine expression by macrophages were 
first examined in vitro. Bone marrow derived macrophages were infected with M. tuberculosis.  
Following infection the macrophage expression of many inducible C-C and C-X-C chemokines 
increased relative to uninfected macrophages, and mRNA levels peaked between 4 and 12 hours 
post-infection depending on the gene (Figure 10).  Expression of CXCL10, CCL12, CCL2 and 
CCL4 peaked at 4 hours, whereas expression of CXCL9, CXCL11, CCL3, and CCL5 did not 
peak until 12 hours post infection.  Although expression decreased rapidly after 12 hours of 
infection, the levels remained elevated compared to uninfected macrophages.   
These data were generated using a real time RT-PCR assay, which evaluates expression 
on a population basis relative to the chosen calibrator (in this study, uninfected macrophages).  
The value, ∆Ct, or the change in cycle threshold between the endogenous control (HPRT) and 
the gene of interest (a chemokine), allows examination of constitutive expression of chemokines.  
Constitutive expression in macrophages (highest to lowest) was:  
CCL4>CCL12>TNF>CXCL10>CCL2>CCL5>CCL3>CXCL9>CXCL11  
Following M. tuberculosis infection of the macrophages, the relative RNA induction (normalized 
to the HPRT gene and relative to uninfected macrophages) of CCL5 and CXCL9 was highest in 
the panel of chemokines examined, followed by induction of CXCL10 and CCL3.  Relative 
expression of CCL4 (Figure 10) and CCL12 was very low compared to other chemokines.  
Interestingly, these two chemokines also had the highest constitutive expression.  In most cases 
after the reduction in expression after 12 hours, the expression of chemokines remained stable 
between 24 and 48 hours post infection; by 72 hours the macrophages began to die in culture.  
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  In the first set of experiments anti-TNF Ab was added to the cell culture at the time of 
infection. As early as 4 hours post infection, TNF expression was induced (Figure 10). Anti-TNF 
Ab treatment at the time of infection reduced expression of many chemokines (Figure 10), 
indicating that optimal expression of these chemokines was dependent on TNF. Expression of 
some chemokines, such as CCL5, was sustained at a higher level as infection progressed in vitro, 
and in the presence of anti-TNF Ab the expression of CCL5 was reduced 30-70%. CCL2 
expression was reduced by TNF neutralization only at the 4 hr time point (Figure 10). TNF 
neutralization modestly reduced CCL3 expression early in infection, but high levels of CCL3 
mRNA were sustained in the anti-TNF Ab treated, but not control macrophage cultures (Figure 
10). CCL12 also had reduced expression in TNF-neutralized cultures early after infection, but 
then was upregulated in the presence of anti-TNF Ab by 24 hours post infection and back down 
by 48 hours (Figure 10). 
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Figure 10.  Macrophage expression of chemokines is partially dependent on TNF.   
Real time RT-PCR was performed on RNA isolated from macrophages infected with M. tuberculosis at 0, 4, 8, 12, 
24, and 48 hours post infection, with or without addition of anti-TNF Ab. Expression of CXCR3 ligands CXCL9 
and CXCL10, CCR5 ligands CCL3, CCL4 and CCL5, and CCR2 ligands CCL2 and CCL12 were determined. 
Expression levels reported are relative to uninfected macrophages. This experiment was performed twice with 
similar results.   
 In a separate set of experiments, macrophages were infected with M. tuberculosis, and 
anti-TNF Ab was added 4 hours after infection (when unincorporated bacteria were removed 
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 from the culture); expression of chemokines was examined 24 and 48 h after infection. The 
mRNA levels of CCL5, CXCL10, and CXCL11 were still significantly reduced at 24 and 48 
hours post-infection (60%, 58%, and 84%, respectively, Figure 12). The expression of CCL12 
was significantly increased (Figure 12).  Treatment of infected macrophages with isotype control 
antibody did not alter the chemokine expression (Figure 11). Chemokines were still induced 
upon infection in anti-TNF Ab treated cultures, indicating that TNF was only partially 
responsible for controlling the expression of these chemokines.  Addition of recombinant TNF to 
the infected macrophage cultures did not lead to additional chemokine expression (Figure 11), 
suggesting that the TNF induced by M. tuberculosis infection was sufficient to affect expression 
of the chemokine genes.  These data indicated that TNF induced expression of CCL5, CXCL9, 
CXCL10 and CXCL11, but downregulated expression of CCL12. 
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Figure 11.  Control macrophage experiment. 
Treating uninfected bone marrow derived macrophages with anti-TNF Ab or murine rTNF, did not significantly 
change expression of chemokine mRNAs.  Addition of murine rTNF to infected macrophages did not increase 
expression of chemokine mRNAs to levels above those of untreated infected macrophages. 
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Figure 12.  Macrophage expression of chemokines is partially dependent on TNF.   
Real time rt PCR was performed on RNA isolated from macrophages infected with M. tuberculosis for 24 hours.  A.  
Expression of CXCR3 ligands, CXCL10 and CXCL11, was significantly reduced by anti- TNF treatment of 
macrophages.  B.  Expression of CCR2 ligand, CCL2 was unaffected by anti-TNF treatment, but CCL12 expression 
increased.  C.  Expression of CCR5 ligand, CCL5 was also significantly reduced following anti-TNF treatment.  D.  
Proteins were isolated from the supernatants of macrophages infected for 48 hours to look at protein expression 
following anti-TNF treatment of macrophages.  Consistent with RNA results, CCL5 and CXCL10 expression was 
significantly reduced.  Contrary to RNA results, expression of CCL2 was significantly reduced and expression of 
CCL12 was unaffected.  (Protein expression of CXCL11 was not addressed.) 
 
Chemokine protein production in M. tuberculosis infected macrophages.  
 There are little data regarding post-transcriptional regulation of chemokine expression 
[148, 149]. To confirm the gene expression results, we used two different immunoassays to 
quantify protein production.  Supernatants were collected from uninfected and infected 
macrophages at time 0, 4h, 8h, 12h, 24h and 48 hours post infection (from the cultures used to 
make RNA in Figure 10).  The supernatants were used in the immunoassay for CXCL9 and 
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 CXCL10 in our laboratory, and used for multiplex sample testing to quantify CCL2, CCL3, 
CCL5, CCL12, CXCL8 and TNF. 
 Uninfected macrophages do make small quantities of chemokines in cell culture. 
Constitutive protein expression from highest to lowest was:  
CCL2>CCL12>CCL3>CXCL10>CXCL8>CCL5>TNF>CXCL9. 
 Many of the chemokines examined had reduced levels of protein present in the supernatant in 
the presence of anti-TNF Ab.  The protein levels, especially in the wild type mice, either 
increased throughout the time course (e.g., CCL5) or increased during the first 12 hours of 
infection and then stabilized (Figure 13).  Expression of CXCL9 was reduced 30-70% in the 
presence of anti-TNF Ab compared to control macrophages, depending on the time point.  
Expression of CXCL10 was reduced 20-30%, CCL5 was reduced 50-90%, CCL3 was reduced 
10-90%, and CXCL8 was reduced 25%-70% (data not shown).  Expression of CCL2 and CCL12 
(data not shown) followed a similar pattern where in the presence of anti-TNF Ab, expression 
was reduced initially, then increased, but by 48 hours post infection there was clearly a reduction 
in the amount of protein present. 
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Figure 13.  Chemokine protein expression in M. tuberculosis infected macrophages was affected by anti-TNF 
Ab treatment.  
Supernatants from macrophages cultures infected for 0, 4, 8, 12, 24 and 48 hours were collected to quantitate protein 
expression following anti-TNF Ab treatment (or no treatment) of macrophages. Supernatants are from the cultures 
used for RNA preparations in Figure 10.  ELISAs were performed for CXCL9 and CXCL10, while protein 
concentrations for the other chemokines and TNF were determined by multiplex protein array.  This experiment was 
performed twice with similar results.   
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  Protein analysis of supernatants from cultures where anti-TNF Ab was added at 4 hours 
post infection confirmed the macrophage mRNA data in that CCL2, CCL5, CCL12, CXCL9, and 
CXCL10 were induced by M. tuberculosis infection, and that CXCL9, CXCL10 and CCL5 were 
downregulated in the presence of anti-TNF Ab (Figure 12).  On the other hand, although there 
was no difference in the expression of CCL2 mRNA in anti-TNF-treated macrophages, there was 
a significant reduction in the amount of the protein (p=0.011).   
Chemokine expression in the whole lung of M. tuberculosis infected mice. 
 Based on the results from the macrophages and the findings in the spleen and liver of 
infected mice from a published study [150], we addressed the expression of chemokines in the 
whole infected lung by both RNase protection assay and real time RT-PCR.  We expected to 
observe differences similar to our findings in the in vitro macrophage experiments, but following 
low dose aerosol infection, the induction of chemokines over uninfected lung was not detectable 
until 10-12 day post infection.   
 In anti-TNF Ab-treated mice, lower expression of a number of chemokines in the lungs 
was observed at the early times post infection using RNase protection assay and real time RT-
PCR, especially at day 9 post infection, but these differences, although consistent, were not 
significant (Figure 14).  By 15 days post infection the TNFRp55-/- or MP6-treated mice had 
significantly higher expression (compared to their controls) of CCL3, CCL4, CCL5, CXCL9 and 
CXCL10, but significantly less CCL12.   
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Figure 14.  Chemokine RNA expression in the whole lung of TNFRp55-/- mice and wild type mice after M. 
tuberculosis infection. 
Real time rtPCR was used to examine mRNA expression of chemokines in the whole lungs of mice after aerosol M. 
tuberculosis infection.   Relative units represents a measure of the RNA relative to the endogenous control, HPRT, 
and the calibrated sample of uninfected lung.  Expression above uninfected, or constitutive levels would be >1.  
Levels are not detected >1 until 9 or 10 days post infection. 
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 We have observed repeatedly that increases in chemokine expression in the lungs 
correlate with increases in bacterial burden; since TNF-deficient mice have higher bacterial 
burdens than control mice by 10-12 days post-infection, differences in chemokine expression at 
these later time points were more likely due to bacterial numbers than to direct effects of TNF on 
gene expression. Therefore, focusing on early time points before bacterial burdens are different 
was essential in deciphering differences in chemokine expression due the absence of TNF 
independently of the effects of increased bacterial numbers.  Most likely, chemokine induction 
was not detectable early after infection because the aerosol infection model used delivers 50-100 
CFU, and only a small percentage of macrophages are infected.  There is very little time between 
the detectable induction of expression in the whole lung and increasing bacterial growth in the 
TNF-deficient mice, complicating analysis of the role of TNF in control of chemokine 
expression.   
 In the chronic model of tuberculosis, TNF neutralization also resulted in increased 
bacterial burden in the mice relatively early after antibody treatment (within 12 days). When 
focusing on chemokine expression at early time points post-antibody treatment, using real time 
RT- PCR and RNase protection assay, there were no significant differences in the chemokine 
levels between anti-TNF Ab-treated and control mice; as before, chemokine expression increased 
in parallel with bacterial burden (Figure 15).  It is important to note that granuloma 
disorganization was observed in the lungs of TNF-neutralized mice prior to bacterial numbers 
increasing, indicating that early time points were important for differentiating the effects of TNF 
from the effects of increased bacterial burden.  In addition the increasing bacterial burden in the 
TNF deficient mice may result in higher numbers of cells migrating to the lungs in response to 
the inflammatory stimulus, complicating the analysis.  (We attempted to control for bacterial 
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 growth during chronic infection in mice by treating mice with pyrazinamide in conjunction with 
the anti-TNF or IgG treatment- these data represented in APPENDIX B). 
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Figure 15.  Chemokine expression in the lungs of chronically infected mice.   
RNase protection assay was performed on pulmonary RNA isolated from whole lung.  Expression is relative to the 
housekeeping gene L32.  Mice were either treated with anti-TNF Ab (MP6- solid lines) or IgG (perforated lines).    
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 Relative Chemokine Expression of Lung Granuloma by Laser Capture Microdissection. 
The local nature of the immune response to M. tuberculosis, as characterized by a 
granuloma, suggests that gene expression measured in whole lung tissue might not accurately 
reflect the relevant gene expression within the granuloma [137]. For this reason, chemokine 
expression was measured from RNA obtained specifically from granulomatous tissue procured 
by LCM.  Lung sections from early time points after MP6 or IgG treatment were chosen to 
assess the effects of TNF neutralization during a time where bacterial numbers remained similar 
in both groups.  Relative expression of CXCL9, CXCL10 and CCL5 was measured by real-time 
RT-PCR at 0, 4 and 6 days post antibody treatment (Table 4). No significant differences in 
CXCL9, CXCL10 or CCL5 expression were detected between MP6 treated and control groups of 
mice.  The variability within the groups was very high, indicating that the disease state or 
bacterial replication at the level of the granuloma varied widely within an individual mouse and 
between mice in chronic infection. 
Table 4.  Gene Expression by Laser Capture Microscopy  (LCM) in granulomas isolated through Laser 
Capture Microscopy.   
Granulomas were procured from fixed, embedded tissue and RNA was isolated to examine RNA expression of 
CXCL9, CXCL10 and CCL5 through real time RT-PCR.  The values in the table represent relative units of 
expression.  Each sample’s analysis included comparing the expression of the chemokine to the expression of the 
endogenous control (HPRT) and comparing the expression relative to the calibrator (in this case uninfected lung).  
Tissue sections from 4 mice per time point were used to prepare RNA. 
 Day 0 Day 4 Day 6 
  IgG MP6 IgG MP6 
CXCL9 498.8 ± 276.8 333.7 ± 71.9 287.4 ± 122.1 249.4 ± 119.2 258.0 ± 300.9 
CXCL10 85.6 ± 46.0 52.7 ± 32.2 41.3 ± 28.0 36.0 ± 22.5 49.3 ± 44.2 
CCL5 5.0 ± 5.6 5.1 ± 2.8 2.9 ± 1.6 4.3 ±1.4 3.9 ± 1.5 
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 Ex vivo macrophage isolation 
 
 Macrophages are a major reservoir for M. tuberculosis, and play a key role in 
orchestrating granuloma formation. Due to the low level of macrophage infection early after 
aerosol infection, gene expression of infected macrophages may have been diluted in the whole 
lung gene expression analysis.  A more sensitive technique for assessing the effect of TNF on 
macrophage chemokine expression in vivo was needed.  We enriched for macrophages by 
isolating CD11b+ cells from the lungs of acutely infected TNFRp55-/- and WT mice at various 
time points after low dose (50-100 CFU) aerosol infection.  RNA was isolated from the CD11b+ 
population and real time RT-PCR was performed.  At day 10 post infection, the CD11b+ 
population of cells was 50% F4/80+ and 46% Gr1+ following MACs column isolation, 
indicating that this technique purified both macrophages and neutrophils from the lungs (Table 
5). Using this method, induction of chemokines in CD11b+ cells was still difficult to detect prior 
to 9 days post infection; at this time point there was reduced relative expression of chemokines in 
the TNF deficient mice compared to wild type, but the expression was very low (Figure 16).  Just 
three days later (day 12) chemokine expression rose dramatically and the TNF deficient mice had 
higher expression of CCL5 and CCL12 chemokines (Figure 16).   
Table 5.  MACs column isolation of CD11b+ cells.   
Flow cytometric analysis results from the MACs column isolation.  These data represent the results of one sample 
from 3 pooled mice. 
 
 CD3+ B220+ F4/80+ Gr1+ 
- selection 48% 34% 3% 15% 
+ selection 1% 3% 50% 46% 
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Figure 16.  Chemokine expression in CD11b+ cells isolated from low dose infection of TNFR and WT mice.   
A.  At Day 9 chemokine expression was reduced in TNFR-/- mice in many of the chemokines tested.  B.  At day 12 
expression of the chemokines was more highly induced.  Each bar represents the combined sample of 3 mice.  This 
experiment was repeated 3 times with similar results. 
  
When we increased our aerosol dose 20-fold to increase the number of macrophages 
initially infected in the lungs, we detected induction of chemokines in the macrophage 
population as early as 4 days post infection.  There were differences between TNFRp55-/- and 
wild type mice in the expression of CXCL9, CXCL10, CCL3, CCL4, CCL5 and CCL12 (Figure 
17).  By 7 days post infection the bacterial burdens in the TNFRp55-/- mice were significantly 
higher at this dose (Figure 17). There were still reduced levels of expression of CXCL9, 
CXCL10 and CCL4, and but now increased expression of CCL5 and CCL12 in TNFRp55-/- 
mice compared to wild type mice (Figure 17). By day 10 the expression was 10-fold higher than 
at day 7, and the differences between the mouse strains were no longer observed (Figure 17).   
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Figure 17.  RNA expression of CCR5 ligands and CXCR3 ligands is transiently reduced in CD11b+ cells of 
TNFRp55-/- mice infected with a high dose of M. tuberculosis. 
Ex vivo isolation of CD11b+ cells was performed on the lungs of TNFRp55-/- mice and wild type mice following 
high dose (300 CFU) aerosol M. tuberculosis infection.  Real time RT-PCR performed on the RNA from those cells 
revealed that chemokine expression was transiently reduced in the lungs of the TNFRp55-/- mice compared to wild 
type mice.  By day 7 post infection when bacterial burdens were higher in TNFRp55-/- mice reduced levels of 
expression were still observed.  CD11b+ cells from 4-5 mice per time point were pooled to prepare RNA. Relative 
Units is used to represent the induction of chemokine expression compared to uninfected CD11b+ cells isolated 
from the lung (represented by line). 
 
To follow the effect of TNF neutralization at the level of macrophages in vivo in the 
chronic model of tuberculosis, CD11b+ cells were isolated ex vivo from the lungs of M. 
tuberculosis chronically infected mice (treated with IgG or anti-TNF Ab) and real time RT-PCR 
was performed on isolated RNA. The expression of CCL3, CCL4, CCL5, CXCL9, and CXCL10 
were transiently reduced in CD11b+ cells isolated from chronically infected MP6 treated mice 
(Figure 18).  The expression of these genes increased as bacterial burdens increased and by 12 
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 days post infection, when the bacterial burdens in MP6 treated mice were substantially higher 
than in IgG-treated mice, chemokine mRNA levels were higher than in control mice.   
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Figure 18.  In chronically infected, MP6XT22 treated mice, chemokine RNA expression was transiently 
reduced in CD11b+ cells isolated ex vivo from the lungs.   
MP6XT22 treatment of chronically infected mice led to transient reductions in the levels of many chemokines 
compared to IgG treatment. Relative Units in panel B are relative to day 0 of antibody treatment  (represented as 
dashed line). CD11b+ cells from 4-5 mice per time point were pooled to prepare RNA.  This experiment was 
repeated and similar results were obtained.   
   
In situ hybridization 
 To obtain additional information on effects of TNF on the localized chemokine 
expression in the lungs early in infection, in situ hybridization (ISH) was performed to visualize 
expression of CXCL9 and CXCL10 mRNAs.   
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Figure 19.  Sense and anti-sense in situ hybridizations to detect CXCL9, CXCL10 and CCL5 in lung tissue 
infected with M. tuberculosis.  
In situ hybridization was performed using 35S-labelled sense and anti-sense riboprobes.  Exposures were for 7 days 
in all cases. The images on the left and in the middle were photographed at 20X.  The images on the right were 
photographed at 60x. 
 
An algorithm was designed to accurately assess two aspects of this study.  First the 
number and size of the cellular infiltrates was studied.  Second, the location and quantity of gene 
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 expression with respect to pathology within the lung was evaluated (Table 6).  Single cells or 
non-clustered cells (<20 cells together) that expressed the gene of interest were classified as 
Category 1.  Infiltrating clusters of cells were classified as Category 2 or Category 3, on the basis 
of histology and regardless of gene expression.  Category 2 infiltrates were clusters or infiltrates 
of 20-100 cells, whereas Category 3 infiltrates were defined as clusters of >100 cells.  After 
classifying the infiltrates, the ISH signal for a gene was analyzed in each infiltrate.  If no signal 
was detected, the infiltrate was designated -.  If <50% of the cells within a cellular aggregation 
were positive for expression, the infiltrate was designated +, but if >50% of the cells within a 
cellular cluster were signaling for expression, the infiltrate was considered ++.  Therefore each 
category 2 or 3 infiltrate could be either -, +, or ++.   
Table 6.  Algorithm used for ISH analysis.   
Twenty 20X fields were counted for all analyses.  All cellular infiltrates were counted and classified into a category 
based on their size.  In addition, all signals for CXCL9 and CXCL10 were also counted and classified based on the 
cellular infiltrate expressing them.   
Category ISH signal Description 
1 - Individual cells or a group of <20 cells negative for gene expression (normal tissue) 
1 + Individual cells or a group of <20 cells positive for gene expression 
2 - Clusters of 20-100 cells, negative for gene expression 
2 + Clusters of 20-100 cells, <50% of cells positive for gene expression 
2 ++ Clusters of 20-100 cells, >50% of cells positive for gene expression 
3 - Clusters of >100 cells, negative for gene expression 
3 + Clusters of >100 cells, <50% of cells positive for gene expression 
3 ++ Clusters of >100 cells, >50% of cells positive for gene expression 
 
 The number of category 1 areas expressing CXCL9 or CXCL10 was counted in twenty 
20X fields.  Category 1 (normal tissue) expression of CXCL10 was detected as early as 3 days 
post infection, and the expression increased gradually as infection progressed.  By 12 days post 
infection the number of category 1 areas expressing CXCL10 (in the 20 fields counted) increased 
to an average of 8 (+2) in the IgG treated mice and 4 (+1) in the anti-TNF Ab treated mice (per 
20 fields).  Expression of CXCL9 was not detected until day 6 but at this time point it was not 
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 detected in all mice.  By 12 days post infection the number of category 1 areas counted was 
4(+1) in the IgG treated mice and 1(+0.75) in the anti-TNF Ab treated mice in the 20 fields 
counted. 
 The overall number of category 2 and 3 infiltrates was not different between MP6 treated 
and control mice (Figure 20) up to 12 days post infection.  This was not surprising since at these 
early time points the overall number of cells migrating into the lungs was not significantly 
affected by anti-TNF Ab treatment (Figure 7), and this is prior to true granuloma formation.   
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Figure 20.  The number of cellular infiltrates, whether classified as category 2 or 3, was not different between 
anti-TNF Ab treated and IgG treated mice. 
The number of CXCL9 Category 3++ clusters was significantly lower in the anti-TNF Ab 
treated mice by 12 days post infection, but there were no differences in the number of CXCL9 
Category 2+/++ clusters (Figure 21).  CXCL10 gene expression followed a different pattern: 
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 there were significantly fewer CXCL10 Category 2+ clusters in MP6-treated mice, but no 
differences in the number of CXCL10 Category 3+/++ clusters (Figure 21).  These data confirm 
that TNF neutralization affects the expression of a subset of chemokines in the lung, and that 
effects on timing of chemokine expression may be important in granuloma formation.    
Expression of CCL5 was addressed in the tissue of MP6 and IgG treated through in situ 
hybridization, but the analysis was more complicated than analysis of CXCL9 and CXCL10.  
Due to higher background expression of CCL5 it was near impossible to apply the algorithm to 
CCL5 expression.  There was specific expression within the inflammatory cellular infiltrates, but 
there is also evidence of  many endothelial and epithelial cells expressing the CCL5 mRNAs. 
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Figure 21.  Expression of CXCL9 and CXCL10 are reduced in MP6XT-22 treated mice during acute aerosol  
In situ hybridizations were performed on fixed frozen sections of lung tissue.  Expression of CXCL10 was reduced 
in infiltrates of intermediate size (Category 2) in MP6XT-22 treated mice.  Expression of CXCL9 was reduced in 
larger category 3, infiltrates in the MP6XT-22 treated mice compared to the wild type mice.  Each panel represents 
an example of the categorization used in the algorithm, where category 1 + cells were either single positive cells or a 
cluster of less than <20 cells that were positive.  Category 2 infiltrates were clusters of cells with 20-100 cells 
contained within the cluster.  If <50% of the cells were positive in the cluster than the infiltrate was classified as 2+, 
If > 50% of the cells in the infiltrate were positive the infiltrates was classified as 2++.  Category 3 infiltrates were 
classified as clusters of >100 cells.  Again, percent % cells was used to classify the infiltrates as -, +, or ++.  20, 20X 
fields were counted for the analysis.       
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 7.4  Discussion 
 TNF is required for granuloma formation and the absence of TNF affects the expression 
of many inducible chemokines in the acute and chronic models of tuberculosis.  In the absence of 
TNF, the cell-mediated immune response fails to control infection and the bacterial burden 
increases.  Interestingly, in the chronic model of infection, the mice succumb to infection before 
the bacterial burdens rise to moribund levels, indicating that lung pathology is presumably 
leading to a decrease in lung function and death [106].  Deciphering the difference between the 
influences of TNF and bacterial burden on chemokine expression, in a model where TNF affects 
bacterial burden, was technically challenging.  Focusing attention at early time points in the 
experimental models allowed us to diminish the impact of higher bacterial burdens in TNF 
deficient mice.  In addition, we focused on macrophage chemokine expression since this cell is a 
major M. tuberculosis reservoir and is responsive to TNF.  This enabled detection of the effects 
of anti-TNF Ab on chemokine expression prior to changes in pathology, granuloma formation, 
and increased bacterial burden.  Following increased bacterial burdens, the chemokine gradients 
were even more dramatically altered.  The initial changes in chemokine expression may lead to a 
cascade of inappropriate cellular communication, impaired cell migration within the lung, and 
loss of cell mediated immune response.     
 Control of cell migration is a complex process involving not only chemokines and 
receptors, but also adhesion molecules.  The complexity of this process has been illustrated in 
this study.  We also examined expression of adhesion molecules, using gene expression filter 
arrays (GEArray Q Series SuperArray Bioscience Corporation), but no striking differences were 
observed after anti-TNF Ab treatment (APPENDIX C).  Clearly changes in pathology are 
compounded by the other roles that TNF plays in control of M. tuberculosis infection and the 
effects on chemokine expression are probably not solely responsible for the severe pathology 
77 
 observed in TNF-deficient mice.  Studies on low dose aerosol M. tuberculosis infection in CCR2 
and CCR5 chemokine receptor transgenic knockout mice [[63] and Section 9.3 Results.], and in 
vivo models of CXCL9 and CXCL10 neutralization [[72] and Section 8.3 Results.] have 
revealed some differences in cell migration.  But even in these models, the pathology does not 
mirror the destructive pathology observed in the absence of TNF, where signaling by some of the 
same chemokines that were affected by TNF neutralization is diminished.  CCR2-/- mice have 
fewer macrophages throughout infection, but have sufficient numbers to control low dose 
infection, although the mice are quite susceptible to high dose infection [62, 63], see Section 
10.0.  CCR5-/- mice had a greater lymphocytic infiltrate in their lungs, but controlled infection 
(See Section 9.0).  CXCL10-/- and mice treated with both anti-CXCL9 and anti-CXCL10 
antibodies controlled infection with no apparent lymphocyte migration deficiencies (See Section 
8.0) to the lung but a slight delay in lymphocyte migration to the lymph nodes.  
 A recently published study provided data that anti-CXCL9 Ab treatment in M. 
tuberculosis infected mice did not affect control of infection, but the mice had smaller, although 
still organized, granulomas [72]. These authors suggested that CXCL9 was produced by 
neutrophils and played a key role in granuloma formation.  However, the differences we 
observed in pathology and granuloma formation in TNF-deficient mice was not reflected in the 
anti-CXCL9 Ab treated mice.  Therefore, TNF-mediated control of CXCL9 expression may be 
only one factor in the influence this cytokine has on granuloma formation.  
 Our studies on whole lung chemokine RNA expression consistently revealed differences 
in gene expression at early time points post infection and after antibody treatment when 
comparing control and TNF deficient mice.  Although these differences were consistent (in 3 
experiments), they were not significant.  The laser capture microscopy technique was employed 
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 to examine more localized gene expression patterns in granulomas.  To isolate enough RNA 
from fixed, embedded tissue to perform real time RT PCR on the LCM samples, multiple 
granulomas had to be isolated from each mouse.  Although the granulomas isolated were from 
the same lobe of the lung, there was still high variability among mice and probably between 
granulomas, since granuloma size and the number of bacteria in each granuloma can be variable.  
Although the LCM data revealed that the chemokine expression was higher within the 
granuloma compared to the whole lung, the pattern of expression was similar to whole lung 
chemokine expression.   
 We next focused our in vivo studies on the CD11b+ population of cells, enriching for 
macrophages.  The technique used removed epithelial cells and lymphocytes from the lung 
homogenates, but the neutrophils (which are CD11b+) were not removed.  We have focused on 
the macrophages, since direct effects of TNF on chemokine production by this population was 
observed in vitro.  However, TNF may also affect chemokine production by neutrophils.  The 
number of neutrophils at early time points post infection and after antibody treatment in 
chronically infected mice was similar to the number of macrophages present in the lungs [[63], 
Figure 7 and 7]. There were 3-5x104 macrophages and 3-5x104 neutrophils 6 days post infection 
and 4x105 of each cell type at 4 days after initiation of antibody treatment in the chronic model. 
 Recently, there has been published evidence of TNF affecting chemokine levels in the 
liver during intravenous M. smegmatis and M. tuberculosis infection [142, 143].  Our study has 
gone beyond these by focusing on the localized chemokine expression in the lungs following 
aerosol infection, and by addressing chemokines that have not previously been studied.  We also 
carefully controlled for the confounding effects of bacterial numbers on chemokine expression 
by studying very early time points in the infection or neutralization.  We demonstrated that the 
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 chemokine deficiency in the absence of TNF was at the macrophage level, using in vivo and in 
vitro studies.  The macrophage likely plays a key role in granuloma formation as an initial site of 
infection, a reservoir for M. tuberculosis, and a potent producer of both TNF and chemokines. 
 The chemokines affected by TNF are known to influence the migration of cell types 
found within the lung during M. tuberculosis infection.  CCL5, produced in the lung and by 
macrophages at high levels, induces migration of T lymphocytes, monocytes, and immature 
dendritic cells through CCR1 and CCR5.  Disruption in the CCL5 gradient, seen in TNF 
deficient mice, likely affects the migration of these cells within the lung.  T lymphocyte 
migration in the lungs could also be affected by the reduction in CXCL9, CXCL10, CCL3 and 
CCL4.  Monocyte and macrophage migration may be affected by similar chemokines including 
CCL3 and CCL4 through CCR5, and CCL2 and CCL12 through CCR2.  The increased 
expression of these chemokines following increased bacterial load also likely leads to increased 
cell migration to the lungs.  Therefore, we propose that the initial reduction in chemokines in the 
absence of TNF leads to localized changes in the gradients, decreased cell responsiveness and 
disorganized cellular infiltrate.  As a result the cells do not interact with each other in a 
coordinated manner, thus reducing the cell mediated response [106].  The reduced cell mediated 
response leads to increased bacterial burden, increased chemokine expression and an increase in 
cells migrating into the lungs, including neutrophils.   
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Table 7.  Summary of the effects of anti-TNF Ab on the expression chemokines in M. tuberculosis infected  
macrophages. 
A down arrow (↓) indicates that expression was reduced in the presence of anti-TNF Ab (when added at the time of 
infection).   The symbol (←→) indicates that there was no difference in the expression of this gene.  ND= not 
determined. *When anti-TNF Ab was administered 4 hours after infection, expression of CCL12 increased. 
CHEMOKINE RNA PROTEIN
CXCL9  (CXCR3 ligand) ↓ ↓ 
CXCL10  (CXCR3 ligand) ↓ ↓ 
CXCL11  (CXCR3 ligand) ↓ ND 
CCL3  (CCR5 ligand) ↑ ↓ 
CCL4  (CCR5 ligand) ←→ ND 
CCL5  (CCR5 ligand) ↓ ↓ 
CCL2 (CCR2 ligand) ←→ ↓ 
CCL12*  (CCR2 ligand) ↓ ↓↑ 
 
 The chemokine expression studies performed in vitro advance our understanding of the 
role of TNF in chemokine expression and in post-transcriptional regulation of chemokines.   The 
RNA analysis serves as a snapshot of the RNA at that moment in the cell, whereas collecting 
supernatant from cell culture was a representation of the accumulated proteins in the media. 
Gene expression of most chemokines tested diminished by 48 hours post infection (except 
CCL5); this may indicate that there was a negative feedback loop for gene expression. CCL3 
expression was interesting because although mRNA expression peaked at a similar point in the 
anti-TNF Ab treated and control macrophages, the mRNA levels remained higher in the TNF-
neutralized cultures.  However, the protein level peaked at a lower point, and was reduced in the 
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 TNF-neutralized cultures. The anti-TNF Ab treated macrophages may continue to express the 
gene in these cultures because the protein has not accumulated to a level to turn down 
transcription.  In addition the expression of CCL2 was only reduced very early after infection in 
the presence of anti-TNF Ab, but the protein expression was reduced as late as 48 hours post 
infection.  This suggests that CCL2 and CCL3 post-transcriptional regulation may be affected by 
TNF.  
 The in situ hybridization analysis of CXCL9 and CXCL10 expression highlighted the 
extensive variability between different stages of cellular infiltrates, granuloma formation, and 
their chemokine expression.  First, analyzing the number and size of the infiltrates confirmed that 
at early time points, the cellular infiltration in the lungs was not different in the anti-TNF Ab 
treated mice compared to control mice.  As infection progressed, the control mice developed 
organized granulomas, while the TNF-deficient mice did not.  Early patterns of chemokine 
expression presumably affect this organization of the cellular infiltrate.  The size of the 
collection of cellular infiltrate in the lungs can reasonably be attributed to the time of formation: 
as the infiltrate grows and collects more cells, the granuloma forms.  Expression of CXCL10 in 
smaller (early) infiltrates (Category 2) was affected by TNF, but CXCL9 expression was only 
influenced by TNF in larger infiltrates (Category 3). This may suggest a differential timing of 
chemokine expression in granuloma formation, or that expression of these chemokines is 
sensitive to different levels of TNF. Alternatively, in the larger infiltrates, there are more cellular 
interactions, and possibly more cytokines to signal CXCL10 expression, overcoming a 
deficiency in TNF. Comparing this to our findings in the macrophages, it was similarly observed 
that CXCL9 was more dramatically affected by the anti-TNF Ab treatment than was CXCL10. 
The kinetics of chemokine expression is clearly complex in the lungs, and the dynamics of 
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 granuloma formation may depend on TNF signaling expression of different chemokines at 
specific times.   
 In summary, this in depth study of localized chemokine expression patterns during acute 
and chronic M. tuberculosis infection presents evidence for TNF playing a direct role in 
chemokine expression and granuloma formation.  We demonstrated that macrophages in vitro 
and CD11b+ cells in vivo, are partially dependent on TNF for expression of many inducible 
chemokines following M. tuberculosis infection. Our findings are relevant to understanding the 
immune response and granuloma formation during aerosol M. tuberculosis infection, and will 
contribute to an appreciation of the potential effects of anti-inflammatory or anti-chemokine 
therapies on infections.   
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 8.0 Chapter 2  CXCL9 and CXCL10 are not required for granuloma formation and control 
of M. tuberculosis infection 
8.1 Introduction 
 A Th1 cell mediated immune response is required for control of M. tuberculosis.  Th1 
associated responses include both CD4 and CD8 lymphocytes and expression of inflammatory 
cytokines such as IL-12, TNF, IFNγ, and IL-1.  The migration of T lymphocytes to the lungs 
during M. tuberculosis infection begins about one week post infection and as bacterial burdens 
increase, the numbers of T lymphocytes migrating to the lungs also increases in a similar pattern.  
The signals required for T lymphocyte migration to the lungs have been studied to a limited 
degree.  Presumably the cells migrate through a cascade of events including rolling, adherence, 
transmigration and response to chemotactic gradients.  
It has been reported that CXCR3, a chemokine receptor, is expressed on Th1 
lymphocytes, circulating CD4 and CD8 lymphocytes, NK cells, plasmacytoid and myeloid 
dendritic cells and leukemic B cells.  This receptor is more promiscuous than initially thought, 
but the highest expression appears to be on Th1 lymphocytes.  The ligands for CXCR3 in the 
mouse include CXCL9 (Mig), CXCL10 (IP10), CXCL11 (ITAC) and CCL21 (SLC) [151].  The 
CXCR3 ligands were originally described as IFNγ-inducible proteins, but other signals, such as 
LPS or high antigenic stimulation, have also been shown to induce expression of these 
chemokines [119].  We observed induced expression of CXC chemokines, CXCL9, CXCL10, 
CXCL11, in bone marrow derived macrophages following M. tuberculosis infection (Figure 10 
and 10).  The expression of CXCL9 and CXCL10 increased in the lungs following aerosol M. 
tuberculosis infection.  Until recently it was believed that CXCR3 was the only receptor for 
CXCL10, but there is new evidence of a receptor for CXCL10 on epithelial cells and possibly 
endothelial cells which may induce antiangiogenic properties [152].  The expression level of 
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 CXCL10 appears to correlate with T lymphocyte infiltration during Th1 inflammatory responses, 
such as multiple sclerosis [153] and inflammatory bowel disease (unpublished, Grimm, MC, St 
George Clinical School, University of New South Wales). 
Although CXCL9, 10 and 11 share a common receptor, there is some evidence that their 
functions may not be redundant [151].  Transgenic knockout models and neutralizing antibody 
for CXCL9 and CXCL10 have been utilized to study lymphocyte migration and effector function 
in various infectious disease models.  Studies in a murine viral hepatitis model show that anti-
CXCL10 treatment led to increased mortality and delayed viral clearance during the chronic 
stage of infection [154].  On the other hand, treatment with anti-CXCL9 antibody did not lead to 
a change in the course of disease.  These data indicate that in vivo the biological function of 
CXCL9 and CXCL10 may be different.  Treating Toxoplasma gondii infected mice with anti-
CXCL10 antibody increased susceptibility [155] with a greater than 1000 fold increase in 
parasite burden.  In addition CXCL10-/- mice infected with mouse hepatitis virus were unable to 
control viral replication in the brain.  These mice exhibited decreased antigen specific 
lymphocyte migration to the brain and decreased IFNγ responses compared to wild type 
littermates [154]. However, no significant differences were found in mortality in CXCL9-/- mice 
infected with Listeria monocytogenes, Salmonella typhimurium, Francisella tularensis, M. 
avium, T. gondii, vaccinia virus, ectromelia virus, Herpes Simplex Virus type 1, Histoplasma 
capsulatum, or Cryptococcus neoformans [120].  The CXCL9-/- mice infected with F. tularensis 
did have lower antibody responses than control mice, suggesting that CXCL9 may play a role in 
the T lymphocyte/APC/B lymphocyte interaction [120].  
The available data support that the primary role of CXCR3 and its ligands is in 
recruitment of effector T lymphocytes, especially Th1 subsets during inflammatory responses.  
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 Given that M. tuberculosis induces a Th1 response and requires T lymphocytes to migrate to the 
lungs during infection, we hypothesized that CXCL9 and/or CXCL10 may be necessary for 
migration of these cells to the lungs during infection.  To test this hypothesis, we used both a 
knockout model and an antibody neutralization model of infection.  CXCL10-/- mice and their 
CXCL10+/+ littermates, and wild type mice treated with anti-CXCL10 and anti-CXCL9 along 
with control wild type mice were infected with M. tuberculosis via aerosol.  Our results indicated 
that with or without bioactive CXCL9 and CXCL10, mice controlled M. tuberculosis infection, 
formed granulomas and mounted a Th1 response in the lungs.     
8.2 Materials and Methods. 
Mice. 
B6/129 CXCL10-/- mice, their wild type littermates, 129 CXCL10-/- mice and their wild type 
littermates were provided by Andrew Luster (Harvard University School of Medicine).  
Following quarantine these mice were transferred to the BSL3 facility.  Mice were 5-7 months 
old when infected.  C57BL/6 female mice (Charles River, Rockland, MA) (8-14 weeks old) were 
used in chemokine neutralization experiments.  All infected mice were maintained in the BSL3 
animal laboratories and routinely monitored for murine pathogens.  The University Institutional 
Animal Care and Use Committee approved all animal protocols employed in this study.   
Antibodies and chemicals. 
Anti-CXCL10 and anti-CXCL9 were provided by Andrew Luster (Harvard University School of 
Medicine).  These antibodies were administered at 100µg/ i.p. every other day.  Control mice 
received a non-specific rat IgG (Jackson ImmunoLabs). All chemicals were purchased from 
Sigma Chemical Co. (St. Louis, MO.) unless otherwise noted.  Middlebrook 7H9 liquid medium 
and 7H10 agar were obtained from Difco Laboratories (Detroit, MI).  Antibodies used in flow 
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 cytometry were obtained from Pharmingen (San Diego, CA).  
Bacteria and infections. 
To prepare bacterial stock, M. tuberculosis strain Erdman (Trudeau Institute, Saranac Lake, 
N.Y.) was used to infect mice, and then bacteria were harvested from their lungs, expanded in 
7H9 liquid medium and stored in aliquots at -80°C.  Mice were infected via the aerosol route 
using a nose-only exposure unit (InTox Products, Albuquerque, N.M.), and exposed to M. 
tuberculosis (1 x 107 CFU/ml in the nebulizer chamber) for 20 minutes, followed by 5 minutes of 
air. This resulted in reproducible delivery of 50-100 viable CFU of M. tuberculosis, which was 
confirmed by CFU determination on the lungs of 2-3 infected mice 1 day post-infection.   The 
tissue bacillary load was quantified by plating serial dilutions of the lung homogenates in 0.05% 
PBS/Tween 80 onto 7H10 agar.  Total colony forming units were calculated. 
Culture and infection of DCs. 
Dendritic cells are derived from the C57Bl/6 mice bone marrow.  The bone marrow was obtained 
as previously described [82].  After the cells were washed and counted, the cells were 
resuspended in two non-tissue culture treated deep dish petri dishes in 20 ml DC media/ plate 
(10% FBS, 1% sodium pyruvate, 1% L-glutamate) overnight.  The following day, the 
nonadherent and semi-adherent cells were removed from the plates, spun down and cultured at 
1x106 cells/ ml in DC media with 20ng/ml of GM-CSF and 20ng/ml of IL-4 (PeproTech Inc., 
Rocky Hill, NJ) in p75 filter flasks.  On day 3 of culture the cells were fed with and additional 
5ml DC media and 100ng of GM-CSF and IL-4.  Dendritic cells were infected with M. 
tuberculosis on day 6 of culture (MOI 4) in the presence of GM-CSF.  M. tuberculosis culture 
from day 5 or 6 was centrifuged at 4000 RPM for 10 minutes and then resuspended in DC media.  
The M. tuberculosis suspension was then sonicated twice in a closed cup-horn sonicator at a 
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 power of 5 for 10 seconds each time.  Following sonication the bacillus was added to the DC 
culture at a multiplicity of infection of 4.  Cells were infected for 14-20 hours.  Extracellular 
bacteria were separated from the cells by low speed centrifugation.  Infected and uninfected DCs 
were used for stimulation assays. 
FACS analyses of Cell Surface Markers. 
To determine cellular infiltrate in the lung, at 10-day intervals lungs were removed for flow 
cytometric analysis.  Lungs were subjected to a short period (20 min.) of digestion with 1mg/ml 
collagenase A and 25 Units/ml DNAse (Boehringer Mannheim, Mannheim, Germany) at 37°C.  
The suspension was then pushed through a cell strainer as previously described [63].  Red blood 
cells were lysed with lysis buffer (0.14M NH4Cl/ 0.017Mtris pH= 7.65) and the single cell 
suspension was counted.  The samples were stained with 0.2 µg anti-CD4 (clone H129.19), anti-
CD8 (clone 53-6.7), and anti-CD69 (clone H1.2F3) in FACS buffer (0.1% NaAzide, 0.1% BSA, 
20% mouse serum).  Following washes, the cells were fixed in 4% PFA for 1 hour and collected 
on a FACSCaliber (Beckon Dickinson).  Cells were gated on the lymphocyte population by size 
and granularity.  Analysis was performed on Cell Quest software (BD-Pharmingen, San Diego, 
CA). 
Intracellular Cytokine Staining. 
Single cell suspensions of the lung were prepared as described above.  The lung cells were then 
cultured at 0.5x106 cells/ml in the presence of 2µM monensin and with or without anti-CD3 
(0.1µg/ml) and anti-CD28 (1µg/ml) for 4 hours (37°C and 5%CO) in 24 well plates.  Following 
stimulation, the cells were collected, spun down and stained for T lymphocyte surface markers as 
described above, following fixation with 100µl 4% PFA, the cells were transferred to a 96 well 
plate, washed 2 times with permeablization buffer (FACS buffer + 0.1% saponin), stained with 
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 anti-IFNγ (2µl neat) for 20 minutes at 4°C, and then washed 2 times with permeablization buffer 
and once with FACs buffer.  The cells were then resuspended in 4% PFA and collected on the 
FACS Caliber (Beckon Dickinson). 
T cell proliferation Assay. 
DCs uninfected and infected at a MOI of 4 for 18 hours were plated in triplicate in a 96-well U-
bottom plate (Corning Incorporated, Corning, NY) at different concentrations of DC: T cell 
ratios (1:25, 1:50 and 1:100) in T cell media (DMEM containing 10% certified FBS, 10mM 
sodium pyruvate, 2mM L-glutamine, 25mM HEPES (Gibco, Gaithersburg, MD) and 50µM 2-
ME.  As a source of T lymphocytes, splenocytes were obtained from CXCL10-/- and WT mice 
by crushing the spleens in cell strainers.  Red blood cells were lysed as described above and 
macrophages were depleted by adherence on plastic petri dishes for 2 hours at 37°C/5% CO2.   
Cells suspensions were added at 2x105cells/ well (in a final volume of 100µl) and cultured in 
media alone (negative control), 5µg/ml ConA  (a positive control), uninfected, or infected DCs 
for 3 days.  Cells were pulsed for the final 18 hours of culture with 1µCi/well [3H] thymidine 
(Amersham Life Sciences, Inc., Arlington Heights, IL) and the incorporation of radioactivity was 
measured by counting cell lysates on filters in a scintillation counter.  The simulation index was 
determined by (CPM T Cells+infected DCs)/(CPM Tcells+uninfected DCs).     
Culture of lung cells. 
Lung cells from CXCL10-/- and WT mice infected for 4 weeks were obtained as described 
above and plated in 96-well U-bottom plates in T cell media supplemented with 30µg/ml 
gentamicin (Gibco, Gaithersburg, MD), 15-20 U/ml rIL-2 (Boehringer Mannheim, Indianapolis, 
IN), and 1mM aminoguanidine at 2x105 cells/well.  MHC Class II DCs were infected for 20 
hours as described above and were added to the cell cultures at 6x103 cells/well.  After 2-3 days 
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 of culture 100µl of media were removed from each well and replaced with fresh media 
containing IL-2.  Cells were cultured for an additional 3-4 days prior to the CTL assay. 
Cytotoxicity Assay. 
Lymphocytes harvested from 5-7 day stimulation cultures were tested in a 4-h 51Cr release assay.  
Bone marrow derived macrophages were prepared (as described in Section 7.2  Materials and 
Methods) and used as targets (uninfected or infected at MOI 3).  2x106 macrophages were 
labeled with 100ul Na51CrO4 (Amersham) in Teflon jars (Savillex, Minnetonka, MN) for 1 hour 
at 37°C.  Macrophages were washed 3 times and then added to 96-well U-bottom plates at 4x103 
cells/ well.   Cultured T cells were added at various effector: target ratios (1:12, 1:25, 1:50) in a 
total volume of 100µl in T cell media.  After 4 hours, 85µl of supernatant was removed from 
each well and 100ml of undiluted vesphene was mixed with the supernatant.  This mixture was 
counted in a gamma counter.  Spontaneous release was determined by culturing target cells in 
medium along and total release was calculated by lysing target labeled macrophages with 0.1% 
Triton-X.  Percent specific lysis was calculated using the formula: 100x[(experimental CPM- 
spontaneous CPM)/ (total CPM-spontaneous CPM)]. 
Statistics. 
Statistical analysis was performed comparing CXCL10-/- vs. wild type littermates and 
comparing anti-CXCL10/anti-CXCL9 to their controls.  Student t-test was preformed using 
GraphPad Prism3 software for the analyses.  
8.3 Results. 
In the absence of CXCL10 and CXCL9, mice control M. tuberculosis infection. 
  
 CXCL10 deficient mice (CXCL10-/-), wild type littermates, C57Bl/6 mice treated with 
anti-CXCL10 and anti-CXCL9 antibodies, and C57Bl/6 control mice were aerosol infected with 
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 approximately 100 colony forming units of Erdman M. tuberculosis. One group of CXCL10-/- 
mice was from a pure 129 background, while the second group was B6/129 mixed background.  
These mice were matched with their wild type littermates.  In all experiments performed, the 
data between these two groups were very similar.  Data from the B6/129 mixed litters will be 
presented here.  CXCL10-/- mice controlled M. tuberculosis infection as well as their wild type 
littermates (Figure 22).  As seen in wild type C57Bl/6 mice, the bacterial burdens increased 
rapidly after infection, and by 3-4 weeks post infection the number of bacteria in the lungs 
reached a plateau.  The anti-CXCL10/anti-CXCL9 treated mice also controlled infection as well 
as their controls (Figure 22).  No mice succumbed to infection during the course of the 
experiment.  Therefore CXCL10 and CXCL9 may not be necessary for control of mycobacterial 
growth. 
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Figure 22.  Mice control M. tuberculosis infection in the absence of functional CXCL9 and CXCL10. 
CXCL10-/- mice and anti-CXCL9/anti-CXCL10 treated mice control aerosol M. tuberculosis infection.  Total 
colony forming units in the lung were calculated from plating serial dilutions of lung homogenates.  Each point 
represents 4 mice and the error bar is the standard error of the group.  There were no significant differences found 
between experimental and control groups at any time. 
 
Migration of lymphocytes to the lungs is unaffected after M. tuberculosis infection of mice 
lacking functional CXCL10 or CXCL9. 
 
Due to evidence that the receptor for CXCL9 and CXCL10, CXCR3, is expressed on Th1 
lymphocytes and a large lymphocytic infiltrate occurs in the lungs during M. tuberculosis 
infection, we examined the numbers of lymphocytes migrating to the lungs by flow cytometric 
analysis.  Upon infection the numbers and percentages of lymphocytes migrating to the lungs of 
CXCL10-/- mice and anti-CXCL10 /anti-CXCL9 treated mice were similar to the experimental 
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 control mice (Figure 23, data not shown).   Despite this, two weeks after infection, the 
percentage of lymphocytes expressing early activation marker, CD69, was lower in CXCL10-/- 
mice compared to controls (Figure 24).  Unfortunately, the activation of the immune response in 
the experiment with anti-CXCL9/anti-CXCL10 treated mice and control mice may have started 
slower, since at two weeks post infection, the early activation marker, CD69 was not yet 
observed on lymphocytes.  This may have been due to a lower than expected inoculum.  By three 
weeks post infection the numbers of CD69+ lymphocytes was similar in all groups of mice 
(Figure 24).  
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Figure 23.  T lymphocytes migrate to the lungs of CXCL10-/- and anti-CXCL9/anti-CXCL10 treated mice.  
Flow cytometric analysis was performed to determine the number of lymphocytes within the lungs following M. 
tuberculosis infection in CXCL10-/- and anti-CXCL9/anti-CXCL10 treated mice.    CD4+ and CD8+ lymphocytes 
migrate to the lungs in similar numbers in the experimental and control groups.  Each point represents 3-4 mice.  
The error bars represent standard error. 
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Figure 24.  T lymphocytes in the lung are activated in CXCL10-/- and anti-CXCL9/anti-CXCL10 treated 
mice. 
The number and percentage of CD69+ cells in the CXCL10-/- and anti-CXCL9/anti-CXCL10-/- is similar to control 
mice by 3 weeks post infection.  In the CXCL10-/- mice the percentage of CD69+ lymphocytes is lower at 2 weeks 
post infection, but the reduction is transient.  Each point represents 3-4 mice.  The error bar represents the standard 
error. 
 
Cell migration to the lymph nodes. 
 
 The lymph nodes serve as a priming and activation site for antigen specific lymphocytes.  
Naïve cells migrate to the lymph nodes, where they are primed and expanded to generate effector 
lymphocytes.  In the anti-CXCL9 and anti-CXCL10 treated mice, we examined the numbers of 
cells and the number of activated cells in the lymph nodes after infection.  There was either a 
delay in migration, activation or expansion of CD4 and CD8 lymphocytes in the antibody treated 
mice.  Clearly the number of lymphocytes and the number of activated lymphocytes present in 
the lung draining lymph nodes was lower in the antibody treated mice early after infection 
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 (Figure 25).  By two months post infection, the numbers of cells in the antibody treated mice was 
higher than in controls, but the number of activated lymphocytes was similar.  
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Figure 25.   Cell migration to the lymph nodes was delayed in anti-CXCL9/anti-CXCL10 treated mice. 
Flow cytometric analysis was performed to determine the number of lymphocytes and activated lymphocytes 
present in the lung draining lymph nodes of anti-CXCL9/anti-CXCL10 treated and control mice.  Each point 
represents 3-4 mice.  The error bar represents the standard error.  * p<0.05, **p<0.005 
 
IFNγ production in the absence of functional CXCL9 and CXCL10. 
 
 IFNγ production is essential for control of M. tuberculosis infection [64, 98].  There is 
increasing evidence that the signaling of chemokines not only leads to migration of cells, but can 
also lead to activation.  Intracellular cytokine staining was performed to determine whether the 
lymphocytes in the lungs were activated and capable of producing IFNγ.  By three weeks post 
infection (the earliest we examined IFNγ production in this experiment), the lymphocytes from 
CXCL10-/- and anti-CXCL9/anti-CXCL10 mice produced levels of IFNγ similar to that 
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 produced by wild type and control mice (Figure 26).  There were slightly higher levels of IFNγ 
present in the wild type or control mice, but the differences were not significant.   ELIspot 
analysis performed on the anti-CXCL9/anti-CXCL10 mice confirmed that there were similar 
amounts of IFNγ being produced in the experimental and control groups (data not shown). 
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Figure 26.  IFNγ production in the absence of functional CXCL9 and CXCL10.   
Intracellular cytokine staining was performed on lymphocytes following a short ex vivo stimulation with anti-CD3 
and anti-CD28.  Each point represents 3-4 mice.  The error bars represent standard error. 
 
Lymphocytes from CXCL10-/- mice can serve as cytotoxic lymphocytes and proliferate. 
 
 To determine whether lymphocytes in the lungs were responsive to M. tuberculosis, we 
tested the cells for cytotoxicity and ability to proliferate.  Following expansion of CD8 
lymphocytes, a cytotoxic T cell lysis assay was performed.  The lymphocytes from the lungs of 
CXCL10-/- or wild type mice were equally capable of lysing infected macrophage targets with 
96 
 very little nonspecific lysis of uninfected macrophages.  In addition the lymphocytes when 
stimulated with infected DCs at various ratios, proliferated in the presence of antigen.  This 
proliferation increased as the ratio of DC: T cells decreased and the probability of interaction 
with antigen presenting cells increased.  (Figure 27) 
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Figure 27.  Cytotoxic activity and proliferative ability of T lymphocytes from CXCL10-/- mice.   
A.  A Cytotoxic Lysis Assay (CTL) was performed on lymphocytes isolated from the lungs at 4 weeks post 
infection.  Targets were either infected or uninfected macrophages.  The graph represents the % specific lysis for 
each of these targets.  B.  At 4 weeks post infection the ability of the lymphocytes to proliferate in response to 
antigen was tested in a [3-H] thymidine incorporation assay.   The error bar represents 4 mice at each ratio of 
lymphocyte to antigen presenting cell. 
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 8.4 Discussion 
 The signaling behind migration of cells to the lung and the formation of the granuloma 
appears to be a very intricate, complicated system.  There has been evidence for the role of 
CXCL9 and CXCL10 in migration of T lymphocytes both in vitro and in vivo.  The evidence for 
their roles in migration of cells to the lungs during an inflammatory response has been less 
defined, although in T. gondii infection there is evidence that CXCL10 is required for the 
recruitment of CXCR3+ cells to the lung.  Our data indicates that CXCL9 and CXCL10 are not 
necessary for migration of effector lymphocytes to the lung and for control of M. tuberculosis 
infection.  The CXCL10-/- mice showed no signs of exacerbated disease.  In addition the 
CXCL10-/- lymphocytes migrated to the lung and were activated.  The T lymphocytes produced 
IFNγ, proliferated and had cytolytic potential.  Even when both CXCL9 and CXCL10 were 
neutralized with antibodies, the mice had a similar pattern of disease as control mice.  The 
experiment utilizing the monoclonal antibody administration also addressed the migration of 
lymphocytes to the lymph nodes, and although there appeared to be early differences in the 
numbers of lymphocytes present in the lung draining lymph nodes, the mice controlled infection.   
Early migration of T lymphocytes into the lung draining lymph node was affected by 
neutralization of CXCL9 and CXCL10, but enough T lymphocytes were primed and activated in 
the lymph node to travel to the lung and control infection in this model.  The ability of mice to 
overcome deficiencies in chemokines and chemokine receptors is not a novel phenomenon.  In 
CCR2-/- mice, the immune response was more robust than necessary to control infection (see 
Section 10.4 Discussion).  In this case there were no differences in the numbers of cells in the 
lungs, even though there are fewer cells in the lymph nodes.  This raises a number of questions. 
Where are the cells coming from in the anti-CXCL9/anti-CXCL10 treated mice? In wild type 
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 mice, are the excess cells in the lymph nodes migrating to an organ other than the lung?  Or is 
there more cell death in the wild type lymph nodes or lungs?    
We did not test the effectiveness of the administration of the antibodies.  This regimen 
was effective in the T. gondii model, where the mice were susceptible to infection following 
infection with a lymphocytic migration deficiency [155].  Whether redundancy exists in vivo 
truly is a difficult question to ask.  Another CXCR3 ligand does exist, CXCL11 (I-TAC); 
although there was induction of this chemokine following in vitro infection of macrophages, we 
have been unable to find reagents to address its function in vivo. 
 Interestingly the experiments that drove us to study CXCR3 ligands were rooted in the 
regulation of chemokine expression by TNF.  In the absence of TNF, there is a down regulation 
in the expression of CXCL10 and CXCL9 as described in Chapter 1 (Section 7.0).  Although 
CXCL9 and CXCL10 are not the only chemokines affected by the loss of TNF, the loss of 
CXCL9 and CXCL10 did not recapitulate the pathology seen in the absence of TNF.   
 The role of CXCL10 in the immune response to T. gondii may be very different than the 
role of this chemokine in M. tuberculosis response for many reasons.  Although both infections 
are controlled through a strong cell-mediated immune response, control of T. gondii also was 
very dependent on the innate immune response.  Infection with T. gondii led to very early (day 3) 
detectible induction of CXCL10 in the spleen and liver by RNase protection assay, whereas 
during M. tuberculosis infection in mice, induction of CXCL10 was not detected in the lungs 
until at least day 9 post infection.  In addition, the peak of CXCL10 expression during T. gondii 
infection was as early as day 7, on the other hand during M. tuberculosis infection of mice the 
expression of CXCL10 reached a plateau between 3-4 weeks.  This implies that CXCL10 is 
necessary during acute infection of T. gondii- even at a time point where CXCL10 was difficult 
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 to detect in M. tuberculosis infection.  Another possible explanation for the differences observed 
is that M. tuberculosis itself can induce expression of other chemokines, which can signal 
lymphocyte migration.  This induction could occur through the presence of PAMPs signaling 
through toll-like receptors or other pattern recognition molecules.  The induction of these 
chemokines may override the necessity for IFNγ dependent induction of chemokines such as 
CXCL10, as in T. gondii infection.  Another difference could purely be due to basic differences 
in the model.  Replication of the M. tuberculosis bacillus is slower than replication of T. gondii, 
therefore initially the antigenic load is not as high and the immune response may have more time 
to develop after M. tuberculosis infection.  
A recent study demonstrated that CXCR3-/- mice infected with M. tuberculosis exhibited 
delayed granuloma formation [72].  Surprisingly, the lymphocyte migration was not affected in 
these mice, but anti-CXCL9 Ab treated and PMN depleted mice had similar pathology.  In short, 
they describe PMNs as a major producer of CXCL9 and important for early granuloma 
formation.  Despite the differences in pathology, these mice (CXCR3-/-, anti-CXCL9 Ab treated 
and PMN depleted mice) are all capable of developing pulmonary granulomas and there were no 
differences observed in the survival or mycobacterial burden.  On one hand, this study attempts 
to argue that early granuloma formation is not necessary for control of infection. Although there 
were fewer granulomas and the size of the granulomas was smaller, the granulomas that form in 
PMN- depleted or CXCR3-/- mice are organized.  We can argue that within these granulomas the 
cell mediated immune response is effective in controlling the low dose aerosol infection.   
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 9.0 Chapter 3 Enhanced dendritic cell migration and T cell priming in lymph nodes result 
in increased pulmonary lymphocytic infiltration in chemokine receptor 5 (CCR5)-deficient 
mice following Mycobacterium tuberculosis infection. 
This chapter has been submitted to Journal of Immunology.  The chapter in this form is more 
inclusive that the submitted paper and includes additional data that was not shown in the 
submitted paper. 
9.1 Introduction 
In this study, we addressed the role of CCR5 in murine M. tuberculosis infection.  M. 
tuberculosis infection causes an increase in the expression of β- chemokines, CCL3, CCL4 and 
CCL5 and their receptors, including CCR5, in the lungs.  CCR5 is a co-receptor for HIV [156], 
and as a result, interest has emerged in the role of CCR5 in infectious diseases and as a target for 
HIV therapy.  CCR5 is expressed on granulocytes, macrophages, immature DCs, CD8+ 
lymphocytes and at a high level on T helper 1 lymphocytes [157, 158].  Studies in infectious 
disease models illustrate the variety of functions of CCR5 in the immune response.  In CCR5-/- 
mice infected with Leishmania donovani, the boundaries of the granulomas were difficult to 
demarcate, yet the mice had fewer parasites than wild type mice [159].  On the other hand, 
CCR5-/- mice were more susceptible to influenza A virus, Cryptococcus neoformans, Listeria 
monocytogenes, and Toxoplasma gondii [160-163].  CCR5 was associated with elimination of 
extracellular polysaccharide during C. neoformans infection [160], induction of IL-12 during T. 
gondii infection [161], and trafficking of cells to sites of infection [162, 163].  An understanding 
the use of CCR5 by the immune system will benefit the development of anti-microbial drugs and 
vaccines.   
The data presented here support a role for CCR5 in dendritic cell migration.  In this study 
we demonstrate that CCR5 transgenic knockout mice were capable of recruiting immune cells to 
the lung to form granulomas.  CCR5-/- mice controlled M. tuberculosis growth in the lungs, 
spleen and liver, but had higher bacterial loads in the lung-draining lymph nodes.  Substantially 
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 higher numbers of T lymphocytes were found in the lungs of CCR5-/- mice, compared to 
controls.  Our data are consistent with the hypotheses that higher bacterial loads in the lymph 
nodes are due to more dendritic cells carrying M. tuberculosis from the lungs to the lymph nodes 
or that there is retention of dendritic cells in the lymph nodes presenting antigen, resulting in 
more priming of lymphocytes in the lymph nodes.  These primed/ activated lymphocytes then 
migrate to the site of infection (the lungs).  These results suggest that CCR5 may be important 
for the migration to and retention of dendritic cells in lymph nodes during infection. 
9.2 Materials and Methods. 
Mice. 
C57BL/6 female mice (Charles River, Rockland, MA) and CCR5-/- (Cmkbr5) male and female 
mice (8-14 weeks old) were used in all experiments. CCR5-/- mice (Jackson Laboratory, Bar 
Harbor, ME) were bred at the University of Pittsburgh in specific pathogen-free facilities. All 
infected mice were maintained in the BSL3 animal laboratories and routinely monitored for 
murine pathogens.  The University Institutional Animal Care and Use Committee approved all 
animal protocols employed in this study. 
Chemical and reagents.  All chemicals were purchased from Sigma Chemical Co. (St. Louis, 
MO.) unless otherwise noted.  Middlebrook 7H9 liquid medium and 7H10 agar were obtained 
from Difco Laboratories (Detroit, MI).  Antibodies used in flow cytometry were obtained from 
Pharmingen (San Diego, CA).  
Mycobacteria and infection of mice.   
To prepare bacterial stock, M. tuberculosis strain Erdman (Trudeau Institute, Saranac Lake, 
N.Y.) was used to infect mice, and then bacteria were harvested from their lungs, expanded in 
7H9 liquid medium and stored in aliquots at -80°C.  Mice were infected via the aerosol route 
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 using a nose-only exposure unit (InTox Products, Albuquerque, N.M.), and exposed to M. 
tuberculosis (1 x 107 CFU/ml in the nebulizer chamber) for 20 minutes, followed by 5 minutes of 
air. This resulted in reproducible delivery of 50-100 viable CFU of M. tuberculosis, which was 
confirmed by CFU determination on the lungs of 2-3 infected mice 1 day post-infection.   Mice 
were infected i.v. via tail vein with 1x104 CFU in 100 µl PBS/0.05% Tween 80.  The tissue 
bacillary load was quantified by plating serial dilutions of the lung homogenates in 0.05% 
PBS/Tween 80 onto 7H10 agar.  Total colony forming units were calculated. 
Bone marrow derived macrophages.   
Macrophages were derived from the C57BL/6 mice bone marrow based on adherence.  The mice 
were euthanized and bone marrow was flushed out of the femur and tibia bones with DMEM as 
previously described [82].  The bone marrow suspension was washed twice with 2% FBS in PBS 
and the cells were counted.  2x106 cells were plated on non-tissue culture treated petri dishes 
(Labtek) in 25ml macrophage media (25% L cell supernatant, 20% FBS, 1% L-glutamine, 1% 
sodium pyruvate, and 1% nonessential amino acids).  After 4 days in culture the cells were fed 
with 10 ml fresh macrophage media.  On Day 6 macrophages were infected with M. tuberculosis 
(MOI 4).  Four hours post infection the supernatant was removed, cells were washed and fresh 
media added.   
DC preparation. 
Dendritic cells are derived from the C57Bl/6 mice bone marrow.  The bone marrow was obtained 
as described as above.  After the cells were washed and counted, the cells were resuspended in 
two non-tissue culture treated deep dish petri dishes in 20 ml DC media/ plate (10% FBS, 1% 
Sodium pyruvate, 1% L-glutamate) overnight.  The following day, the nonadherent and semi-
adherent cells were removed from the plates, spun down and cultured at 1x106 cells/ ml in DC 
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 media with 20ng/ml of GM-CSF and 20ng/ml of IL-4 (PeproTech Inc., Rocky Hill, NJ) in p75 
filter flasks.  On day 3 of culture the cells were fed with and additional 5ml DC media and 100ng 
of GM-CSF and IL-4.   Dendritic cells were infected with M. tuberculosis on day 6 of culture 
(MOI 4) as previously described [82].   
Flow cytometric analysis of lung cells.  
To determine cellular infiltrate in the lung, at 10-day intervals lungs were removed for flow 
cytometric analysis.  Lungs were subjected to a short period (25 min.) of digestion with 1mg/ml 
collagenase A and 25 Units/ml DNAse (Boehringer Mannheim, Mannheim, Germany) at 37°C.  
The suspension was then pushed through a cell strainer as previously described [164].  Red blood 
cells were lysed with lysis buffer (0.144M NH4Cl/ 0.017Mtris pH= 7.65) and the single cell 
suspension was counted.  The samples were stained with 0.2 µg anti-CD4, anti-CD8, and anti-
CD69, or 0.15 µg anti-Gr1 and 0.2 µg anti-CD11b in FACS buffer (0.1% NaAzide, 0.1% BSA, 
20% mouse serum).  Following washes, the cells were fixed in 4% PFA for 1 hour and collected 
on a FACSCaliber (Beckon Dickinson).  Analysis was performed on Cell Quest software (BD-
Pharmingen, San Diego, CA). 
Intracellular Cytokine Staining. 
Single cell suspensions of the lung were prepared as described above.  The lung cells were then 
cultured at 0.5x106 cells/ml in the presence of 2µM monensin and with or without anti-CD3 
(0.1µg/ml) and anti-CD28 (1µg/ml) for 4 hours (37°C and 5%CO) in 24 well plates.  Following 
stimulation, the cells were collected, spun down as stained for T lymphocyte surface markers as 
described above, following fixation with 100µl 4% PFA, the cells were transferred to a 96 well 
plate, washed 2 times with permeablization buffer (FACS buffer + 0.1% saponin) stained with 
anti-IFNγ (2µl neat) for 20 minutes at 4°C, and then washed 2 times with permeablization buffer 
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 and once with FACs buffer.  The cells were then resuspended in 4% PFA and collected on the 
FACS Caliber (Beckon Dickinson). 
Histopathology.   
Tissue samples for histological studies were fixed in 10% normal buffered formalin followed by 
paraffin embedment.  For histopathological studies 5- to 6- µm sections were stained with 
Harris’ hematoxylin and eosin. 
Immunohistochemistry. 
5- to 6- µm sections of formalin fixed paraffin embedded lung were stained for CCL5, using 
anti-CCL5 (RANTES) antibody (Santa Cruz Biotechnology, Santa Cruz, CA). 
Immunohistochemistry was performed as recommended by manufacturer the goat ABC Staining 
System (Vector Laborabories, Inc., Burlingame, CA).  The slides were deparaffinized and 
hydrated using a xylene, EtOH, water gradient.  Antigen unmasking was performed with citrate 
buffer by microwaving the slides for 5 minutes x2.  Following a wash in PBS and blocking with 
2% donkey serum, the slides were stained with anti-CCL5 or goat anti-mouse IgG (at 1:50 in 2% 
donkey serum) overnight at 4°C.  The slides were washed, and the secondary donkey anti-goat 
IgG- biotin (1:200) applied for 30 minutes at room temperature.  Following additional washes 
the sections were incubated with AB enzyme reagent for 30 minutes.  Following additional 
washes the sections were developed in peroxidase substrate (AEC substrate with 20ml N,N 
dimethlyformamide in 0.02M Na Acetate Buffer + 200ul H2O2) for 4 minutes.  The sections 
were then washed with deionized H2O and counterstained by dipping aqueous hemotoxylin.  
After rinsing the sections they were brightened in PBS and air dried.  Crystal mount was applied 
overnight and then the sections were coverslipped. 
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Apoptosis Staining. 
TUNEL staining was performed on formalin fixed paraffin embedded lung sections.  The 
procedure was followed exactly as described by the ApopTag Manual using the ApopTag 
Peroxidase In Situ Apoptosis Detection Kit (Intergen Co, New York). 
Apoptosis staining on lung cells was also performed using Annexin V and 7-Amino-actinomycin 
D (7-AAD) in conjuction with surface staining for lymphocytic markers.  In short, after surface 
staining as described above, 1x106 cells were washed in 100µl binding buffer (BD-Pharmingen, 
San Diego, CA) resuspended in 50µl of binding buffer and stained with Annexin V and 7-AAD 
(3µl each neat) for 15 minutes at room temperature.  The cells were then washed with binding 
buffer and fixed in a 1:2 solution of 4%PFA:binding buffer.   Cells were collected on the FACS 
Caliber within 1 hour of staining. 
RNase Protection Assay (RPA).   
A multiprobe RNase protection assay system (Pharmingen, San Diego, Ca) was used to 
determine the levels of mRNA for genes of interest at 10 day intervals post-aerosol infection in 
murine lung or infected macrophages in vitro.  At the time of harvest, the lungs were snap frozen 
in liquid nitrogen and stored at -80°C.  Total RNA was extracted using Trizol reagent (Life 
Technology, Grand Island, N. Y.) followed by treatment with RNase free-DNase (Roche, 
Indianapolis, IN) and RNase Inhibitor (Roche).  Macrophage RNA was obtained from bone 
marrow derived macrophages by treating ~4 x 106 adherent cells with 1ml Trizol reagent. The 
RNA was subjected to RPA according to Pharmingen’s protocol.  In short, mRNA from 
macrophages or the lungs was hybridized overnight to [32P]-UTP-labeled probes.  The protected 
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 [32P]-UTP-labeled RNA probes were resolved on a 6% polyacrylamide gel and analyzed by 
autoradiography.  Cytokine analysis was performed using a custom-made template set specific 
for NOS2, IL-4, IL-12p40, TNF, IL-1β, IL-1α, and IFN-γ.  Chemokine analysis was performed 
using mCK5 multiprobe template set (Pharmingen).  The expression of specific genes was 
quantified on a densitometer (ImageQuant Software, Molecular Dynamics, Sunnyvale, CA), 
relative to the abundance of housekeeping gene, L32.  We also performed phosphorimaging 
quantification on some samples but found results identical to densitometry; therefore, only 
densitometry quantifications are shown. 
Real time RT-PCR. 
RNA was isolated from the lung using the TRIZOL isolation protocol with slight modifications.  
The lung was homogenized in 3ml of TRIZOL reagent and then two chloroform extractions were 
performed.  Following an isopropanol precipitation, the RNA was washed with 70% ethanol and 
treated with RNase Inhibitor (Applied Biosystems, Foster City, CA) for 45 minutes.  Following 
treatment at 65° C for 15 minutes the RNA was cleaned and DNase digested using the Qiagen 
RNA isolation kit, as directed by the manufacturer (Qiagen Inc., Valencia, CA).  The RNA was 
reverse transcribed using Superscript II enzyme, as directed by the manufacturer (Invitrogen, 
Carlsbad, CA).  For Real time RT-PCR we used the relative gene expression method [165].  
HPRT served as the endogenous control, and uninfected lung or macrophages as the calibrator.  
Each primer and probe set was tested for efficiency (results efficient >97% for all primer/probe 
sets).  All samples were run in triplicate and with “no reverse transcriptase” controls on an ABI 
Prism Sequence Detector 7700.  Relative gene expression was calculated as 2 ^-∆∆Ct, where 
∆Ct = Ct (gene of interest)- Ct (endogenous control) and the ∆∆Ct= ∆Ct (sample) - ∆Ct 
(calibrator).  Results are expressed as relative gene expression to uninfected samples. The primer 
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 and probe concentrations were used as suggested by Applied Biosystems with the final 
concentration of each primer at 400nM and probe at 250nM.   
ELIspot analysis for IFNγ. 
The ELIspot plates (96-well filtration plates Millipore MultiScreen MAIPS4510, Millipore Co., 
Bedford, MA) were pretreated with 95% EtOH and then washed three times with sterile PBS.  
The rat anti-IFNγ capture antibody (clone R4-6A2 BD Pharmingen, San Diego, CA) was added 
to the wells overnight at a concentration of 10µg/ml.  The capture antibody was washed off (all 
washes PBS/0.1%Tween 20) and the plate blocked with T cell media containing 20% FBS for 2 
hours.  Single cell suspensions were prepared from the lung by pushing the lung sections through 
a cell strainer (Fisher, Pittsburgh, PA) using the plunger of a 5ml syringe.  The cells were treated 
with red blood cell lysis buffer, washed twice in 2% fetal bovine serum in PBS and counted. 
150,000 cells per well were incubated for 40-48 hours in the presence of 20U/ml IL-2 and either 
with media alone, uninfected bone marrow derived dendritic cells, M. tuberculosis infected 
dendritic cells (MOI = 3-4), or 10µg/ml Con A.  Following the incubation at 37°C in 5% CO2, 
the cells were washed off, the biotinylated anti-IFN-γ detection antibody (clone XMG1.2 BD 
Pharmingen) added for 2 hours at 37°C at 5µg/ml, followed by more washes and the addition of 
streptavidin – peroxidase for 1 hour at room temperature in a humidified chamber (Vectastain 
ABC Kit, Vector Laboratories, Burlingame, CA).  After additional washing the plate was 
developed using the AEC substrate kit as directed by the manufacturer.  ELIspot plates were read 
on the ImmunospotTM CTL plate reader (Cellular Technology LTD, Cleveland, OH) 
Statistical Analysis.   
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 3-4 mice per group per time point were used for all studies.  Statistical analysis was performed 
on the data utilizing GraphPad Prism Software for an unpaired t-test.  For bacterial numbers and 
cell numbers, log transformation was performed prior to statistical analysis to normalize the data.  
9.3 Results. 
Expression of CCR5 and its ligands following M. tuberculosis aerosol infection. 
CCR5 and its ligands are associated with the migration of Th1 cells and macrophages, 
two cell types important in a protective immune response to M. tuberculosis.  Infection of bone 
marrow derived macrophages with M. tuberculosis induced CCL3, CCL4 and CCL5 expression 
(Figure 28A).  Next we examined in vivo expression of these chemokines as well as CCR5 
following M. tuberculosis infection. RNA from the lungs of C57BL/6 mice infected with M. 
tuberculosis via aerosol was isolated and real-time RT-PCR was performed on the RNA (Figure 
28B).  The expression of all known CCR5 ligands increased within the first two weeks of 
infection.  CCL4 had the lowest relative expression of the CCR5 ligands.  The expression of 
CCL5, when compared with other CC- chemokines was very high.  Through 
immunohistochemical staining for CCL5 on granulomatous lung sections, we observed CCL5 
protein expressed locally in both macrophage and lymphocytic areas of the granuloma (Figure 
28C). CCR5 mRNA levels also increased in the mice following infection (data not shown).  
Whether this is an upregulation of CCR5 or merely a reflection of cells expressing CCR5 
migrating into the lungs cannot be determined by this assay, and an appropriate anti-CCR5 
antibody for use in flow cytometry is not available. 
109 
 C.
Anti-CCL5 IgG
CCL3
CCL4
CCL5
A.
Uninfected Infected
0
10
400
500
600
Chemokine RNA expression in 
Bone Marrow Derived 
Macrophages
R
el
at
iv
e 
U
ni
ts
 to
 U
ni
nf
ec
te
d 
(2
^-
∆∆
C
t)
Macrophages
Chemokine RNA expression in 
the Lung
B.
0 10 20 30 40 50
0
10
20
30
40
D a y s P o s t A e ro s o l In fe c t io n
R
el
at
iv
e 
U
ni
ts
 to
 U
ni
nf
ec
te
d 
(2
^-
∆∆
C
t)
CCL5
CCL4
CCL3
 
Figure 28. Expression of CCR5 ligands increased in M. tuberculosis-infected bone marrow derived 
macrophages and in the lungs of aerosol M. tuberculosis-infected mice.   
A. Bone marrow derived macrophages were infected with Erdman strain of M. tuberculosis (MOI 4).  RNA was 
isolated 24 hours post infection and real time RT-PCR was performed using HPRT as an endogenous control and 
uninfected macrophages as a calibrator.  B. Expression of all CCR5 ligand RNAs increased in the lungs of C57Bl/6 
mice during the first 4 weeks post aerosol infection.  C.  Protein expression of CCL5 can be localized to the 
granuloma during infection (100x).  Immunohistochemistry was performed on lung tissue sections from C57BL/6 
mice; expression of CCL5 was detected as early as 7 days post-infection.  Shown are lung sections from 60 days 
post-infection. 
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 M. tuberculosis infection in CCR5-/- mice. 
To determine whether CCR5 plays a role in control of M. tuberculosis infection, C57Bl/6 
and CCR5-/- mice were infected via the aerosol route with ~50 colony forming units (CFU).  
The survival of CCR5-/- mice was unaffected by M. tuberculosis infection.  The mice survived 
>180 days, at which point experiments were terminated. There was no difference in bacterial 
loads, as determined by CFU, in the lungs (Figure 29A), liver or spleen (Figure 29D and E).  
Intravenous infection of CCR5-/- mice with 2x105 CFU delivered via the tail vein, showed 
similar results (Figure 29B).  In contrast, by 8 weeks post-aerosol infection, there were 
significantly higher bacterial loads in the lymph nodes of CCR5-/- mice (Figure 29C).   
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Figure 29.  CCR5-/- mice control aerosol and intravenous M. tuberculosis infection.  
A. Aerosol infection of C57Bl/6 and CCR5-/- mice led to increasing bacillary loads during the first 4 weeks post 
infection and then the number of colony forming units levels off as infection is controlled.  Each point represents 4 
mice and similar results were obtained in 3 independent experiments.  B. Intravenous infection showed a similar 
pattern of M. tuberculosis growth in the lungs of the C57Bl/6 and CCR5-/- mice.  C. The colony forming units in the 
lymph nodes of CCR5-/- mice was significantly higher by 7.5 weeks post infection (at week 5 p=0.01, week 8 
p=0.03, and at week 10 p=0.008).  Each point represents 3-4 mice.  Similar results were obtained in 2 independent 
experiments. 
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 Cell migration to the lungs and granuloma formation during M. tuberculosis infection in CCR5-
/- mice. 
  
Since CCR5 plays a role in migration of T cells and macrophages, we examined the 
cellular infiltrate in the lungs following infection.  At predetermined time points, the lungs were 
removed, the total number of cells was calculated, and flow cytometric analysis was performed 
to determine cell populations.  The single cell suspension was stained for T cell markers (CD4, 
CD8 and activation marker CD69) and macrophage and neutrophil differentiating markers 
(CD11b and Gr1).  During initial infection the number of cells in the lungs was not significantly 
different between CCR5-/- mice and wild type mice.  However, by 6 weeks post infection the 
numbers of CD4 and CD8 lymphocytes were significantly higher in CCR5-/- mice (Figure 30A 
and B). The number of macrophages and neutrophils increased in the CCR5-/- mice and the 
differences were significant at later time points (Figure 30C and D).   The increased lymphocytic 
infiltrate in CCR5-/- mice was still evident at 6 months post infection (Table 8). The colony 
forming units in the lungs were not statistically different at this or any time point between CCR5-
/- and wild type mice (Table 8). 
Table 8.  Cell migration in chronic infection in CCR5-/- and wild type mice (6 months post-infection).   
The increased cellular infiltrate observed in CCR5-/- mice by 2 months post infection was also evident during the 
chronic stages of infection.  CFU remained similar between the two groups of mice. (* p =0.047). For CD8 T cells, p 
= 0.072. 
Cells (x105) Macrophages Neutrophils CD4+ Cells* CD8+ Cells CFU (log) 
CCR5-/- 1.12+0.04 1.28+1.44 7.37+1.59 7.97+3.25 6.39+0.25 
CCR5+/+ 0.88+0.02 0.49+0.08 4.62+0.68 4.26+0.68 6.13+0.01 
 
The engagement of CCR5, especially by CCL5, plays a role in T lymphocyte activation in some 
infection diseases [166].  Therefore the expression of early activation marker, CD69, on the 
lymphocytes in the lungs was examined.  There was no difference in the expression of the early 
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 activation marker on CD4+ lymphocytes until 6 weeks post infection, when the CD4+ 
lymphocyte numbers were significantly higher in the CCR5-/- mice, 1.2x106+0.08x106 v. 
0.57x106+0.05x106, but the percentage of CD69+ lymphocytes was continuously similar.  On the 
other hand there was a significantly greater percentage of CD8+ lymphocytes expressing CD69 
present in the lungs of the CCR5-/- mice compared to WT mice (58+2.8% vs. 41+0.5%, 
p=0.004).  
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Figure 30.  Infection of CCR5-/- mice led to greater numbers of lymphocytes in the lungs compared to wild 
type mice.   
Flow cytometric analysis was performed on single cell suspensions from the lungs. The total number of CD4+ (A) 
and CD8 (B) lymphocytes increased to a significantly higher number in the CCR5-/- mice compared to wild type 
mice (**p=0.004,  *p=0.01).  Each point represents 3-4 mice.  Similar results were obtained in three independent 
experiments and with intravenous infection. 
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 Histology. 
 
Histological analysis of the lung revealed that organized granulomas did form in CCR5-/- 
mice.  These granulomas were similar to wild type mice granulomas at early time points.  By 5 
weeks post infection, the increased lymphocytic infiltrate in the lungs of CCR5-/- mice compared 
to lungs of wild type mice demonstrated by flow cytometry was evident in the histologic sections 
(Figure 31).  The increased lymphocytic infiltrate is even more evident at 10 weeks post 
infection (Figure 31). 
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Figure 31.  CCR5-/- mice formed granulomas with greater lymphocytic infiltrate.   
Sections of the lung were stained with hemotoxylin and eosin  (100x).  Early after infection (2 weeks post infection), 
CCR5-/- mice and C57Bl/6 mice had similar cellular infiltrate in the lungs, but by 5 weeks post infection the greater 
lymphocytic infiltrate in the lung was apparent in the CCR5-/- tissue sections and granulomas.   
Chemokine expression in CCR5-/- mice. 
The results above indicated that CCR5-/- mice had no deficiency in cell migration to the 
lung, but rather have more cells migrating to the lung in response to infection.  To address 
115 
 potential compensatory mechanisms that could account for increased cell migration in the 
absence of CCR5, we looked for increased expression of CCR5 ligands and their alternative 
receptors, CCR1 and CCR3.  Real time RT-PCR was used to determine whether there was 
increased expression of CCL3, CCL4, or CCL5 in the lungs of CCR5-/- mice (Figure 33).   
There was significantly greater CCL3 expression in CCR5-/- mice by day 41 post aerosol 
infection (p=0.03); although there was a trend toward greater expression of other inflammatory 
chemokines, such as CXCL10 and CCL2, these differences were not significant.  Through 
RNase protection assays on lung RNA, no differences in the expression of CCR1 and no 
expression of CCR3 was detected in the CCR5-/- or C57Bl/6 mice (Figure 32).  
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Figure 32.  CCR1 mRNA expression in the lungs of M. tuberculosis infected, wild type and CCR5-/- mice. 
RNase protection assay was used to determine the expression of CCR1 in the lungs of aerosol 
infected mice.  Expression is measured relative to L32.  There were no significant differences in 
the level of expression. 
116 
 Day 25
CCR5-/- WT
0
50
100
150
CCL3
CCL4
CCL5
CXCL10
CCL12
CCL2
Mouse Background
R
el
at
iv
e 
U
ni
ts
Day 41
CCR5-/- WT
0
50
100
150
CCL3
CCL4
CCL5
CCL3 *p=0.04
CXCL10
CCL12
CCL2
*
Mouse Background
R
el
at
iv
e 
U
ni
ts
 
Figure 33.   CCR5-/- mice had altered chemokine expression late in infection.   
Real time rt PCR was performed on RNA isolated from the lungs of CCR5-/- and wild type mice.  The relative units 
represented here are relative to uninfected wild type lung expression of these genes.  There was a trend toward 
greater expression of chemokines in the CCR5-/- mice but only the difference in expression of CCL3 was 
significantly different.  This could be a reason for increased cellular infiltrate to the lungs, but it could also be a 
result of a greater number of cells in the lungs. 
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 Cytokine expression. 
Control of M. tuberculosis infection depends on the activation of macrophages by IFNγ 
and TNF, leading to the induction of inducible nitric oxide synthase (NOS2) and production of 
reactive nitrogen intermediates, such as nitric oxide.  To determine whether these components of 
the immune response were affected by CCR5 deficiency, RNase protection assay was performed 
on total lung RNA  (Figure 34A).  Early after infection the expression of TNF, IFNγ and NOS2 
was similar in CCR5-/- and wild type mice, but by day 36 the CCR5-/- mice had higher 
expression of many inflammatory cytokines.  There were significant differences in expression of 
NOS2 and TNF at day 36, but variability at day 45 resulted in differences that did not reach 
statistical significance.  Relative units in the RNase protection assay is standardized to L32, a 
housekeeping gene, therefore the expression is relative on a per cell basis. Even though there 
were not significant differences per cell at later time points, since there were significantly more 
lymphocytes in the CCR5-/- mice, there was clearly higher expression of lymphocytic genes, 
such as IFNγ and TNF overall.  The IFNγ gene expression differences were verified by 
intracellular cytokine staining (Figure 34B), and through these studies it is evident that the 
increased expression of IFNγ was due to an increase in the percentage of CD8+IFNγ+ 
lymphocytes in the lungs of CCR5-/- mice. 
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Figure 34.  T helper 1 inflammatory cytokines increased to significantly higher levels in CCR5-/- mice 
compared to C57Bl/6 mice.   
A. RNase protection assay was performed on whole lung RNA from CCR5-/- and wild type mice at predetermined 
time points.  Expression of IFNγ, NOS2 and IL-12 is shown relative to L32 housekeeping gene.   Each point 
represents 3-4 mice.  Similar results were obtained in 2 independent experiments.  *p<0.05.  B. Intracellular 
cytokine staining for IFNγ using anti-CD3/anti-CD28 as non-specific stimulus revealed that a similar percentage of 
CD4+IFNγ + cells were present in the lungs, while there were a greater percentage of CD8+IFNγ + cells in the 
CCR5-/- mice, compared to wild type mice.  **p<0.01 
 
Immune regulation in CCR5-/- mice. 
There were a number of possible explanations for the higher numbers of lymphocytes in 
the lungs of CCR5-/- mice in response to M. tuberculosis infection. We hypothesized that there 
was less apoptosis in the CCR5-/- mice, therefore the cells were accumulating in the lungs 
instead of undergoing normal turnover.  Using both TUNEL staining for apoptotic bodies and 
flow cytometric analysis for 7-AAD and Annexin V, there was no difference in the percentage of 
apoptotic cells between the CCR5-/- mice and wild type mice (data not shown), but due to the 
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 increase in lymphocytes present in the lungs, there were actually significantly more apoptotic 
lymphocytes in the CCR5-/- mice (Figure 35).   
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Figure 35.  CCR5-/- mice did not have a decrease in apoptosis. 
A. and B. Through FACS, the number of apoptotic lymphocytes was actually higher in the CCR5-/- mice.  
Therefore, the increase in cellular infiltrate in the CCR5-/- mice was not due to lack of apoptosis. C.  Through 
TUNEL staining of sections of lung, it was evident that the CCR5-/- mice have similar levels of apoptotic cells 
present.   
We also hypothesized that CCR5 was required to recruit regulatory T lymphocytes to the 
lungs during M. tuberculosis infection in mice, and that this absence could interfere with normal 
immune regulation in the lungs.  Using CD4+ CD25+CD45RBlo as markers for a regulatory T 
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 cell population [167], flow cytometric analysis of lung cells demonstrated that significantly 
greater numbers of these cells infiltrated the CCR5-/- mice by 6 weeks post infection, indicating 
that CCR5 was not required for their recruitment to the lung (Figure 36). 
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Figure 36.  CCR5-/- mice do not have fewer CD4+CD45RBloCD25+ cells than wild type mice, but rather have 
significantly more cells of this phenotype.  
This analysis was done using flow cytometric analysis on single cell suspensions from the lungs and lymph nodes of 
aerosol M. tuberculosis infected mice.  Each time point represents 4 mice.  ***p<0.005 **p<0.001.   
Priming in the lymph nodes. 
The lung-draining lymph nodes of CCR5-/- mice contained more M. tuberculosis bacilli 
than C57Bl/6 mice (Figure 29C).  We hypothesized that this was due to greater numbers of 
dendritic cells migrating from the lungs to the lymph nodes carrying M. tuberculosis.  As a result 
more T lymphocytes were being primed in the lymph node and then migrating to the lungs.  To 
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 explore this hypothesis, flow cytometric analysis was performed on the mediastinal lymph nodes 
of CCR5-/- mice following M. tuberculosis infection.   
The overall total cell numbers of the lymph nodes of CCR5-/- and C57Bl/6 mice were 
similar, but at 5 weeks post infection there were statistically significant differences in the number 
of dendritic cells (defined as CD11c+CD11bhi (or lo) B7.2+ cells) in the CCR5-/- mice (Figure 
37A).  ELIspot analysis confirmed that significantly more lymphocytes from lymph nodes of 
CCR5-/- mice were primed to produce IFNγ when stimulated by either ConA or M. tuberculosis-
infected dendritic cells (Figure 37B).  
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Figure 37.  CCR5-/- mice had more dendritic cells and more primed lymphocytes within the lung draining 
lymph nodes.   
The number of DCs was determined by flow cytometric analysis.  A. There were significantly more 
CD11c+CD11bhi (or lo) B7.2+ cells in the lymph nodes of CCR5-/- mice at 5 weeks post infection (CD11bhi **p=0.003, 
CD11blo *p=0.01).  B. ELIspot analysis for IFNγ was performed on single cells suspensions from the lymph nodes.   
By 10 weeks post infection, the number of IFNγ producing cells in the lymph nodes was significantly greater when 
the cells were simulated with M. tuberculosis infected DCs (*p=0.013) or ConA (*p=0.011).  Each bar represents 4 
mice. 
 
Intravenous infection. 
In CCR2-/- mice, the requirement for CCR2 in control of M. tuberculosis infection was 
dose dependent. These mice were unable to control M. tuberculosis when it is administered at a 
standard dose of 2.5x105 CFU delivered intravenously, but could control lower dose aerosol or 
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 i.v. infection [63].  We investigated whether the ability of CCR5-/- mice to control infection was 
route or dose dependent.  CCR5-/- mice infected i.v. (2 x 105 CFU/mouse) controlled M. 
tuberculosis growth and the cell migration pattern were similar to that of CCR5-/- mice infected 
via the aerosol route (data not shown).  The CCR5-/- mice again had strikingly high cell 
infiltration to their lungs, but with no apparent long-term detrimental effects of this increased 
infiltration. 
9.4 Discussion. 
CCR5 is expressed on many immune cells that are present in the lung following M. 
tuberculosis aerosol infection in mice, and the ligands for this receptor are induced in the lung by 
this infection.  Whether the CCR5 is required for the migration of these cells to the lungs and 
subsequent control of infection was unknown.  The results of this study provide evidence that 
CCR5 is not required for migration of immune cells to the lungs during M. tuberculosis 
infection, but may influence the retention of DCs in the lungs and migration to the lymph nodes.  
CCR5-/- mice had more bacilli in the lung-draining lymph nodes, as well as more dendritic cells. 
This coincided with enhanced priming of M. tuberculosis-specific T cells in the lymph nodes.  
Such increased priming likely accounts for the substantially increased numbers of T lymphocytes 
migrating to the lungs of CCR5-/- mice following M. tuberculosis infection. 
Although CCR5 is known to be present on many immune cells, CCR5 function may be 
compensated for by other chemokine receptors and chemokines expressed in the lungs during 
infection.  Although CCL4 and CCL5 can also signal through CCR1, the immune cells express 
many other chemokine receptors that may be responsible for the migration of these cells to the 
lung.  These include CXCR3, CCR2, CCR1 and CXCR2.  There is no reported increase in 
susceptibility to tuberculosis in humans carrying a deletion in the CCR5 gene (CCR5delta32).  
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 The finding that CCR5-/- mice had more inflammation in their lungs was intriguing and 
unexpected. Recent data in other systems support an immunoregulatory role for CCR5.  CCR5-/- 
mice had enhanced delayed-type hypersensitivity and humoral responses to T cell- dependent 
antigenic challenge [162].  When infected with influenza A virus, CCR5-/- mice had a 
hyperinflammatory response resulting in increased pulmonary inflammation and a decrease in 
survival [163].  In a murine model of colitis utilizing dextran sodium sulfate, CCR5 deficient 
mice had increased infiltration of CD4+ and NK1.1+ lymphocytes, along with a decrease in Th1 
and an increase in Th2 cytokine expression [168]. 
We explored several possibilities for the increased numbers of lymphocytes in the lungs 
of the M. tuberculosis-infected CCR5-/- mice. There was increased expression of other 
chemokines (such as MIP1α) in the lungs of the CCR5-/- mice compared to wild type.  Such 
increased expression/circulation of chemokines signaling through receptors other than CCR5 in 
the lungs could have resulted in the influx of immune cells. However, the increased expression 
may also have been a reaction to the numbers of cells in the lungs.   
An alternative hypothesis was that there was less turnover of cells in the lungs of CCR5-
/- mice.  Recent studies have suggested that CCR5 signaling induces apoptosis in some 
situations.  The HIV protein, Env, can activate CCR5 to induce the Fas and caspase-8 pathway 
resulting in CD4+ cell death [169].  However, in our studies there were equal or greater numbers 
of apoptotic cells in the CCR5-/- mice detected by two different methods, discounting this 
hypothesis in our system. 
We also assessed whether CCR5 was important for migration of regulatory T 
lymphocytes to the lungs and the down regulation of Th1 responses, which could account for the 
observed increased inflammation in the absence of CCR5.  Using the best markers known for 
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 regulatory T cells [167] there were actually significantly more cells of this phenotype in the 
lungs of CCR5-/- mice.  Therefore, CCR5 does not appear to be playing a role in regulatory T 
cell migration, but rather the increased migration may be a response to the increased 
inflammation, or simply related to the overall increase in cell numbers in the lungs of these mice. 
A final hypothesis was that CCR5 is required for normal dendritic cell migration.  We 
observed greater bacterial numbers in the mediastinal lymph nodes of CCR5-/- mice.  Dendritic 
cells infected in the lungs are likely migrating and carrying M. tuberculosis bacilli to the lymph 
nodes.  Previous studies demonstrated that infection of dendritic cells with M. tuberculosis 
matures the cells [26, 82, 170, 171], and mature dendritic cells migrate to the lymph nodes [172-
174] where they prime naive T cells. At 5 weeks post infection there were more dendritic cells in 
the lymph nodes of CCR5-/- mice.  The increased antigen dose (i.e. bacterial numbers) in 
conjunction with increased numbers of dendritic cells within the lymph nodes likely leads to 
enhanced priming of lymphocytes, as seen in the ELIspot assays.  More primed T lymphocytes 
then are available to migrate to the site of infection in the lungs, resulting in the higher T 
lymphocyte numbers observed in the CCR5-/- mice. 
Upon maturation, dendritic cells are believed to down regulate expression of CCR5 and 
CCR6 while they upregulate other receptors such as CXCR4 and CCR7, targeting these cells to 
the lymph nodes [reviewed in [175]].  We observed increased numbers of dendritic cells in the 
lymph nodes following infection in CCR5-/- mice, suggesting that during M. tuberculosis 
infection the expression of β-chemokines such as CCL3, CCL4 and CCL5 may normally retain 
CCR5+ dendritic cells in the lungs or recruit the dendritic cells out of the lymph nodes to the 
lungs.  The absence of CCR5 apparently results in either increased migration from the lungs to 
the lymph nodes, or retention of dendritic cells in the lymph nodes.   
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 This study further supports our previous finding that although there may not be striking 
differences in bacterial loads in the lungs of some transgenic mouse models, these models are 
very useful for studying the immune response [63, 176].  Addressing the function of molecules 
in the immune response requires careful experimental design and execution, and interpretation of 
experimental results.  Roles may exist for molecules in the immune response even if the mouse is 
controlling infection at the level of bacterial burden.  The immune response in the C57BL/6 
mice, although not sufficient to eliminate bacterial numbers in the lungs, does control the 
infection.  In this study, as well as other models (IL-10-/-, for example, H.M.S., J. Chan, and 
J.L.F, unpublished data), enhancing the Type 1 T cell response or the ability of T lymphocytes to 
enter the lungs over the wild type level, does not have an obvious beneficial effect on control of 
the infection.  These data indicate that there are additional factors that must be induced or 
enhanced for increasing the ability of the host to eliminate M. tuberculosis infection. 
In summary, our study supports a role for CCR5 in controlling dendritic cell migration to 
the lymph nodes, possibly by maintaining these cells in infected lungs.  Thus, the absence of 
CCR5 resulted in increased numbers of both dendritic cells and M. tuberculosis bacilli in lymph 
nodes; we assume that the bacteria were carried from the lungs in dendritic cells.  The result of 
the increased numbers of dendritic cells and antigens was enhanced T lymphocyte priming, 
leading to increased inflammation in the lungs.   
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 10.0 Chapter 4 Mycobacterium tuberculosis in chemokine receptor 2 (CCR2) deficient mice: 
the influence of dose on disease progression.  
This chapter has been modified from the published paper Scott, et. al. [63].  Copyright 
permission is on file. 
10.1 Introduction 
As described in the introduction to the thesis, the hallmark of Mycobacterium tuberculosis 
infection is granuloma formation.  Following infection of alveolar and resident macrophages or 
dendritic cells in the lungs, monocytes and mycobacteria-specific lymphocytes migrate from the 
blood to the lungs and form granulomas.  Within the localized environment of the granuloma, the 
immune cells control the bacterial replication and limit the spread of infection within the lung 
and to other organs.  In M. tuberculosis-infected hosts, CD4+ and CD8+ T lymphocytes produce 
IFN-γ and TNF, cytokines which aid in control of infection and macrophage activation [64, 98, 
103, 177].  Activated macrophages also produce TNF and reactive oxygen and nitrogen 
intermediates, which have anti-mycobacterial properties [177, 178].  Identifying factors involved 
in migration of cells to the lungs and granuloma formation is a key to understanding the immune 
response to M. tuberculosis. 
 There have been studies on the contribution of various chemokines to granuloma 
formation.  Using “bead” instillation (PPD or schistosomal egg antigen beads) or injection of 
schistosomal eggs to induce granulomas in lungs of mice, roles for CCR1 and CCR2, as well as 
CCL5 and CCL2 in granuloma formation were demonstrated [179-182].  CCR2 is present on 
monocytes, macrophages and dendritic cells, as well as activated T cells.  This chemokine 
receptor is a logical candidate for monocyte/macrophage recruitment to the lungs because 
macrophages and monocytes are chemotactic towards CCR2 ligands, macrophage chemotactic 
protein CCL2, CCL7 (MCP-3) and CCL12 (MCP-5).  Studies in CCR2-/- mice have indicated 
that this receptor plays a major role in mediating monocyte/macrophage recruitment in response 
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 to intracellular pathogens such as Listeria monocytogenes or Cryptococcus neoformans and to 
nonspecific inflammatory stimuli, such as thioglycollate or mycobacterial antigens [183-185], 
although resident macrophages were unaffected by the absence of CCR2 [185]. 
 In this study we addressed the requirement for CCR2 in various infection models of M. 
tuberculosis, including aerosol infection and both high and low dose i.v. infection.  Previously 
we, with co-workers, reported that CCR2-/- mice were highly susceptible to i.v. M. tuberculosis 
infection with significantly higher bacterial loads by 14 days post infection, severe pathology, 
and increased mortality [135].  These mice demonstrated macrophage and dendritic cell 
migration deficiencies and delays in IFN-γ and inducible nitric oxide synthase (NOS2) 
expression [135].  To determine whether the migration defects were evident following aerosol or 
i.v. infections with low doses of M. tuberculosis, we infected CCR2-/- mice and compared the 
development of the immune response to CCR2+/+ mice.  Our results confirm that CCR2 plays a 
major role in migration of monocytes to the lung during M. tuberculosis infection.  It also 
appears to affect early migration of T cells to the lung, which could result in the observed 
transient delay in IFN-γ and NOS2 expression.  Surprisingly, the deficiencies in cell migration 
and cytokine expression did not noticeably affect the ability of CCR2-/- mice to control low dose 
M. tuberculosis infection.  Finally, these data demonstrate that when studying infectious disease 
in knockout models, clear phenotypes may not be evident when solely evaluating bacterial 
numbers and survival.  Functional assays may be necessary to reveal roles for components of the 
multifactorial immune system. 
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 10.2 Methods and Materials 
Mice.   
C57BL/6 female mice (Charles River, Rockland, Mass.) and CCR2-/- [184] (8-14 weeks old) 
were used in all experiments.  CCR2 +/- or -/- mice (heterozygous breeding pair provided by Dr. 
I. Charo, University of California, San Francisco) were bred and genotyped by PCR on tail DNA 
and maintained under specific pathogen-free conditions at the University of Pittsburgh 
Biotechnology Center.  Only CCR2-/- mice were used.  Mice were transferred to the Biomedical 
Science Tower Biosafety Level 3 animal facility at 7-8 weeks of age.  All infected mice were 
maintained in the BSL3 animal laboratories and routinely monitored for murine pathogens by 
means of serological and histological examinations.  The University Institutional Animal Care 
and Use Committee approved all animal protocols employed in this study. 
Chemical and reagents.   
All chemicals were purchased from Sigma Chemical Co. (St. Louis, MO.) unless otherwise 
noted.  Middlebrook 7H9 liquid medium and 7H10 agar were obtained from Difco Laboratories 
(Detroit, MI).  Antibodies used in flow cytometric analyses were obtained from Pharmingen (San 
Diego, CA).  Pyrazinamide was purchased from Acros.   
Mycobacteria and infection of mice.   
To prepare bacterial stock, M. tuberculosis strain Erdman (Trudeau Institute, Saranac Lake, 
N.Y.) or H37Rv (Dr. John Belisle, Colorado State University, Fort Collins, Colorado) was used 
to infect mice, and then bacteria were harvested from their lungs, expanded in 7H9 liquid 
medium and stored in aliquots at -80°C.  Mice were infected via the aerosol route using a nose-
only exposure unit, as described in [94], which was confirmed by CFU determination on the 
lungs of 2-3 infected mice 1 day post-infection.   High dose aerosol infection using 2x108 or 
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 1x108 CFU in the nebulizer resulted in delivery of 1500 or 4000 viable CFU, respectively, of 
H37Rv M. tuberculosis in two different experiments, and was confirmed by day 1 CFU in the 
lungs.  Mice were infected i.v. via tail vein with either 1x104 (low dose) or 2x105 (high dose) 
CFU in 100 µl PBS/0.05% Tween 80.  The tissue bacillary load was quantified by plating serial 
dilutions of the lung, liver, and spleen homogenates onto 7H10 agar as described previously [64]. 
Bone marrow derived macrophages.   
Macrophages were derived from C57Bl/6 bone marrow based on adherence.  The mice were 
euthanized and their bone marrow was flushed out of the femur and tibia bones with DMEM as 
previously described [82].  The bone marrow suspension was then washed twice with 2% FBS in 
PBS and the cells were counted.  2x106 cells were plated on non-tissue culture treated petri 
dishes (Labtek) in 25ml macrophage media (25% L cell supernatant, 20% FBS, 1% L-glutamine, 
1% sodium pyruvate, and 1% nonessential amino acids).  After 4 days in culture the cells were 
fed with 10 ml fresh macrophage media.  On Day 6 macrophages were infected with M. 
tuberculosis at an MOI of 4.  Four hours post infection the supernatant was removed, cells were 
washed and fresh media was added.   
Flow cytometric analysis of lung cells.  
To determine cellular infiltrate in the lung, at 10-day intervals lungs were removed for flow 
cytometric analysis.  Lungs were subjected to a short period (25 min.) of digestion with 1mg/ml 
collagenase A and 25 Units/ml DNAse (both from Boehringer Mannheim, Mannheim, Germany) 
at 37°C.  The suspension was then pushed through a cell strainer as previously described [164].  
Red blood cells were lysed with red blood cell lysis buffer (NH4Cl/Tris Solution) and the single 
cell suspension was counted.  The samples were stained with 0.2 µg anti-CD4, anti-CD8, anti-
CD69, or 0.15 µg anti-Gr1 and 0.2 µg anti-CD11b in FACS buffer (0.1% NaAzide, 0.1% BSA, 
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 20% mouse serum).  Following washes, the cells were fixed in 4% PFA for 1 hour and collected 
on a FACSCaliber (Beckon Dickinson).  Analysis was performed on Cell Quest software (BD-
Pharmingen, San Diego, CA). 
Histopathology.   
Tissue samples for histological studies were fixed in 10% normal buffered formalin followed by 
paraffin embedment.  For histopathological studies 5- to 6- µm sections were stained with 
Harris’ hematoxylin and eosin.   
RNase Protection Assay (RPA).  
 A multiprobe RNase protection assay system (Pharmingen, San Diego, CA) was used to 
determine the levels of mRNA for genes of interest at 10-day intervals post-aerosol infection in 
murine lung or infected macrophages in vitro.  At the time of harvest, the lungs were snap frozen 
in liquid nitrogen and stored at -80°C.  Total RNA was extracted using Trizol reagent (Life 
Technology, Grand Island, N. Y.) followed by treatment with RNase free-DNase (Roche, 
Indianapolis, IN) and RNase Inhibitor (Roche).  Macrophage RNA was obtained from bone 
marrow derived macrophages by treating ~4 x 106 adherent cells with 1ml Trizol reagent. The 
RNA was subjected to RPA according to Pharmingen’s protocol.  In short, mRNA from 
macrophages or the lungs was hybridized overnight to [32P]-UTP-labeled probes.  The protected 
[32P]-UTP-labeled RNA probes were resolved on a 6% polyacrylamide gel and analyzed by 
autoradiography.  Cytokine analysis was performed using a custom-made template set specific 
for NOS2, IL-4, IL-12p40, TNF, IL-1β, IL-1α, and IFN-γ.  Chemokine analysis was performed 
using either a custom-template set specific for CCL2, CCL7, CCL12, CCR2, CCL19 (MIP-3β) 
and CXCL10 (Pharmingen, provided by Joel Ernst, UCSF) or mCK5 multiprobe template set 
(Pharmingen).  The expression of specific genes was quantified on a densitometer (ImageQuant 
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 Software, Molecular Dynamics, Sunnyvale, CA), relative to the abundance of housekeeping 
gene, L32.  We also performed phosphorimaging quantification on some samples but found 
results identical to densitometry; therefore, only densitometry quantifications are shown. 
Statistical Analysis.   
3-4 mice per group per time point were used for all studies.  Statistical analysis was performed 
on the data utilizing Prism Software for an unpaired t-test.  For bacterial numbers and cell 
numbers, log transformation was performed prior to statistical analysis. 
10.3 Results 
Expression of CCR2 ligands, CCL2, CCL7 and CCL12, increases following infection.   
To determine whether expression of CCR2 ligands was enhanced following M. 
tuberculosis infection, RNase protection assays were performed on infected bone marrow 
derived macrophages and the lungs of infected C57Bl/6 mice.  The expression of three major 
CCR2 ligands and CCR2 increased upon in vitro infection of macrophages (Figure 38A).  There 
was also enhanced expression of genes for CCL3, CCL4 (MIP-1β), CCL5, CXCL2, and 
CXCL10 in macrophages (data not shown). In the lungs, expression of the macrophage 
chemotactic proteins (CCL2, 7, 12) increased following aerosol M. tuberculosis infection (Figure 
38B).  The pattern of expression was similar to that of a number of other chemokines following 
infection in the lung, including CCL3, CCL4, CCL5, and CXCL10 (as described in previous 
chapters). 
133 
 CCL12 CCL7 CCL2 CCR2
0.00
0.25
0.50
0.75
Uninfected
Infected
Macrophage Gene Expression
A.
CCR2 Ligand Expression
0 5 10 15 20 25
0.00
0.25
0.50
0.75
CCL2
CCL12
CCL7
Days post infection
B.
 
Figure 38.  Expression of CCR2 ligands, CCL2, CCL7 and CCL12 increases following M. tuberculosis 
infection.   
RNase protection assay on mRNA isolated from bone marrow derived macrophages (A) or C57Bl/6 mice (B) 
reveals enhanced expression of CCL2, CCL7 and CCL12 following M. tuberculosis infection.  Representative 
samples from the lung RNase protection assay are shown (C). 
CCR2-/- mice control low dose infection with M. tuberculosis. 
 
 Mice were infected via the aerosol route (~50 CFU) with M. tuberculosis, and sacrificed 
to determine bacillary burdens in the lung, liver and spleen at various time points post-infection 
(Figure 39A).  The bacterial numbers in the lungs of CCR2-/- and wild type mice were not 
significantly different at any time post infection.  There was no significant difference in bacterial 
dissemination to the spleen or liver between the mouse strains, although the initial growth of M. 
tuberculosis in the spleens of CCR2-/- was impaired compared to wild type mice (p=0.0019).  
However, at late time points (70 days) there were ~10-fold more CFU in the CCR2-/- spleens 
compared to wild type.  No differences in the bacterial growth in the liver were observed (data 
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 not shown).  No CCR2-/- mice succumbed to the aerosol infection during the course of the 
experiment; mice were maintained up to 5 months.  At 5 months post infection the CCR2-/- mice 
had similar bacterial loads in the lungs  (data not shown).  The low dose aerosol infections were 
performed using M. tuberculosis strains H37Rv (twice) and Erdman (twice) with similar results. 
 These results were in sharp contrast to the published results on CCR2-/- mice infected i.v. 
with 4-10 x105 CFU [135], where a majority of mice did not survive beyond 23 days.  We 
repeated these studies with our standard i.v. dose of 2 x 105 CFU using strain H37Rv.  This dose 
does not cause mortality in C57BL/6 mice in our hands.  As reported previously [62], the CCR2-
/- mice infected with a relatively high dose of M. tuberculosis had 5-fold higher bacterial 
numbers than wild type mice by 10 days post-infection, and 100-fold more CFU by 20 days post-
infection (Figure 39B).  The CCR2-/- mice infected with 2 x 105 CFU i.v. did not survive past 23 
days post-infection.   
 The decreased susceptibility of CCR2-/- mice to the aerosol infection could have been 
due to either the route used to infect the mice, or the substantially lower dose that is delivered to 
the lungs by aerosol (compared to i.v.) infection.  To distinguish between these possibilities, we 
infected CCR2-/- mice with a lower dose i.v., using 1 x 104 CFU H37Rv.  This delivers <100 
CFU to the lungs [7, 186] which is similar to the dose delivered directly to the lung by our 
aerosol infection.  CCR2-/- and wild type mice infected i.v. with the lower dose were equally 
capable of controlling the infection, similar to aerosol-infected mice (Figure 39C).   When a high 
dose of M. tuberculosis strain H37Rv was administered via aerosol (4000 CFU or 1500 CFU), 
the CCR2-/- mice had significantly higher bacterial loads in their lungs than wild type mice by 3 
weeks post infection (data not shown), yet both strains of mice succumbed by 4 weeks post-
infection to these high doses of M. tuberculosis. Thus, the susceptibility of CCR2-/- mice is 
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 dependent on dose, rather than route of infection.   
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Figure 39.  CCR2 deficient mice control low dose infection with M. tuberculosis.  
CCR2-/- mice and wild type C57BL/6 mice were infected via aerosol route with ~50 CFU M. tuberculosis H37Rv 
(circles) (A), intravenously with 2x 105 CFU M. tuberculosis H37Rv (B), intravenously with 1x104 CFU M. 
tuberculosis Erdman (triangles) or H37Rv (C).  CCR2-/- mice (open symbols) controlled growth of M. tuberculosis 
similar to wild type (closed symbols) mice in the two lower dose models (A, C), but had much higher bacterial 
numbers in the higher dose model (B).  For (A) both lung and spleen CFU are shown; for (B, C) lung CFU only are 
shown.  Each time point represents 3-4 mice and the bars represent standard error.  The aerosol route experiment 
was performed twice with H37Rv and twice with Erdman strain with similar results.  The i.v. route experiments 
were performed twice. 
Monocyte/macrophage migration deficiencies were observed even in low dose infection. 
 
 Murine macrophages express CCR2 and show chemotactic ability to CCR2 ligands, 
CCL2, CCL7, and CCL12.  Monocyte/macrophage migration deficiencies have been observed in 
inflammatory models in CCR2-/- mice [135, 182-185, 187-189].  Since the CCR2-/- mice were 
capable of controlling low dose M. tuberculosis infection, we examined whether the lungs of the 
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 CCR2-/- mice were also deficient in macrophages following low dose M. tuberculosis infection.  
Antibody staining followed by flow cytometric analysis was performed on single cell lung 
homogenates.  A substantial macrophage deficiency was observed in the CCR2-/- mice infected 
with a low dose of M. tuberculosis. There was a 10-fold increase in macrophages by 32 days post 
infection, but the number of macrophages in the CCR2-/- mice remained much lower than in 
wild type mice  (Figure 40A), even up to 5 months post-infection (data not shown).  In the low 
dose i.v. model of M. tuberculosis infection (1x104 CFU), the CCR2-/- also exhibited at least 2-
fold fewer macrophages in the lungs (Table 9).   
These data and those previously reported [135] demonstrate that CCR2 plays an essential 
role in macrophage migration to the lung during M. tuberculosis infection, regardless of dose, 
route or strain of M. tuberculosis used for infection.  In high dose i.v. and aerosol  infection 
models, the numbers of neutrophils increased to greater than 50% of the total lung homogenate 
[190].  An increase in neutrophils was evident in low dose models of infection in CCR2-/- mice, 
but by 4 weeks post infection the percentage of neutrophils was greatly reduced (Figure 40B and 
Table 9). 
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Table 9.  Numbers of immune cells within the lungs 3 weeks post infection.   
Numbers of macrophages, neutrophils, CD4+ lymphocytes and CD8+ lymphocytes are represented from low dose 
aerosol infection, low dose i.v. infection and high dose i.v. infection.  Each value represents the mean of 3-4 mice 
and the standard error of the mean is in parentheses. *p<0.05, **p<0.005, and ***p<0.001 Numbers of immune 
cells within the lungs 3 weeks post infection.  Numbers of macrophages, neutrophils, CD4+ lymphocytes and CD8+ 
lymphocytes are represented from low dose aerosol infection, low dose i.v. infection and high dose i.v. infection.  
Each value represents the mean of 3-4 mice and the standard error of the mean is in parentheses. *p<0.05, 
**p<0.005, and ***p<0.001 
Cellular 
Infiltrate 
(x105)(3wks) 
WT  
(aerosol) 
CCR2-/-
(aerosol) 
WT  
(low dose iv) 
CCR2-/- 
(low dose iv) 
WT  
(high dose iv) 
 
CCR2-/-  
(high dose i.v.) 
 
Macrophages  0.81 (+0.06) 0.28 (+0.06) 0.64 (+0.10) 0.36 (+0.05) 5.06 (+0.50) 0.7 (+0.16) 
Neutrophils 1.57 (+0.24) 2.35 (+0.29) 0.65 (+0.29) 1.70 (+0.45) 2.16 (+0.26) 24.54 (+7.15) 
CD4 T cells 6.01 (+0.88) 3.72 (+0.62) 5.04 (+1.11) 3.58 (+0.66) 30.42 (+5.31) 16.81 (+0.53) 
CD8 T cells  3.84 (+0.46) 4.28 (+0.28) 3.25 (+0.64) 2.50 (+0.36) 16.46 (+3.21) 8.7 (+0.53) 
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Figure 40.  Macrophages are present in fewer numbers throughout M. tuberculosis infection in the CCR2 
deficient mice.   
Migration of macrophages  (A) and neutrophils (B) to the lung following aerosol infection (50 CFU) with M. 
tuberculosis H37Rv in CCR2-/- mice (open squares) and CCR2+/+ mice (closed triangles). Flow cytometric 
analysis was performed on single cell suspensions of the lung.  Within the macrophage/granulocyte gate (determined 
by SSC v FSC), macrophages were defined as CD11b+Gr1- and neutrophils were CD11b+ Gr1+.  Each data point 
represents 3 to 4 mice and the bars represent standard error.  *p<0.05, **p<0.005, and ***p<0.001.  This experiment 
was repeated twice with similar results.  
 
Lymphocyte migration to the lung following aerosol infection is affected. 
 Because CD4+ and CD8+ lymphocytes play important roles in M. tuberculosis infection 
[reviewed in [23]] and can express CCR2, the migration of these cells to the lung following M. 
tuberculosis infection was evaluated by flow cytometry. The percentage of CD4+ T cells was 
significantly less in the CCR2 deficient mice compared to wild type mice up to 50 days post-
infection (Figure 41A).  There was a more modest delay in CD8+ lymphocyte migration to the 
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 lung, but this delay was overcome by 4 weeks post infection (Figure 41B).  We assessed 
activation status of the lung T cells by staining for the early activation marker, CD69.  There was 
no difference in CD69 expression on CD4+ T cells at any time point between wild type and 
CCR2-/- mice.  However, at 13 days post infection there was a significantly higher percentage of 
CD8+ lymphocytes expressing CD69 in wild type mice (p=0.004); at other time points the 
expression of CD69 was not significantly different between CCR2-/- and CCR2+/+ mice (data 
not shown). 
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Figure 41.  Migration of T lymphocytes to the lung is delayed following low dose aerosol M. tuberculosis 
infection.   
Flow cytometric analysis using anti-CD4 (A) and anti-CD8 (B) antibodies was performed on single cells 
suspensions of the lung at various time points post infection.  Points represent the percent antibody positive within 
the lymphocyte gate (determined by SSC v. FSC parameters). Each data point represents three to four CCR2-/- mice 
(open squares) or CCR2+/+ mice (closed triangles), and the bars represent standard error.  *p<0.05, **p<0.005. This 
experiment was repeated twice with similar results. 
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Histological analysis of CCR2 deficient mice. 
 Granuloma formation parallels development of cell mediated immunity in murine models 
of tuberculosis.  This occurs in the M. tuberculosis-infected lung 3-4 weeks post-infection.  The 
granuloma consists primarily of clusters of macrophages, including epithelioid macrophages, and 
lymphocytes.  In human tuberculous granulomas, typically the lymphocytes surround the 
macrophages, which may fuse to form multinucleated giant cells.  Following aerosol infection, 
the CCR2-/- mice did form granulomas in the lungs, but the formation was delayed and the 
reduction in macrophages could clearly be observed in the overall granuloma structure and 
pathology of the lungs (Figure 42). By 13 days post infection, perivascular and peribronchial 
lymphocytic infiltrate was evident in wild type mice but to a lesser extent in CCR2 deficient 
mice.  This correlates with the delay in lymphocytic and macrophage infiltration evident in the 
flow cytometric analysis of the lung (Figure 40 and Figure 41).  By 21 days post infection the 
perivascular and peribronchial infiltrate was more noticeable in the CCR2 deficient mice, but in 
the wild type mice the lymphocytes were infiltrating deeper into the parenchymal space.  By 33 
days post-infection granulomas were evident in both groups of mice, but were more organized in 
wild type mice with tighter lymphocytic clusters.  By day 48 the granulomas were organized in 
the CCR2 deficient mice, but as a result of fewer macrophages in the lungs, the granulomas 
consisted of lymphocytic cuffs surrounding epithelioid macrophages, rather than the lymphocytic 
aggregates within sheets of epithelioid macrophages as previously described in wild type mice 
[26].  Thus, granuloma formation in the lungs was delayed and ultimately the granulomas 
appeared to contain fewer macrophages in CCR2-/- mice compared to wild type mice. 
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Figure 42.  Granulomas form in the lungs with delayed kinetics in CCR2 deficient mice.   
Hematoxylin and Eosin staining was performed on 5-6µm formalin-fixed lung tissue sections at each time point, 
post infection.  Panels from day 13, 21, and 33 are 40X while panels from day 48 are 100x magnification.  
Infiltration is delayed in CCR2-/- mice, but granulomas do form, although they are histologically different from 
those found in CCR2+/+ mice. 
 
IFN-γ and NOS2 production is delayed in CCR2 deficient mice. 
 Mice deficient in CCR2 have transient delays in IFN-γ production [159, 188, 191].  Since 
IFN−γ is required for control of M. tuberculosis [64, 98, 192] and the CCR2-/- mice control 
infection in the low dose models, we examined whether the defect in IFN-γ production reported 
in the high-dose infected mice [62] was evident in the aerosol model.  Using RNase protection 
assays on whole lung RNA preparations, there was a substantial delay in the IFN-γ gene 
expression (Figure 43).  Concomitant with the delay in IFN-γ  there was a delay in mRNA levels 
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 of the gene for inducible nitric oxide synthase (NOS2). RNA from the lungs of uninfected mice 
was also used in RNase protection assays; the genes of interest were below the level of detection 
with this RNA (data not shown).  The delayed NOS2 gene expression was confirmed at the 
protein level by immunostaining of lung tissue from the mice at each time point post-infection 
(data not shown). Expression of a number of other cytokines was addressed through RNase 
Protection Assay, and no significant difference in the mRNA expression of IL-12, TNF, or IL-1 
in CCR2-/- compared to wild type mice was observed (data not shown). 
IFN-γ
0 10 20 30 40 50 60 70 80
0.0
0.1
0.2
0.3
0.4
CCR2-/-
CCR2+/+
Days Post Infection
NOS2
0 10 20 30 40 50 60 70 80
0
1
2
3
Days Post Infection
***
*
**
*
 
Figure 43.  Expression of IFN-γ and inducible nitric oxide synthase (NOS2) is delayed in the lungs of CCR2-/- 
mice infected with a low dose of M. tuberculosis H37Rv via aerosols.   
RNase Protection Assays were performed on whole lung RNA preparations, as described.   Each data point 
represents three to four CCR2-/- mice (open squares) or CCR2+/+ mice (closed triangles), and the bars represent 
standard error.  *p<0.05, **p<0.005, and ***p<0.001.  This experiment was repeated once with similar results. 
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 Memory response 
 To determine whether CCR2 was required in the secondary immune or memory response 
to M. tuberculosis, we infected wild type and CCR2-/- mice via aerosol (~50 CFU/mouse) and 4 
months later, treated the mice with isoniazid and pyrazinamide for 8 weeks, reducing bacillary 
loads below detection.  After allowing the mice to “rest” for 8 weeks, the mice were challenged 
via the aerosol route with ~50 CFU M. tuberculosis.  No CFU were detectable in the mice prior 
to challenge.  Following challenge, the bacterial loads were determined and cell migration was 
addressed by flow cytometric analysis.  The macrophage defect in CCR2-/- mice was evident 
throughout the 6 weeks of observation, but again there was no sign of increased susceptibility 
(Table 10).  There was no difference in T cell migration to the lungs observed in these mice. 
Table 10. Cell migration to the lung following challenge of memory mice with aerosol M. tuberculosis.   
C57Bl/6 mice and CCR2-/- mice were infected with M. tuberculosis H37Rv (50 CFU) via aerosol route.  Four 
months post infection the mice were drug-treated for 2 months.  The mice were then challenged with aerosol M. 
tuberculosis H37Rv (50 CFU) and flow cytometric analysis was performed at the times indicated in the table.  * p= 
0.02 and ***p=0.001. 
Days post 
Rechallenge
% CD4+T 
cells (+/- 
SEM) 
CCR2-/- 
% CD4+T 
cells (+/- 
SEM) 
CCR2+/+ 
% CD8+T 
cells (+/- 
SEM) 
CCR2-/- 
% CD8+T 
cells (+/- 
SEM) 
CCR2+/+ 
% 
Macrophages 
(+/- SEM) 
CCR2-/- 
%Macrophages 
(+/-SEM) 
CCR2+/+ 
CFU/Lung 
x105  
(+/-SEM) 
CCR2-/- 
CFU/Lung 
x105  
(+/-SEM) 
CCR2+/+ 
18 20.2 (2.6) 27.6 (7.5) 18.4 (2.4) 16.0 (2.5) ND ND 3.1 (0.25) 5.0 (0.4) 
28 21.9 (1.5) 22.5 (1.3) 21.1 (0.9) 17.3 (1.2) 11.2 (0.8) 18.3 (1.14) 5.8 (1.56) 5.2 (1.66) 
49 16.4 (1.7) 19.0 (1.4) 18.4 (1.1) 16.5 (0.9) 8.2 (1.98) 16.5 (1.62) 6.4 (1.27) 6.8 (1.94) 
 
10.4 Discussion 
CCR2-/- mice are clearly deficient in monocyte/macrophage migration to an inflammatory site 
[62, 184, 185, 187-189, 191, 193].  Here we confirmed the previous findings of impaired 
migration of cells to the lungs of CCR2-/- mice following M. tuberculosis infection.  However, 
in contrast to CCR2-/- mice infected with a relatively high dose of M. tuberculosis, CCR2-/- 
mice infected with a low dose of M. tuberculosis controlled the infection, despite a substantially 
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 reduced macrophage population in the lungs.  Thus, in a low dose infection, a delayed or 
deficient immune response does not necessarily lead to higher bacterial numbers in the lungs. 
The absence of CCR2 resulted in prolonged macrophage deficiency in the lungs in the 
low dose model of infection.  There was 2-5 fold fewer macrophages in the CCR2-/- lungs 
compared to wild type lungs. There was also a less pronounced but definite defect in macrophage 
migration to the lungs following challenge of previously infected and drug-treated (i.e. immune) 
mice.  However, the level of macrophages was apparently sufficient to control the primary or 
secondary infection, suggesting that the macrophage response in wild type mice to M. 
tuberculosis is more robust than necessary to control a low dose infection.  However, even a very 
robust response is insufficient to clear the infection in mice.  
T cell migration, particularly CD4 T cells, was also deficient in CCR2-/- mice during the 
early stages of the infection.  This may be a direct effect of the absence of CCR2, since this 
receptor is found on activated T cells and may be important in T cell trafficking to the lungs from 
the bloodstream.  However, the delay in T cell migration could also be an indirect effect of 
CCR2 deficiency.  Macrophages produce additional chemokines that signal T cell migration, and 
the reduction in macrophages in the lungs may result in altered chemokine levels contributing to 
reduced T cell migration. Alternatively, priming of T cells by dendritic cells in the lymph nodes 
could also be affected by the absence of CCR2, and this would result in a delay in T cell 
responses in the lungs. The T cell migration delay was not observed in the memory response to 
challenge in the lungs, suggesting that chemokine responses for memory cells may differ from 
those required for a primary response, or that priming of T cell response by dendritic cells may 
be the cause of the delay in the primary response. 
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  A significant delay in IFN-γ gene expression was also observed in the lungs.  This may 
be due to the delayed T cell migration to the lungs, or to reduced stimulation of the T cells that 
are present in the lungs because of macrophage deficiencies.  Regardless of the mechanism 
responsible, the finding that a substantial delay in IFN-γ production does not necessarily lead to 
increased bacterial numbers is surprising.  IFN-γ is an essential cytokine for control of M. 
tuberculosis infection, regardless of dose or route of challenge [64, 98].   Nonetheless, it appears 
that IFN-γ levels substantially reduced from wild type levels are sufficient to control low dose 
infection, at least in the early stages of infection.  This again implies that the immune response in 
the lungs is more robust than necessary for bacterial control.  The delayed IFN-γ levels may be 
responsible for the reduced NOS2 gene expression, or this may also result from the deficiency of 
macrophages, the cells that produce NOS2, in the lungs.  In any event, the control of bacterial 
growth in the lungs of CCR2-/- mice following low dose infection suggests that the level of 
NOS2 production is sufficient; however, at higher doses, this level of macrophage activation was 
apparently not adequate to control bacterial growth. 
 One striking difference between the low dose and high dose infection in CCR2-/- mice 
was the neutrophilic infiltration to the lungs.  The increased neutrophilic infiltration as a result of 
CCR2 deficiency was previously observed [62]; the results in the low dose infected mice suggest 
that the continued infiltration of neutrophils may be due to uncontrolled bacterial replication in 
the high dose model rather than a direct result of CCR2 deficiency.  It is possible that the 
presence of large numbers of neutrophils in the lungs is damaging to the tissue, and affects the 
ability of the macrophages to control infection.  In the low dose mice, the neutrophil infiltration 
is not significantly different at any time point, although there is a trend toward higher numbers of 
neutrophils in the CCR2-/- lungs.  Coincident with the induction of cell-mediated immunity and 
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 control of bacterial growth in the lungs (at 3-4 weeks post-infection), the numbers of neutrophils 
decreased. 
 More recently, a more detailed study demonstrated that CCL2-/- mice have very similar 
infection profile to CCR2-/- mice following low dose aerosol infection [73].  In these studies the 
authors report fewer macrophages migrating to the lung and a very small transient increase in 
bacterial burden in the CCL2-/- mice compared to wild type mice.  In addition the CCL2-/- mice 
had a transient reduction in IFNγ production.  These data indicate that CCL2 ligation of CCR2 is 
required for macrophage migration and early lymphocyte focusing in the lung. 
In summary, these studies confirm that CCR2 is an important chemokine receptor in the 
trafficking of macrophages to the lungs during M. tuberculosis infection. However, for low dose 
infection, the prolonged paucity of macrophages and transient delay in T cell recruitment and 
IFN-γ expression did not noticeably impair control of the infection in the lungs.  These results 
imply that the wild type immune response to M. tuberculosis in the lungs is more vigorous than 
necessary. Clearly, CCR2 is important for macrophage infiltration into the lungs following M. 
tuberculosis infection, and there is not a molecule that can replace CCR2 in this function.  This 
striking phenotype was observed regardless of infection dose, route or strain of M. tuberculosis.  
The importance of macrophages to control of M. tuberculosis is well established.  The ability of 
mice to control a low dose, but not a relatively high dose M. tuberculosis infection with a 
substantial deficiency in macrophage numbers in the lungs does not imply that CCR2 is not 
playing a role in the immune response to this pathogen.  Instead, the ability of mice to control a 
low dose infection with a minimal inflammatory response in the lungs, with respect to 
macrophages and T cells early in infection, can be observed in these studies.  A higher dose 
infection clearly overwhelms this reduced response, and the reduced subsequent IFN-γ and 
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 macrophage infiltration is not sufficient to gain control of the infection.  The induction of T cell 
response in the lungs in the high dose mice at ~2-3 weeks post-infection coincides with very high 
bacterial numbers, and thus cannot contribute to the reduction of the bacterial load.  This has 
been observed in other systems as well, including mice deficient in CD4 T cells [7].  However, 
as with many immunologically deficient mice and tuberculosis, CD4 T cell deficient mice cannot 
control even low dose aerosol infections [194].  In contrast, in the low dose infection, the 
minimal innate and inflammatory response that occurs in the absence of CCR2 is sufficient to 
control the infection until cell mediated immunity is fully induced.   
These studies have provided insight into the use of immunologic knockout mice to study 
M. tuberculosis.  The use of CFU as the primary measure of the contribution of a specific 
immune component in the response to this infection can be misleading.  In studies designed to 
unravel a complex system, such as cell migration and granuloma formation, the choice of model 
can be crucial to the outcome and interpretation of the results.  The use of models, in vitro or in 
vivo, that are deficient in one component enables the assessment of a possible role for that 
component in cell migration or control of infection.  However, the presence of a multitude of 
components can complicate the interpretation of the data, particularly in in vivo studies.  An 
increase in bacterial numbers in a knockout mouse, compared to wild type, has been a standard 
for determining whether a particular component is essential in the immune response to M. 
tuberculosis.  The infiltration of cells to the lungs and subsequent granuloma formation is clearly 
a complex process requiring a network of molecules and receptors.  Nonetheless, although our 
data confirmed that CCR2 is clearly important in migration of macrophages to the lungs 
following infection, under certain infection conditions this deficiency does not impair control of 
bacterial growth in the lungs.  Our interpretation of these data is that comparison of bacterial 
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 numbers is only one measure of the function of certain molecules.  The data provided here 
demonstrate that CCR2 is an important molecule in monocyte/macrophage migration, and also 
affects, perhaps indirectly, T cell migration and IFN-γ expression.  In the low dose infection 
model, other immune components are sufficient to control the infection, whereas when a higher 
dose is administered to the mice, the absence of CCR2 results in lethal infection.  Thus, there is a 
critical dose that can overwhelm the ability of macrophage-deficient lungs to control infection. 
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 11.0 Summary 
 My evaluation of cell migration and chemokine expression during M. tuberculosis 
infection has provided novel information that will aid in understanding the cascade of events in 
response to infection. I have also made important contributions to our general understanding of 
the immune responses to M. tuberculosis and the utility of the mouse model.  This study began 
with a broad focus, which we narrowed to evaluate a specific subset of inducible chemokines.  
Early analysis of anti-TNF Ab treated mice revealed granuloma deficiency after M. tuberculosis 
infection [106], and one set of logical candidates for control of granuloma formation was 
chemokines.  Therefore, after defining a subset of chemokines that were affected by anti-TNF 
Ab treatment in vitro, we designed experiments focusing on the expression of those chemokines 
in vivo and in vitro during M. tuberculosis infection.  The chemokine functions analyzed fell 
mainly into three groups based on their receptors:  ligands for CXCR3 (CXCL9, 10 and 11), 
ligands for CCR5 (CCL3, CCL4, CCL5), and ligands for CCR2 (CCL2 and CCL12). 
 Many cell types are required for an effective, controlled immune response to be initiated 
and maintained in the lungs during M. tuberculosis infection.  These cells include CD4 
lymphocytes, CD8 lymphocytes, and macrophages.  In addition, B lymphocytes and neutrophils 
are involved in the immune response, but their roles are less defined.  In a healthy lung very few 
immune cells are present, rather the tissue is comprised of airways with walls of ciliated 
epithelium with some alveolar macrophages and immature dendritic cells present.  After 
infection, cell migration to the lungs begins and the immune system sets up its defense.   The 
organization of the immune system requires many different cells communicating through many 
different signals.  The granuloma structure in the lungs serves as a site for this cascade of 
communication.  Although the granuloma is also a sign of chronic antigenic stimulation and 
leads to some pathology, it is clearly required for control of infection.  The bacterial burdens in 
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 mice plateau at the time when granulomas form and the cell mediated immune response has been 
initiated.   It is at this critical juncture that TNF- deficient mice are unable to form granulomas 
and control infection.  Therefore these studies, focusing on the signals required for granuloma 
formation and cell migration into the lungs, are very important for understanding the initiation 
and maintenance of a successful cell mediated immune response to M. tuberculosis in the lungs. 
Chemokines, or chemotactic cytokines, are responsible for cell migration into and out of 
lymphatics, the blood and tissue.  We demonstrated that many inducible chemokines, both of the 
C-C and C-X-C classes, are upregulated with M. tuberculosis infection.   
Differences in the organization of cellular infiltrates found in many chemokine deficient 
mice, such as CCR2-/- mice, CXCR3-/- mice, CCL2-/- mice or CCR5-/- mice (Table 1) did not 
result in differences in overall control of tuberculosis infection.  This is very different from a 
situation in TNF-deficient mice.  In the TNF-deficient mice, even though there are as many cells 
migrating into the lungs, the infiltrates are not organized.  As a general point it appears that early 
cell migration can be delayed (such as in CCR2-/- mice), but the bacterial burdens must be 
controlled by 3 or 4 weeks post infection, or an effective cell mediated immune response may 
not be initiated.   
Another important point that can be taken from these studies is that although there may 
not be differences in the bacterial burden or survival, lessons can be learned about the intricacies 
of immune system.   The table below briefly describes the differences found in the cellular 
infiltrates during infection of chemokine knockout mice.  Not all of these mice illustrate 
differences in bacterial burden or in survival, but they do show distinct significant differences in 
the cellular infiltrate to the lungs or the lymph nodes.  Therefore CCR2 is required for 
macrophage migration to the lungs and lymph nodes.  CCR5 is required for normal dendritic cell 
151 
 migration/ retention in the lymph nodes and lung early, influencing T lymphocyte migration late.  
CXCL10 appears play a role in early lymphocyte migration to the lymph nodes. 
 
Table 11.  Cellular infiltrate differences in chemokine or chemokine receptor deficient mice. 
Mouse Strain Cell infiltrate differences 
observed 
When differences 
observed 
Reference 
CCR2-/- Macrophages (Lung, Lymph 
nodes) 
Throughout 
infection 
[63] 
CCR5-/- Dendritic cells (Lymph nodes), 
T lymphocytes (Lung)  
Early, late Section 
9.0 
CXCL10-/- T lymphocytes (Lymph nodes) Early  Section 
8.0 
CXCR3-/- Neutrophils, T lymphocytes 
(Lung) 
Early [72] 
 
We detected increased expression of CCL2, CCL7 and CCL12, ligands for CCR2, in the 
mouse after M. tuberculosis infection in the lung and in vitro in macrophages. We hypothesized 
that CCR2 would be required for macrophage migration to the lung.  We expected the mice to be 
susceptible to tuberculosis with a macrophage deficiency.  During acute inflammatory responses 
in CCR2-/- mice there were obvious deficiencies in macrophage and dendritic cell migration.  
Our studies have demonstrated dose dependent control of M. tuberculosis infection in CCR2-/- 
mice.   
Based on our findings that CCR5 ligands were affected by TNF and that CCR5 is on 
macrophages, dendritic cells and T lymphocytes we hypothesized that the immune response to in 
CCR5 deficient mice would be impaired due to reduced migration of these cells to the lungs.   
Our hypothesis was not supported.  Our studies suggest that CCR5 has either a direct or indirect 
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 role in dendritic cell migration from the lung to the lymph node.  There does not appear to be a 
direct effect on macrophages or lymphocytes.  This may be the consequence of several reasons.  
CCR5 may not be involved in lymphocyte migration, or the ligands for CCR5, CCL4 and CCL5, 
could be signaling through CCR1 to induce migration of lymphocytes and macrophages.  In 
addition, other chemokines may be compensating for the loss of CCR5 signaling. 
In an effort to recapitulate the pathology observed in the anti-TNF Ab treated mice, these 
neutralization and receptor knockout models were utilized.  We were unable to recreate the 
pathology observed in the absence of TNF.  This is likely due to the number of chemokines 
influenced, at least in part, by TNF, and it is impossible to recreate a knockout or an effective 
neutralization model, that could modulate all these chemokines.  The effects of TNF may also be 
temporal, and several chemokines could be modulated at different time points in the infection. 
The effect TNF has on the immune response is not limited to chemokine expression, and 
includes such important roles as macrophage activation and modulation of cytokine expression.  
In addition, chemokines are not solely responsible for cell migration, adhesion molecules play a 
role in these processes and other factors such as matrix metalloproteinases can be involved in 
tissue pathology and granuloma formation.   
Matrix metalloproteinases (MMPs) are implicated in tissue remodeling processes and 
chronic inflammatory conditions.  In addition, recent evidence indicates that transendothelial 
migration of lymphocytes is affected by MMPs [195].  MMP-1 (52kDa collagenase) and MMP- 
9 (92kDa collagenase) are induced in vitro following M. tuberculosis infection in THP-1 cells 
[196], and neutralization of TNF reduced MMP production in response to mycobacteria [197].  
These data indicate that chemokine gradient changes may not be solely responsible in the lung 
pathology observed with anti-TNF Ab treatment in vivo.  We performed some gene expression 
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 (array) studies of MMP expression in the lungs of anti-TNF treated mice, and observed no 
obvious differences between these mice and control mice, but this avenue is complicated by the 
fact that there is extensive post transcriptional processing of MMPs making interpretation of the 
data difficult  (APPENDIX C). 
Through this research we have contributed to generalized concepts of the immune 
response to M. tuberculosis.  Through studies on TNF we have learned that the localized gene 
and protein expression with in the site of a granuloma is very different from expression and 
activity in the whole lung.  Through studies on CCR5-/- mice, we learned that the immune 
response can be more robust than necessary, but a stronger Th1 response does not lead to 
increased clearance of the mycobacteria.   Through studies in CCR2-/- mice we learned that dose 
can have a strong influence on survival in immunocompromised mice, and that the immune 
response can be delayed or reduced without long term detrimental effects to the host, as long as 
the inoculum is reasonable. Both these studies support the contention that the immune response 
to M. tuberculosis in the lungs of mice is much stronger than necessary, and suggest that there 
must be some regulation of this response to avoid excessive immunopathology.   Overall these 
studies will have a major impact on the future design of experiments.  In many experiments 
performed for this thesis, there were no differences in mycobacterial burden or survival in gene-
deficient mice, yet there were still definable roles and mechanisms of action for a particular 
factor.  In other words, the immune response is a very intricate system and knocking out or 
blocking essential elements may lead to very obvious or very subtle changes in the response 
without increased bacterial loads or decreased survival.  Therefore, the experiments need to be 
designed in a way to address mechanisms of action, in addition to outcome of infection in order 
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 to understand the immune response.   We have approached this by not simply following bacterial 
numbers, but also surveying the immune response at many points throughout the infection. 
Our studies on cell migration and chemokine expression have deepened the tuberculosis 
field’s understanding of the immune response in the lungs.   These studies have shown the 
importance of very localized controlled chemokine expression.  The macrophage appears to 
orchestrate granuloma formation and maintenance in the lungs, at least in part through the 
cascade of expression of TNF and chemokines (Figure 44). 
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Figure 44.  Chemokine expression and cell migration in the absence of TNF. 
Chemokines are both down regulated (CCL2, CCL3, CCL4, CCL5, CXCL9, CXCL10) and upregulated (CCL12) in 
the absence of TNF.  In addition granuloma formation is absent and although the cells migrate to the lungs, they do 
not form organized granulomas. 
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APPENDIX A 
 
 
A.0 IL-10 expression during aerosol M. tuberculosis infection is a result of increased 
bacterial burden and does not lead to immunosuppression 
Abstract 
 This study addresses possible interactions between IL-10 and TNF in maintaining a M. 
tuberculosis granulomatous response.  The results indicate that IL-10 production seen in TNF 
neutralized mice was a reaction to the inflammation, rather than contributing to the inflammation 
through immunosuppressive activity.  This response was also observed in other mice that had 
substantial inflammation or high bacterial numbers in the lungs. 
A.1 Introduction 
Recent studies indicate that overproduction of IL-10 results in poor immune responses to 
mycobacterial infections [107, 108]. In vivo production of IL-10 under the control of the IL-2 
promoter lead to reactivation of pulmonary tuberculosis in mice [107].   IL-10 and other Th2 
cytokines are correlated with impaired control of some intracellular pathogens, such as 
Mycobacterium leprae, M. bovis and Leishmania major [108, 198-200]. 
Additional studies have examined the response of IL-10-/- mice to mycobacterial 
infections.  These studies do not collectively define a role for IL-10 in control of mycobacterial 
infections.  When IL-10-/- mice were infected intravenously with BCG, an avirulent M. bovis 
strain, they maintained lower bacterial burdens than C57BL/6 mice, had larger granulomas and 
higher expression of ICAM, MHC II, TNF and NOS2 [201, 202].  On the other hand, when IL-
10-/- mice were infected via aerosol with BCG, there was no significant difference in disease 
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 progression [203]. M. avium infected mice, when treated with neutralizing antibody to IL-10, had 
increased resistance to disease [204, 205].    There was no difference in bacterial numbers in the 
organs of IL-10-/- mice within the first 3 months of infection with M. tuberculosis [65].  In 
another study, infection of IL-10-/- mice with M. tuberculosis led to transient increases in IFNγ 
production and initially better control of M. tuberculosis than wild type mice, but by 8 weeks 
post infection, these differences no longer were apparent [109].  
IL-10 is an anti-inflammatory cytokine primarily associated with Th2 responses 
[reviewed in [206, 207]].  IL-10 enhances activation, proliferation and chemotaxis of CD8+ 
lymphocytes [208], antibody dependent cytotoxicity, B lymphocyte proliferation, differentiation 
and antibody production.  Furthermore, IL-10 can inhibit LPS inducible genes, IFNγ inducible 
genes, reactive oxygen and nitrogen intermediates [reviewed in [209]].   
In this study we sought to determine whether IL-10 and TNF interact in maintaining 
granuloma structure.  When TNF was neutralized in the murine model of chronic persistent 
tuberculosis, IL-10 mRNA levels increased in the lungs of anti-TNF treated mice, but not in 
control mice [106].  These mice had substantial lung pathology, as described in the Introduction 
and Chapter 1 of this thesis.  IL-10 transgenic mice were more susceptible to reactivation of 
chronic M. tuberculosis infection and acute BCG infection[67, 108].  These studies suggested 
that inappropriate regulation of IL-10 may lead to exacerbation of disease.  
A.2 Materials and Methods 
Animals.   
C57BL/6 female mice (Charles River, Rockland, Mass.) and IL10-/- (8-14 weeks old) were used 
in all experiments.  Mice were transferred to the Biomedical Science Tower Biosafety Level 3 
animal facility at 7-8 weeks of age.  All infected mice were maintained in the BSL3 animal 
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 laboratories and routinely monitored for murine pathogens by means of serological and 
histological examinations.  The University Institutional Animal Care and Use Committee 
approved all animal protocols employed in this study. 
Chemical and reagents.   
All chemicals were purchased from Sigma Chemical Co. (St. Louis, MO.) unless otherwise 
noted.  Middlebrook 7H9 liquid medium and 7H10 agar were obtained from Difco Laboratories 
(Detroit, MI).  Antibodies used in flow cytometric analyses were obtained from Pharmingen (San 
Diego, CA).  Pyrazinamide was purchased from Acros.  The cell lines, MP6XT-22 (anti-TNF) 
and JES5-2A5 (anti-IL10), were obtained from DNAX and used to generate ascites (Harlan 
Bioproducts, Indianapolis,IN).  Antibodies were purified endotoxin free from ascites fluid as 
previously described [106] and mice were treated with antibody intravenously every three days 
(0.5mg/dose) starting 4 months post infection.  Control mice received normal rat IgG (Jackson 
Immunoresearch Laboratories Inc.,West Grove, PA) with the same dosing regiment. 
Mycobacteria and infection of mice.   
To prepare bacterial stock, M. tuberculosis strain Erdman (Trudeau Institute, Saranac Lake, 
N.Y.) was used to infect mice, and then bacteria were harvested from their lungs, expanded in 
7H9 liquid medium and stored in aliquots at -80°C.  Mice were infected via the aerosol route 
using a nose-only exposure unit (In Tox Products, Albuquerque, N.M.), and exposed to M. 
tuberculosis (1 x 107 CFU/ml in the nebulizer chamber) for 20 minutes, followed by 5 minutes of 
air. This resulted in reproducible delivery of 50-100 viable CFU of M. tuberculosis as described 
previously [94], which was confirmed by CFU determination on the lungs of 2-3 infected mice 1 
day post-infection.   The tissue bacillary load was quantified by plating serial dilutions of the 
lung, liver, and spleen homogenates onto 7H10 agar as described previously [30]. 
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 Flow cytometric analysis of lung cells.  
 
To determine cellular infiltrate in the lung, at 10-day intervals lungs were removed for flow 
cytometric analysis.  Lungs were subjected to a short period (20 minutes) of digestion with 
1mg/ml collagenase A and 25 Units/ml DNAse (both from Boehringer Mannheim, Mannheim, 
Germany) at 37°C.  The suspension was pushed through a cell strainer as previously described 
[63].  Red blood cells were lysed with red blood cell lysis buffer (NH4Cl/Tris Solution) and the 
single cell suspension was counted.  The samples were stained with 0.2 µg anti-CD4, anti-CD8, 
anti-CD69, anti-CD25 or 0.2 µg anti-B7.1, anti-B7.2, and 0.15 µg anti-Gr1 and 0.2 µg anti-
CD11b in FACS buffer (0.1% NaAzide, 0.1% BSA, 20% mouse serum).  Following washes, the 
cells were fixed in 4% PFA for 1 hour and collected on a FACS Caliber (Beckon Dickinson).  
Analysis was performed on Cell Quest software (BD-Pharmingen, San Diego, CA). 
Histopathology.   
 
Tissue samples for histological studies were fixed in 10% normal buffered formalin followed by 
paraffin embedment.  For histopathological studies 5- to 6- µm sections were stained with 
Harris’ hematoxylin and eosin.   
RNase Protection Assay (RPA).   
A multiprobe RNase protection assay system (Pharmingen, San Diego, Ca) was used to 
determine the levels of mRNA for genes of interest at 10 day intervals post-aerosol infection in 
murine lung or infected macrophages in vitro.  At the time of harvest, the lungs were snap frozen 
in liquid nitrogen and stored at -80°C.  Total RNA was extracted using Trizol reagent (Life 
Technology, Grand Island, N. Y.) followed by treatment with RNase free-DNase (Roche, 
Indianapolis, IN) and RNase Inhibitor (Roche).  The RNA was subjected to RPA according to 
Pharmingen’s protocol.  In short, mRNA from macrophages or the lungs was hybridized 
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 overnight to [32P]-UTP-labeled probes.  The protected [32P]-UTP-labeled RNA probes were 
resolved on a 6% polyacrylamide gel and analyzed by autoradiography.  Cytokine analysis was 
performed using a custom-made template set specific for NOS2, IL-4, IL-12p40, TNF, IL-1β, 
IL-1α, and IFN-γ.  The expression of specific genes was quantified on a densitometer 
(ImageQuant Software, Molecular Dynamics, Sunnyvale, CA), relative to the abundance of 
housekeeping gene, L32.  We also performed phosphorimaging quantification on some samples 
but found results identical to densitometry; therefore, only densitometry quantifications are 
shown. 
A.3 Results 
We followed up our previous work to address the expression and role of IL-10 in M. 
tuberculosis infection.  Aerosol infection was performed using a nose only exposure unit to 
deliver 50-100 CFU to the lungs of IL-10-/- or wild type (C57BL/6) mice.  IL-10 was neutralized 
by administering JES antibody (i.p. 500µg/ mouse every three days) and TNF was neutralized 
with MP6-XT22 antibody (i.p. 500µg/ mouse every three days).   
We have previously reported that IL-10 was expressed at low or undetectable levels in 
lungs of M. tuberculosis aerosol-infected C57Bl/6 mice, as determined by RNase protection 
assay [106].  On the other hand, when bacterial burdens were high in immunocompromised 
mice, such as CCR2-/- (high dose i.v.infection), TNFRp55-/-, anti-TNF treated, CD40-/-, or 
CD4-/- mice, IL-10 expression in the lungs was increased (Table 12) especially when bacterial 
burdens increased to levels above 1x107 CFU.  A good example of the IL-10 expression in mice 
with high bacterial burdens is in CD40-/- mice where at 3 weeks post infection only some of the 
mice have high bacterial burdens.  The subset of CD40-/- mice with pulmonary bacterial 
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 numbers similar to wild type mice also had wild type (low) IL-10 mRNA expression levels. 
However, IL-10 expression was 4-5x higher in the lungs of sick CD40-/- mice (Table 12),  
Table 12.   IL-10 gene expression in the lungs of M. tuberculosis infected mice.  
 Expression of IL-10 was increased in aerosol infected gene-deficient mice that were impaired in the ability to 
control M. tuberculosis infection, compared to wild type C57BL/6 mice.  1Ratio is the ratio of the intensity of the IL-
10 gene over the L32 housekeeping gene.  The results are the average of two mice at each time point.  This 
experiment was performed a minimum of twice for each group of mice with similar results.   
Strain  “N” Days Post Infection Average CFU Ratio (IL10/L32) 
TNFR  3 25 4x107 0.036 
TNFR  3 14 1x105 0.002 
CD4 -/-  3 44 2x107 0.027 
CD4-/-  3 21 2x106 0.007 
CD40-/-  3 21 4x106 0.005 
CD40-/-  2 21 9x107 0.023 
CD40-/-  3 14 2x106 0.001 
CCR2-/-  4 18 1x108 0.011 
CCR2-/-  3 12 8x105 0.001 
GKO  3 28 9x107 0.014 
GKO  3 21 7x106 0.005 
WT  4 21 1x105 0.002 
MP6 txt  3 18 1x107 0.029 
IgG txt   3 18 1x106 0.001 
   
Acute M. tuberculosis infection in IL-10-/- mice  
 
As previously reported [65], IL-10-/- mice controlled aerosol infection with M. 
tuberculosis similar to wild type mice (Figure 45A). Histologically the granuloma structures 
were well organized.   The macrophages appeared larger and more activated in the IL-10 -/- 
mice, but RNase Protection Assays on lung RNA revealed no significant differences in the 
expression of IL-1, IL-15 or IL-12 compared to C57BL/6 mice (data not shown).   Based on our 
previous experience detecting cytokines from the macrophage population, it is possible that our 
technique was not sensitive enough to detect differences. IFNγ expression was measured at 4, 8, 
14, 18, and 22 weeks post infection.  While there was a tread towards higher IFNγ expression in 
the IL-10-/- mice, the differences were only significant at 4 and 14 weeks postinfection.  
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 Therefore, during acute infection, the course of infection in C57BL/6 mice and IL-10-/- was 
relatively similar.   
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Figure 45.  Colony forming units in the lungs of M. tuberculosis infected mice.  
 A.  IL-10-/- mice controlled M. tuberculosis infection in the lung, spleen, and liver (data not shown).  The course of 
infection in IL-10-/- mice was similar to wild type mice.  B. When TNF was neutralized in chronically infected IL-
10-/- mice, through MP6 treatment, the IL-10-/- mice maintained better control of the pulmonary bacterial burden.  
C.  IL-10 neutralization alone in chronically infected wild type mice did not alter the course of infection. On the 
other hand when TNF was neutralized, alone or in conjunction with IL-10, the bacterial burdens in the lungs rose.  
TNF neutralization alone led to uncontrolled infection and death by 20 days post infection. Dual neutralization of 
TNF and IL-10 delayed mortality, but only temporarily. 
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 The role of IL-10 during anti-TNF induced reactivation  
To address the contribution of IL-10 to the pathology observed during anti-TNF Ab induced 
reactivation of tuberculosis [106], we treated chronically infected (4-5 months post-infection) IL-
10-/- and C57BL/6 mice with anti-TNF antibody.  The IL-10-/- mice exhibited reduced bacterial 
burdens in their lungs, livers and spleens compared to C57BL/6 mice treated with anti-TNF, but 
that did not influence the survival of the mice (Figure 45B). Both IL-10-/- and wild type mice 
succumbed to infection by 25 days post anti-TNF antibody treatment.  In addition both IL-10-/- 
and wild type mice developed severe disorganization of the cellular infiltrate in the lungs by 14 
days after anti-TNF treatment began (Figure 46). 
IL-10-/-
IgG MP6 txt.
IL-10+/+
 
Figure 46.  TNF neutralization leads to increased disorganized pulmonary infiltrate in IL-10-/- and wild type 
mice.   
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 Granuloma formation in IL-10-/- and wild type mice was similar throughout infection (here shown at 4 months post 
infection).  By 14 days post MP6 treatment, cellular infiltrate increased in both groups of mice and granuloma 
becomes disorganized 
 
When IL-10 was neutralized in conjunction with TNF neutralization in a chronic mouse 
model, the mean survival time was 8 days longer (m.s.t 24 days (anti-TNF) v. m.s.t. = 32 days 
(anti-TNF/anti-IL10), but there was no overall difference seen in the histology.  These data 
indicate that IL-10 was probably making a very subtle difference in the immune response.   At 10 
days post antibody treatment there was a reduction in the mean fluorescence intensity of 
costimulatory molecules B7.1 (MFI = 240 v. 310: Anti-IL10, anti TNF Abs vs anti-TNF Ab 
alone) and B7.2 (MFI = 389 v. 592) in the dual neutralized mice compared to the anti-TNF 
treated mice, but no difference in the percentage of cells expressing these molecules.  In addition, 
the percentage of CD25+ lymphocytes was increased in the dual neutralized mice (31% v. 15% 
CD25+ in CD8+gate and 39% v. 20% in the CD4+ gate).  This suggests that IL-10 may down 
regulate CD25 expression on lymphocytes, or that a population of proliferating (CD25+) T cells 
is down-regulated by IL-10.  IL-10 neutralization alone resulted in no differences in the course of 
infection (data not shown).   
A.4 Discussion 
 Recent data suggest that IL-10 overproduction in vivo can reactivate chronic pulmonary 
tuberculosis in C57BL/6 mice [107].  Although this is evident in the transgenic system, C57BL/6 
mice do appear to produce amounts of IL-10 capable of producing detrimental 
immunosuppressive effects during M. tuberculosis infection.  IL-10 -/- mice controlled infection 
slightly longer in the face of TNF neutralization, compared to wild type mice.  Clearly, the 
quantity and timing of IL-10 production influences the effects the cytokine can have on the 
immune response and control of the infection.  In the case of TNF neutralization in wild type 
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 mice, the expression of IL-10 may be slightly detrimental to the induced reactivation.  Therefore, 
the results of our study indicate that IL-10 production in TNF neutralized mice was a reaction to 
the inflammation in TNF neutralized mice, and although it may contribute to the pathology, it 
was not responsible for the induction of inflammation observed after TNF neutralization.  The 
data in table 11 also supports this.  IL-10 is not expressed in mice where bacterial burdens are 
below 1x107 CFU.  Most of these mice succumb to infection and have severe inflammation due 
to impaired cell mediated immune responses not due to IL-10 production. 
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APPENDIX B 
 
B.0 Anti-TNF treatment in the presence of antibiotics. 
 
 Anti-TNF treatment quickly results in loss of control of M. tuberculosis granulomas and 
the bacterial burdens increase.  The anti-TNF treated mice succumb to infection despite the fact 
that the number of colony forming units in the lung is not >108 (a level where wild type C57Bl/6 
usually become moribund).  The log increase in CFU observed in the anti-TNF treated mice is 
enough to increase chemokine levels complicating our experimental models by created two 
variables, no TNF and higher CFU, rather than just no TNF.   
 To attempt to eliminate the second variable in our experimental model, we treated both 
the anti-TNF treated and the IgG treated mice with antibiotics 4 months post infection.  The 
treatment led to a reduction in the colony forming units, although the mice treated with MP6XT-
22 had a slower reduction, as seen at day 14 (Figure 47).  By day 42, M. tuberculosis was no 
longer detected in the lung (limit of detection <40 CFU).  As a result no experimental or control 
mice succumbed due to anti-TNF treatment.  The experiment was sustained for 70 days to 
observe the cellular infiltrate, pathology and colony forming units. 
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Figure 47.  Colony Forming Units in the Lung following antibiotic treatment and antibody treatment in 
chronically infected mice. 
 
 With the antibiotic treatment, we never observed reactivation of disease in either group of 
mice.  Histological samples of the lungs were stained at each time point (Figure 48).  Fourteen 
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 days after antibody and antibiotic treatment began, disorganization was observed in the lungs of 
anti-TNF treated mice.  But even when bacterial levels were below detection, the granulomas 
were still present in the lungs at later time point.  The granulomas were still organized even in 
the anti-TNF treated mice, and the size and number of granulomas was decreased by 42 days 
post antibody treatment.  These data suggest that the bacteria are required to drive the chemokine 
gradients for granuloma formation.  In addition, as described earlier, anti-TNF treatment of 
macrophages did not abolish, but rather altered chemokine expression in macrophages (Figure 
18).  The antibiotic treated/ anti-TNF Ab treated mice have very low bacterial burdens compared 
to anti-TNF Ab treated (without antimycobacterials) mice.  If these mice have reduced levels of 
chemokine similar to observations made in anti-TNF Ab treated mice (See section 7.0), the 
existing chemokine expression may be enough to control the infection at the later time points.   
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Figure 48.  Histological Images of chronically infected mice treated with antibiotics and anti-TNF Ab. 
 The flow cytometric analysis performed on the lungs of the mice confirmed the 
observations in the histology.   The numbers of cells in the lungs of the mice gradually decreased 
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 as the bacterial burdens reduced (Figure 49).  Thirty days post antibody/ antibiotic treatment, the 
total number of cells in the lungs of anti-TNF treated mice was significantly lower than the IgG 
treated mice.  Two weeks later the number of cells in the IgG treated mice was also much lower 
and by 70 days after treatment began, the total number of cells in the lungs of both groups was 
significantly reduced compared to the first day of treatment.  
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Figure 49.  Cellular infiltrate in the lungs of chronically infected mice treated with antibiotics. 
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   Antibiotic treatment reduced the bacterial burdens in the anti-TNF Ab treatment group 
and the IgG treatment group, eliminating the morbidity of the anti-TNF Ab treated mice.  
Unfortunately due to the reduced bacterial burden and the decreasing cellular infiltrate in the 
lungs, the pathological changes usually observed with antibiotic/anti-TNF Ab treatment were 
transient and not as profound.  The antibiotic/anti-TNF treated mice cleared the bacteria more 
slowly than the antibiotic/IgG treated mice therefore there were still differences in bacterial 
burden at 14 days post infection.  Therefore using this method did not eliminate the variable of 
bacterial burden differences.   
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APPENDIX C 
 
C.0 mRNA expression of extracellular matrix proteins and adhesion molecules during M. 
tuberculosis infection. 
C.1  Introduction. 
 TNF is clearly required for granuloma formation and control of tuberculosis infection.  
This study was performed to address other molecules and processes in granuloma formation and 
cell migration that might be influenced by TNF during infection.  The two major groups of 
molecules that were addressed include adhesion molecules and matrix metalloproteinases. 
 The process of cell migration and cellular infiltration is mediated in part through the 
interaction of cells with cellular adhesion molecules.  As leukocytes migrate through blood 
vessels they are only slightly tethered to the vessel walls.  This interaction is through a group of 
molecules called selectins, which bind to carbohydrate moieties on the leukocytes.  Subsequently 
firm adhesion and transmigration is mediated through another group of molecules, cellular 
adhesion molecules (such as VCAM, ICAM, or PECAM).  Another critical component to cell 
transmigration is chemokine expression and gradient formation.  The gradient can directly 
influence cell migration by inducing cytoskeletal changes and upregulate the adhesion 
expression, avidity and affinity inducing firm adhesion.    
 Cell infiltration and tissue reconstruction can be influenced my matrix 
metalloproteinases.  There is some evidence that TNF may affect the expression of MMP-2 and 
MMP-9. 
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 C.2  Materials and Methods. 
Animals.  C57BL/6 female mice (Charles River, Rockland, Mass.) 8-14 weeks old were used in 
all experiments.  All infected mice were maintained in the BSL3 animal laboratories and 
routinely monitored for murine pathogens by means of serological and histological examinations.  
The University Institutional Animal Care and Use Committee approved all animal protocols 
employed in this study. 
Chemicals, antibodies and reagents.  All chemicals were purchased from Sigma Chemical Co. 
(St. Louis, MO.) unless otherwise noted.  Middlebrook 7H9 liquid medium and 7H10 agar were 
obtained from Difco Laboratories (Detroit, MI).  The cell lines, MP6XT-22 (anti-TNF) and was 
obtained from DNAX and used to generate ascites (Harlan Bioproducts, Indianapolis,IN).  
Antibodies were purified endotoxin free from ascites fluid as previously described [106] and 
mice were treated with antibody intravenously every three days (0.5mg/dose) starting 4 months 
post infection.  Control mice received normal rat IgG (Jackson Immunoresearch Laboratories 
Inc.,West Grove, PA) with the same dosing regiment. 
Mycobacteria and infection of mice.  To prepare bacterial stock, M. tuberculosis strain Erdman 
(Trudeau Institute, Saranac Lake, N.Y.) was used to infect mice, and then bacteria were 
harvested from their lungs, expanded in 7H9 liquid medium and stored in aliquots at -80°C.  
Mice were infected via the aerosol route using a nose-only exposure unit (InTox Products, 
Albuquerque, N.M.), and exposed to M. tuberculosis (1 x 107 CFU/ml in the nebulizer chamber) 
for 20 minutes, followed by 5 minutes of air. This resulted in reproducible delivery of 50-100 
viable CFU of M. tuberculosis as described previously [94], which was confirmed by CFU 
determination on the lungs of 2-3 mice 1 day post-infection.   In acute experiments where a 
higher inoculum was used, the concentration of M. tuberculosis in the nebulizer was increased, 
and day 1 CFU were determined in the lungs.  The tissue bacillary load was quantified by plating 
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 serial dilutions of the lung, liver, and spleen homogenates onto 7H10 agar as described 
previously [30]. 
RNA Isolation.  RNA was isolated from the lung or cells using the TRIZOL isolation protocol 
with slight modifications.  The lung was homogenized in 3ml (cells were lysed in 1ml TRIZOL/ 
2x106 cells) of TRIZOL reagent and then two chloroform extractions were performed.  
Following an isopropanol precipitation, the RNA was washed with 70% ethanol and treated with 
RNase Inhibitor (Applied Biosystems, Foster City, CA) for 45 minutes.  Following complete 
resuspension of the RNA at 65° C for 15 minutes the RNA was cleaned and DNase digested 
using the Qiagen RNA isolation kit, as directed by the manufacturer (Qiagen Inc., Valencia, 
CA).   
GEArray Q series KIT.  Total RNA was used as the template for 32-P labeled cDNA probe 
synthesis using the following procedure.  5µg of RNA was combined with the GEAprimer Mix 
(Buffer A, SuperArray, Bethesda, MD) and heated to 70C for 3 minutes and then transferred to 
42C for 2 minutes.  The labeling mix( GEA labeling buffer, 3µCi 32P dCTP, RNase Inhibitor, 
Reverse Transcriptase, RNase-free H20) was prepared as described by the manufacturer.  The 
mRNA was reverse transcribed and labeled for 25 minutes at 42C.  The reaction was stopped 
through addition of Buffer C and then the probe was denatured.  The labeled cDNA was added to 
hybridization mix and exposed to a prehybridized filter array O/N with continuous agitation at 
60C, as described by the manufacturer.  The filters were then washed in multiple changes of 
wash solution (2X SCC, 1% SDS).  The filters were then exposed to X-ray film for 24 hours and 
48 hours.  Analysis was performed using the manufacturer’s instructions.  In short, the X-ray 
film was scanned and then a raw data file extracted using the suggested software (Scanalyze by 
Michael Eisen).   
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 C.3  Results and Discussion. 
 Chronically infected mice were treated with either anti-TNF Ab or IgG at 4 months post 
infection.  At 3, 6, 9, and 12 days after antibody treatments began, RNA was isolated from the 
lungs and used in the GEArray, filter array technology by SuperArray Inc.  This array allowed us 
to address the mRNA expression through use of a cDNA radiolabelled probe.  The results of the 
array are presented in Figure 50,Figure 51, and Figure 52.  Figure 50 shows the graphs on the 
immunoglobulin superfamily, cadherin and catenin adhesion molecules.  Figure 51 shows the 
graphs of the integrin adhesion molecules.  Figure 52 shows the data generated on the matrix 
metalloproteinase expression. 
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Figure 50.  Cell Adhesion Molecules (Ig Superfamily, Cadherins and Catenins, Selectins). 
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 Expression of cell adhesion molecule mRNAs was determined using the GEArray Mouse Extracellular Matrix and 
Adhesion Molecule Gene Array.  The graph represents the ratio of the expression of the sample of interest over 
uninfected. 
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Figure 51.   Cell adhesion Molecules (Integrins). 
Expression of cell adhesion molecule mRNAs was determined using the GEArray Mouse Extracellular Matrix and 
Adhesion Molecule Gene Array.  The graph represents the ratio of the expression of the sample of interest over 
uninfected. 
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Figure 52.  Matrix Metalloproteinases. 
Expression of cell adhesion molecule mRNAs was determined using the GEArray Mouse Extracellular Matrix and 
Adhesion Molecule Gene Array.  The graph represents the ratio of the expression of the sample of interest over 
uninfected. 
 
 Expression of many adhesion molecules was different between the MP6 treated and IgG 
treated mice.  Unfortunately within a chronic infection, especially within the IgG treated mice, 
we did not expect to see such variation.  This variability indicates that the assay may be fairly 
sensitive, but the data analysis procedure must be considered carefully because if both a gene has 
expression less than background in both the uninfected sample and in the true sample, a false 
positive value will be generated.  In addition, the mRNA analysis performed here can only be a 
first step when addressing whether these changes in mRNA expression translate to changes in 
178 
 protein production, and consequently have functional consequences.  In addition matrix 
metalloproteinases are highly post transcriptionally regulated.  
In conclusion, our analysis of extracellular matrix and adhesion molecules did not 
revealed any stricking differences between MP6 treated and IgG treated mice.  Even when 
differences were detected between the groups of mice, there was often increased or decreased 
expression in the IgG treated mice compared to other time points.  Further analysis to address the 
protein expression of the proteins is necessary to draw any conclusion as to how TNF affects the 
expression of these molecules. 
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